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Abstract
Cystic Fibrosis (CF) is the most common lethal inherited disease, affecting -1/2000
live births. Although the genetic lesion, a mutation in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene, has been elucidated, the exact
mechanism whereby this causes the debilitating disease phenotype is unclear. CF
patients are prone to repeated bacterial infection of the lung; leading to fibrosis of
this tissue, and eventually respiratory failure. Gene therapy has the potential to cure
CF: by introducing a normal copy of the CFTR gene into epithelial cells of the lung,
it may be possible to abolish the lung phenotype. While early gene therapy vectors
utilised a strong viral promoter (e.g. Pcmv) to drive expression of the CFTR cDNA, it
has become apparent that this approach creates problems: expression is short lived
and may not be targeted to the correct cell types at appropriate levels.
CFTR expression is tightly restricted, both temporally and spatially in affected
tissues, notably the lung. Putative regulatory elements have been identified upstream
of the CFTR gene, both proximaliy and distilliy. In addition, a DNase 1
hypersensitive site has been identified in intron 1 of the gene, and has been
associated with an increase in CFTR expression in cells of the gut. Our approach is
to include genomic components of the CFTR locus fused to cDNA in gene therapy
vectors. These 'genomic context vectors' (GCVs) may be capable of recapitulating
the endogenous CFTR expression pattern.
The aim of this project was to investigate the use of the Enhanced Green
Fluorescent Protein (EGFP) as a reporter of CFTR promoter activity. Six vectors
were created coupling portions of the CFTR locus to EGFP in GCVs. Smail plasmids
were made by conventional cloning procedures, while large PAC vectors were made
by a double recombination method employing both homologous and Cre
recombinase/loxP recombination. Some vectors contained an internal ribosome entry
site (IRES) to allow separate translation of proteins from a single mRNA:
\
Name Size Promoter j CFTR
i Introns
Genes
pi kbcfproEGFP 4.9kb i kb CFTR 5'
region
EGFP
PAc65kbcfproEGFP 81 kb 65kb CFTR 5'
region
EGFP
pCFTR iresEGFP 1 lkb Pcmv CFTR and EGFP
(with IRES)




paCRC2iresEGFP 11 Okh 65kb CFTR 5'
region
Intron 1 CFTR and EGFP
(with IRES)




* The Clontech pEGFP-N vector was used as a control
These vectors were transfected into permanent cell lines COS"/, MDCK-iowa. T84
and CaC02, in order to assess the effects of the genomic context elements upon
EGFP expression. Several transfection methods were compared to optimise
transfection efficiency, including the liposome DOTAP, the Saint-Mix™ synthetic
amphiphile delivery system, a Polyethyieriimine (PE1) method, and the LID method.
A novel transfection method, the 'SID' method (incorporating Saint-Mix ™ and the
integrin targeting peptide Pb), showed early promise. Ultimately, the LID method
was chosen for further studies, as this method was both, efficient and consistent.
The proximal CFTR 5' region in the pi kbcfproEGFP vector drove expression of
the EGFP transgene at low levels in every celi line analysed. This is in agreement
with previous reports that show basal levels of CFTR expression driven by this
proximal 'housekeeping' region. The additional upstream region in the
PAc65bcfproEGFP vector did not appear to modulate expression in any of the cell
lines analysed. A comparison of the twin vectors pacRC 1 iresEGFP and
pa(PC2 ires EGFP. which differ only in the absence or presence of CFTR intron !
respectively, showed similar levels of expression in the COS7 and MDC'K-iowa cell
lines. Thus, the intron I element does not seem to alter expression in these non-gut
cell lines; this is consistent with reports that show regulation of CFTR expression in
response to the intron element to be specific to cells of the gut epithelium. An
investigation of the intron 1 element in gut cell lines T84 and CaC02 was thwarted
by low transfection efficiency in these cell lines, coupled with inefficient translation
from the IRES.
A comparison of pEGFP-N and pacRC2citivEGFP revealed that large PAC vectors
show an intrinsic reduction in expression in comparison to their small plasmid
counterparts. Further experiments showed that this was not an effect of vector copy
number, and that the effect could not act in trans upon a co-transfected molecule.
These studies also revealed an unexpected interaction: diluting a reporter plasmid
with an anonymous plasmid may actually increase its transfection efficiency.
Permanent cell lines form an important starting point for transfection studies, but
ultimately have proved to be poor models for in vivo gene transfer. An ex vivo
primary air interface sheep tracheal culture was utilised as a more realistic model.
These cultures were characterised by electron microscopy, and demonstrated features
of the native tracheal epithelium. A measure of transepitheliai resistance confirmed
the presence of tight junctions. Cultures were transfected with several of the genomic
context vectors. While PAC vectors had shown a dramatic reduction in expression
relative to their small plasmid counterparts in the in vitro studies, only a small
reduction was seen in the ex vivo cultures, thus PAC vectors, such as GCVs, may
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1.1.1 A Brief History of Cystic Fibrosis
Anderson (Anderson, 1938) first described the disease of Cystic Fibrosis (CF). She
reported on a cohort of celiac patients displaying diarrhea and steatorrhea, due to a
pancreatic enzyme deficiency; this disease followed a simple recessive pattern of
inheritance, suggesting that a single gene was responsible (Anderson and Hodges,
1946). Cystic fibrosis was observed in the pancreatic tissue, and hence the disease
was named.
In 1983, Quinton demonstrated a chloride (CI-) transport deficiency in skin biopsies
from CF patients (Quinton, 1983). Further studies revealed that this defect was not
specific to the skin, but applied to a range of CF tissues (Lin and Gruenstein, 1987;
Chen et al, 1989; Bubien et al, 1990).
Linkage analysis and positional cloning techniques, such as chromosome walking
and jumping, indicated that the CF gene was positioned on the long arm of
chromosome seven (Tsui et al, 1985; Rommens et al, 1989). Eventually, a candidate
gene was identified in this region (Riordan et al, 1989; Kerem et al, 1989; Rommens
et al, 1989). Several lines of evidence indicated that this gene was the site of the CF
lesion, including the gene's location, predicted protein structure, and localization of
mRNA transcript to CF-affected tissues. Most convincingly, a 3-bp deletion (AF508)
was found in this gene on 70% of CF chromosomes; this mutation was completely
absent from normal chromosomes (Kerem et al, 1989). This gene was named the
cystic fibrosis transmembrane conductance regulator (CFTR).
1.1.2 CF Patient Profile
CF affects multiple organs. Blockage of the meconium (first feces) and subsequent
intestinal obstructions are common, due to poor absorption in the gut. In patients
with pancreatic insufficiency mutations (see Section l.l.5), the exocrine glands of
the pancreas are destroyed; hence, pancreatic secretions (containing enzymes
important for digestion) are not produced. A high sodium chloride concentration is
present in the sweat. The disease also affects the liver and reproductive organs: males
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with CF are infertile, while females with CF have reduced fertility (Phillipson, 1998).
However, the defining feature of CF is the pathology of the lung: patients are prone
to repeated bacterial infection of the lungs, resulting in fibrosis of this tissue, and
eventually respiratory failure unless a lung transplant is performed (Davidson and
Porteous, 1998;Gaiso, 1998; Korstetal, 1995).
The lung disease in CF follows a generally progressive course, marked by a number
of turning points (Pilewsky and Frizzell, 1999). At birth, the lung appears to be
normal. The earliest pathology of the CF lung is a mucus obstruction of the small
airways, accompanied by inflammation and neutrophil infiltration of the bronchiolar
walls (Korst et al, 1995). There is some evidence that an inflammatory response
might be present in infants below six months of age: such a response might even
precede bacterial infection of the lung (Cantin, 1995), although this hypothesis is
controversial.
By two years of age, the bronchioles and bronchus become infected with
Haemophilus influenzae and Staphylococcus aureus (Pilewsky and Frizzell 1999).
This is accompanied by further inflammation, and thick, sticky mucus, which
obstructs the small airways. Mucociliary clearance is impaired, resulting in a failure
to remove bacteria from the lung. Persistent inflammation and bronchiecstasis
develop between two and ten years. As CF airway disease progresses, the pathogen
profile changes. Pseudomonas aeruginosa is an opportunistic pathogen that is
commonly present, but rarely causes infection, in healthy individuals; this has been
implicated as the major pathogen in CF lung disease. The CF lung first becomes
transiently infected with P. aeruginosa, but eventually mucoid strains emerge,
colonizing the lung. Over the next decade, inflammation and bronchiecstasis are
accelerated and progressive airway obstructions result. Eventually, respiratory
insufficiency develops, leading to death.
1.1.3 Treatments
The use of pancreatic enzymes and nutritional supplements is highly effective in
treating the CF pancreatic insufficiency, leaving lung disease as the major cause of
mortality (accounting for -95% of deaths among CF patients). Aggressive
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physiotherapy and antibiotic regimes have dramatically increased the lifespan of CF
patients (Korst et al, 1995; Gaiso, 1998). Recent advances in CF therapies include:
Pulmozyme®, a drug that reduces the viscosity of the mucus (by digesting DNA
remnants of lysed neutrophils); ibuprofen, which has anti-inflammatory effects; and
TOBI™, a tobramycin solution for inhalation (CF Foundation website).
Potential new treatments for CF are rapidly being tested (Korst et al, 1995; Knowles
et al, 1995; Davidson and Porteous, 1998; CF Foundation website). These include
new anti-microbial agents (such as the promising antibiotic compound IB367),
mucolytics, antiproteases, recombinant human secretory leukoprotease inhibitors,
and aerosolised a-1 antitrypsin. Delivery of aerosolised amiloride, uridine
triphosphate (UTP), or the compound INS37217 to the lung may restore ion
transport, and thus improve mucociliary clearance. We are moving increasingly
towards treating the causes, rather than the symptoms, of CF lung disease.
Despite these advances, a complete cure for CF remains beyond our grasp. CF is the
most common lethal recessive inherited disease, affecting approximately one in
2,500 individuals in European populations. In addition to the personal tragedy, the
medical costs of CF average $27,500 annually per patient, and a heart-lung transplant
costs in the range of $150,000-200,000 (Korst et al, 1995). One possibility for a cure
for CF is gene therapy: by introducing a normal copy of the CFTR gene into
epithelial cells of the lung, it might be possible to correct the pulmonary defect.
1.1.4 The CFTR gene
In the quest for new therapies for CF, such as gene therapy, it will be necessary to
gain a more complete knowledge of the properties of the CFTR protein and its
function within the cell. The CFTR gene lies on the long arm of human chromosome
7 at q3l.3, and spans approximately 188.7 kb, encompassing 27 exons, separated by
large introns (Fig. I. I). This gene produces a messenger RNA of 6.5 Kb (Riordan et
al, 1989). The predicted open reading frame encodes a 1480-residue glycoprotein of
167 Kda. This protein shows structural homology to the membrane-associated
transport ATPase family of proteins (Riordan et al, 1989; Biggins et al, 1990).
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The CFTR protein is composed of discrete domains:
• 12 hydrophobic membrane spanning domains (TM1 - TM12)
• Two ATP-binding domains (referred to as nucleotide binding domains:
NBD1 and NBD2)
• A large 'R domain' which is thought to have a regulatory function (Rich et al,
1997)
Figure 1.2 shows the proposed structure of the CFTR protein (Riordan et al, 1989).
The protein consists of two roughly identical halves, each comprised of a set of six
membrane spanning regions, followed by an NBD. The large R domain lies in the
center, connecting the two halves of the protein (Reviewed in Tsui, 1995; Frizzell,
1995; Davidson and Porteous, 1998). CFTR is an ABC transporter: it is now
generally accepted that CFTR is itself the CI- channel that is lacking in CF. There is
some recent evidence that CFTR may form a dimer, although this is debated (Li et al,
2001; Raghuram et al, 2001; Zerhusen et al, 2001).
CFTR CI- channel activity is tightly regulated. For CI- transport to occur, cAMP-
dependent protein kinases must first phosphorylate sites in the R domain (Rich et al,
1990). ATP hydrolysis of NBD 1 produces a state amenable to CI- transport, while
ATP hydrolysis of NBD2 essentially closes the channel. These ATP hydrolysis
events do not strictly open and close the channel, but rather increase the open
probability, as CFTR rapidly fluctuates between an open and closed state (reviewed
in Frizzell, 1995). The R domain may act as a 'ball and chain' to physically block the
CFTR channel and prevent CI- transport during the closed conformation (Winter and
Welsh, 1997). Forskolin and other cAMP agonists stimulate secretion of CI- by the
CFTR channel (Bargon et al, 1998), but treatment with phorbol myristate acetate
(PMA) prevents this (Trapnell et al, 1991a).
CFTR homologues have been sequenced in mammals such as mouse (Ellsworth et al,
2000) and in organisms as diverse as Fugu (Davidson, H et al, 2000). CFTR is a
highly conserved protein: in comparison with the human CFTR gene, sheep CFTR
shows 90% identity at the nucleic acid level and 95% similarity at the protein level;
mouse CFTR shows 80% identity and 88% similarity; and Fugu CFTR shows 58%
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identity and 75% similarity (Tebbutt et al, 1995; Ellsworth et al, 2000; Davidson, H
et al, 2000).
In addition to its function as a CI- channel, CFTR affects the expression of several
other genes, including ENaC, a sodium channel (Ismailov et al, 1996), and iNOS
(Kelley and Drumm, 1998).
1.1.5 CF mutations
Much work has been done to characterise the mutations responsible for CF (CF
mutations database website; Pilewsky and Frizzell, 1999; Mateu et al, 2002; Tsui,
1995). 996 disease-causing mutations have been identified in the CFTR gene.
Disease-causing mutations are most prevalent among highly conserved amino acids,
particularly in the nucleotide binding domains.
The most frequent mutation, AF508, accounts for approximately 66% of the alleles in
CF patients. This 3-bp deletion leads to the loss of a phenylalanine residue at position
508 in the protein. Other common mutations (frequency > 1 %) include G542X,
N1303K, G551D and W1282X.
CF mutations can be separated into five classes, describing their molecular
consequences on the CFTR protein:
Class I: No synthesis. In this type of mutation, no CFTR protein is produced.
One example is the nonsense mutation G542X (which results in a truncated
mRNA).
Class II: Block in processing. In this type of mutation, CFTR protein is not
processed correctly to its mature form. This may result in the protein being
degraded by proteases, rather than being transported to the apical membrane.
AF508 is an example of a class II mutation. Experiments have shown that a
reduced temperature may allow correct processing of the AF508 mutant CFTR,
resulting in the formation of a functional channel at the apical membrane (Lukacs
et al, 1993). This discovery may have therapeutic potential for class II mutations.
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Class III: Block in regulation. With this class of mutation, CFTR shows correct
localisation, but defective regulation of CI- secretion. For example, the missense
G551D mutant protein cannot be activated for channel function.
Class IV: Altered conductance. In mutations such as missense R1 17H, the
defective CFTR channel still transports some C1-, but at a reduced rate. The ion
specificity of the channel may also be altered.
Class V: Reduced synthesis. Decreased abundance of protein is a feature of
class V mutations. In the alternative splicing mutant 3848 + lOkb C-> T, only a
portion of the CFTR mRNA is spliced correctly, resulting in a decreased channel
number.
A strong correlation has been demonstrated between the class of mutation and the
pancreatic phenotype. The pancreas is normal with 'pancreatic sufficient' (PS)
mutations such as R177H. In contrast, mutations such as G551D and AF508 affect
the pancreas function; these are called 'pancreatic insufficient' (PI) mutations. Other
phenotypic effects are correlated with specific mutations, for example, blockage of
the meconium ileus occurs in 10% of patients with a AF508 mutation, but is less
frequent with G551 D. However, here is no clear-cut correlation between the
mutation and the lung phenotype.
Several other diseases have been associated with mutations in the CFTR gene (CF
mutations database; Tsui, 1995). For example, congenital absence of the vas deferens
is commonly associated with a CFTR mutation. There has been one report of CFTR
sequence variations causing an elevation in sweat chloride, in the absence of CF
(Mickle et al, 1998). 208 sequence variations have been identified in the CFTR gene,
which do not appear to cause disease. Some of these cause amino acid changes which
are apparently benign.
Independently segregating modifier genes and environmental factors are likely to
have an effect on CF disease severity. Mouse model of CF have proved particularly
useful in the dissection of candidate modifier genes (see Section 1.1.1 I).
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A recent report on the phytogeny of CFTR mutations is noteworthy (Mateu et al,
2002). CFTR mutations are most prevalent in Europe, and the allele frequencies
display a gradient from the Northeast to the Southwest. The three most common CF
mutations, AF508, G542X and N1303K, share a common haplotype in the region
surrounding the CFTR gene. This suggests that these mutations arose in single
population, where this haplotype was common. This haplotype is not found at a high
frequency in any of the modern populations that were analysed, which suggests that
the expansion of these alleles predates the divergence of modern-day populations.
Similarly, the alleles G551D and W1282S share a common haplotype. Populations
with a moderate prevalence of this haplotype are widely distributed in multiple
continents; this is compatible with a European origin for these mutations.
Theories of heterozygote advantage (for example, against cholera - McDonald et al,
1995) have been proposed to explain the high prevalence of CFTR mutations in the
population. Knowing the origin of CF-causing mutations would undoubtedly give us
a more rounded picture of the history of the disease.
1.1.6 The mechanism by which CFTR dysfunction produces the lung
phenotype
The precise mechanism by which mutations in the CFTR gene cause the severe lung
phenotype seen in CF is still unclear. However, several attractive hypotheses have
been advanced (Porteous and Davidson, 1997).
The secretory model of CF suggests that the disrupted CI- channel function of CFTR
is directly responsible for the phenotype. CI- transport is a key component of the salt
transport network of the lung; disruption of this function may lead to changes in the
airway surface liquid (ASL), with drastic effects on the lung (Guggino, 1999;
Pilewsky and Frizzell, 1999). Two contrary hypotheses have been proposed: the
hydration hypothesis (Boucher, 1994), suggesting a reduced ASL volume (which
may compromise mucociliary clearance), and the salt hypothesis (Smith, JJ et al,
1996), suggesting a hypertonic ASL (which may compromise salt-sensitive antibiotic-
activity, such as that of defensins).
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A decrease in mucous sulfation, along with an increase in sialylation is observed in
purified CF mucous, in comparison to non-CF mucous. Mucous sulfation may
contribute to the predisposition to bacterial colonization in the CF lung (Zhang et al,
1998b). Alterations in electrolyte transport may affect sulfation; in addition, CFTR
may have a direct function as a transporter of sulfate donor molecules (Pasyk and
Foskett, 1997).
Other models propose that CF is caused by altered binding of pathogens to the CFTR
channel. The internalisation hypothesis suggests that in normal cells, CFTR may act
as a ligand for the internalisation of pathogens (such as P. aeruginosa), and
subsequent cell shedding will rid the lung of these pathogens; thus in CF, effective
pathogen binding and cell clearance cannot occur (Pier et al, 1997 and 2000). A
contradictory theory suggests that P. aeruginosa adheres to CF lung cells at higher
levels than to normal cells (due to an upregulation of the asiagloGMl cell surface
protein in CF), and this results in infection by these bacteria (Davies et al, 1997).
Finally, a model of cytokine dysregulation has been proposed to explain the lung
defect (Cantin, 1995; Richman-Eisenstat, 1996). Rather than being a secondary
response, inflammation may in fact precede infection in CF. Abnormal ion transport
or acidification of intracellular organelles might interfere with the expression of anti¬
inflammatory cytokines. Alternatively, the production of thickened mucus, with
altered composition, by the CF submucosal glands might stimulate the release of pro¬
inflammatory markers such as interleukin-8, to accomplish an inflammatory response
in the absence of a bacterial stimulus. Whatever the mechanism, CF lung disease
appears to be complex, involving a vicious cycle of infection, inflammation and
airway damage.
1.1.7 The CFTR promoter
Much work has been done to elucidate the control elements that drive CFTR
expression. The CFTR proximal 5' region seems to have many characteristics of a
housekeeping promoter (Yoshimura et al, 199lb) (Fig. 1.3); there is no TATA box,
sequences with homology to the CCAAT box have been found at -239 and -123 bp
(all positions given are relative to the ATG start codon) and the region from -500 bp
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Figure 1.3. CFTR regulatory elements. This is a diagram of the regulatory elements which have
been identified in the 5'UTR and intron 1 of CFTR. (a) The first scale describes the region from
-100 bp to the ATG start codon, and shows various transcriptional start sites.(b) The second scale
describes the region from -1000 bp to the ATG codon, and shows more transcriptional start sites,
putative binding sites, potential response elements, regions of homology, a region of high G-C
content, a Y box, a variant CRE, and DHSs. (c) The third scale describes the region from -80 kb
upstream of CFTR to +20 kb downstream of CFTR, and describes DHSs in the distal 5' region,
within CFTR introns and in the 3' region.
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to ATG has a high GC content. There are multiple minor transcriptional start sites (at
-133, -132, -73, -70, -68, -119, -37, -28, -20,-19 and +1 bp) in addition to the major
transcriptional start site at -71 bp. There are also three putative binding sites for the
transcription factor SP-1 at -1021, -405 and -326. These are all features of a
housekeeping promoter (Koh et al, 1993).
However, investigation of the CFTR expression profile reveals that it is regulated in
a tissue-specific manner (see Section 1. 1.10). A search for tissue-specific control
elements in the 5' region flanking the CFTR gene has identified several interesting
features (Fig. 1.3). Chou and colleagues (Chou et al, 1991) claimed to have identified
at least three regions regulating CFTR expression by their effect on expression of the
CAT reporter gene. Sequences between -27 and -296 bp were capable of driving
reporter gene expression. However, an element just upstream of-297 bp repressed
this expression. The endogenous CFTR expression levels suggested the presence of
another positive regulator upstream of-756, which accomplishes de-repression
(however, Chou and colleagues were unable to identify such an element). Two
regions of non-random pyrimidine-purine asymmetry (where one strand contains
more pyrimidine bases and the other more purine bases - commonly called PMRs)
have been found at -319 and -609 bp from the CFTR gene (Hoilingsworth et al,
1994); these are perfect mirror repeat elements about a bisecting plane. Similar PMR
elements have been implicated in noti-B DNA conformations; in addition, an SI
nuclease digestion site (associated with non-B DNA conformations) maps near or
within one of these PMR elements in the CFTR gene. This suggests that these PMR
elements may play a role in regulating CFTR expression, by altering chromatin
conformation, perhaps in a tissue-specific manner.
Matthew and colleagues (Matthews and McKnight, 1996) have confirmed that there
is a functional variant cAMP response element (CRE) binding site at -119, along
with a Y-box at -131, consistent with the cAMP-dependent regulation of CFTR
expression (see Section 1.1.9). Putative AP-2 binding sites exist at -1178 and -415.
Finally, a potential C/EBP binding site was found at -257 relative to the ATG start
codon. Despite the plethora of putative control elements in the 5' region, coupling of
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a 2 kb region 5' of the CFTR gene to the LacZ reporter gene did not fully
recapitulate the endogenous CFTR expression profile (Imler et al, 1996).
The mapping of DNase I hypersensitive sites (DHSs) is a powerful technique to
dissect transcriptional regulators. DNase hypersensitivity in the chromatin is often
(but not always) indicative of a regulatory element. Ann Harris' group has performed
extensive mapping of DHS in the CFTR locus. DHS sites have been found in the
region 5' of the gene, 3' of the gene, and within CFTR introns.
Both tissue-specific and ubiquitous DFIS sites have been mapped in the proximal
region 5' of the CFTR gene. DHS sites at -205 and -796 bp are present in multiple
cell types, while the sites at -3071, -1671, -971 and -271 are present in HT-29
intestinal epithelial cells, but not in HFL-1 fibroblast cells (Yoshimuraet al, 1991a).
The two sites have been found in the more distal 5' region (at -79.5 and -
20.9)(Smith et al, 1995): these sites did not appear to be tissue-specific (Nuthall et al,
1999b). Deletion of the -20.9 DHS and all upstream DNA in a YAC construct
appeared to reduce transgene expression by -60% in permanent cell lines. In
addition, two PMR elements colocalise with the -20.9 DHS (Nuthall et al, 1999b). It
should be noted that there is a predicted gene 52.5 kb upstream of CFTR (Ensembl
database, Ensembl gene ID ENSG00000154438), the DHS at -79.5 will be within
that gene.
A DHS cluster was identified 3' of the gene at 4574 + 5.4-7.4 kb and a single DHS at
4574 + 15.6, these showed some evidence of tissue specificity (Nuthall et al, 1999a).
Finally, several DHS were identified in CFTR introns. A DHS identified in intron 1
(185 + 10 kb) almost certainly has a role in regulating expression (Smith, AN et al,
1996). This element augmented reporter gene expression in the Caco-2 and CHO-K1
cell lines, which express CFTR (Smith, AN et al, 1996; Mogayzel and Ashlock,
2000). CFTR YAC transgenics provide further evidence that the intron 1 DHS is
involved in regulation (see Section 1.1.11).
DHSs have also been identified in intron 2 (296 + 4.4 kb), intron 3 (405 + 0.7 kb),
intron 10(1716 + 23 kb), intron 16 (3120 + 3 kb), intron 17a (3271 + 0.7 kb), intron
Chapter I: Introduction 14
18 (3600 + 7 kb), intron 20 (4005 + 4 kb) and intron 21 (4095 + 7.2 kb) (Smith et al,
2000). The profile of DNase hypersensitivity at these intronic sites varied between
different cell lines and human tissue samples, suggesting that they may be involved
in tissue-specific regulation. In reporter constructs including the CFTR minimal
promoter region and the luciferase reporter gene, inclusion of the intron 20 DHS
increased expression by 4.4-fold, and inclusion of the intron 21 DHS increased
expression by 1.5-fold (Phylactides et al, 2002).
While it is unlikely that every DHS reported has a role in regulation, these studies
form a good starting point for identifying regulatory elements. The presence of these
DHS elements suggests that CFTR regulatory signals are complex and are not
restricted to the minimal promoter. Elements in the distal 5' region, 3' region, and
within CFTR introns may all be involved in determining the CFTR expression
profile.
Mutations in the CFTR promoter are rare (Verlingue et al, 1998). However, a few
have been identified (CF mutations database website): C -> T at -887 bp and T -> G
at -812 bp (Bienvenu et al, 1995), AAGG at -542 bp (Grade et al, 1994), C-> T at -
434 bp. Other possible mutations include T -> A at -173 bp, G ->T at -165 bp and G
-> A at -104 bp. The mutation T -> G at -812 bp is located in a potential AP-1
binding site, and the mutated sequence exhibits an abnormal binding pattern in a gel
shift assay, in comparison to wild-type (wt) sequence (Bienvenu et al, 1995).
Additionally, a T -> G polymorphism (which does not appear to be involved in CF)
has been identified at -966 bp.
A 310 kb YAC containing the CFTR locus demonstrated copy-number dependent
expression, when integrated into the Caco-2 cell line (Vassaux et al, 1997). This
suggests that insulator, or boundary elements may exist in the region flanking the
CFTR gene, which are capable of insulating CFTR expression from adjacent
regulatory elements.
1.1.8 The j3Globin promoter
In studying the CFTR promoter, it is useful to consider what is known of
transcriptional regulation at other loci. The (3gIobin locus has been well
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characterised, and displays an elegant example of transcriptional regulation (Wood,
1996; Chung et al, 1997; Ho and Thein, 2000).
Hemoglobin consists of two aglobin-like chains, and two Pglobin-iike chains.
Alternative Pglobin-like chains are employed at different stages of development;
these alter the oxygen-binding affinity of hemoglobin. The genes encoding the
Pglobin-like chains are clustered at a single locus on the long arm of chromosome
11, and are arranged in the order in which they are expressed: e (foetal) Gy and
Ay (embryonic), 5 and p (adult) (Fig. 1.4a). Expression of these genes is tissue-
specific, being restricted to erythroid cells.
A locus control region (LCR), consisting of five DNase I hypersensitive sites (each
associated with regulatory elements), lies upstream of the gene cluster, from -5 to -
25 kb relative to the 8 ATG start codon. The LCR affects expression in two ways.
Firstly, it produces an open chromatin (euchromatin) conformation at this locus,
conferring position-independent expression (e.g. unaffected by adjacent
heterochromatic regions which would silence expression). Secondly, the LCR acts as
a developmental stage-specific enhancer, regulating the switch in expression between
the different pglobin-like genes. The favored theory for the mechanism of this
enhancement is that a 'holocomplex' forms in the DNA. allowing the LCR to
associate with the proximal promoter of one of the Pglobin-like genes, with the
intervening DNA looping out (Fig. 1.4b). This interaction appears to be governed by
the binding of developmental stage-specific, erythroid-specific transcription factors
to conserved elements within the LCR (CACCC, [T/A]GATA[A/G], and
TGA[C/G]TCA) and the Pglobin-iike genes' proximal promoters (e.g. TATA,
CCAAT and CACCC in the P proximal promoter). For example, erythroid kriippel-
like factor (EKLF) binds to the CACCC box. Evidence suggests that binding of the
LCR to the Pglobin-iike promoters is competitive, such that only one gene may be
transcribed at a time.
Thus, regulation at the pglobin locus is tightly regulated through development in a
tissue-specific fashion. It will be interesting to discover whether similar mechanisms
of regulation are employed at the CFTR locus.
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1.1.9 Modulation of CFTR expression by pharmacological agents
CFTR expression is affected by several pharmacological agents. Forskolin appears to
increase CFTR mRNA levels in HT-29 cells, but conversely, lowers CFTR mRNA
levels in T84. This effect appears to be a result of the cAMP-agonist effect of
forskolin: membrane-permeable cAMP analogues (CPT-cAMP, DB-cAMP and 8-
bromo-cAMP) and cholera toxin (a cAMP agonist) have a similar effect to forskolin,
while ATP, non-membrane permeable cAMP, and dideoxy-forskolin (a forskolin
analogue which does not affect adenosine cyclase) do not affect expression (Bl uer et
al, 1992; Bargon et al, 1998). Most interestingly, cAMP treatment has been shown to
correlate with an increase in DNase I hypersensitivity at the DHS overlapping the Y
box (Pittman et al, 1995). PMA reduces CFTR expression in both the HT-29 and T84
cell lines (Brueretal, 1992; Trapnell et al, 1991a). Inhibitors of protein kinase A
(PKA) suppress even basal levels of CFTR mRNA expression, suggesting that PKA
is required for CFTR transcription (McDonald et al, 1995). Finally, extracellular
hyposmolarity, or the inclusion of urea or mannitol in growth medium reduce CFTR
mRNA expression (Baudouin-Legros et al, 2000).
It is interesting that cAMP agonists and PMA also affect CFTR at the protein level,
altering the channel's CI- gating (see Section 1.1.4). These agents appear to regulate
CI- transport by multiple mechanisms.
1.1.10 CFTR expression profile
CFTR appears to contain a plethora of regulatory elements, and indeed the gene's
expression follows a complex pattern, both temporally and spatially. The CFTR
expression profile has been characterised by reverse transcriptase polymerase chain
reaction (RT-PCR), in situ hybridisation, and immunohistochemistry. The latter has
been complicated by the difficulty to raise specific antibodies to the CFTR protein.
1.1.10.1 The gut
CFTR protein is abundant in epithelial cells of human intestinal crypts. Expression
appears to be restricted to the apical portion of the cells, and a proportion of the
protein is found to be associated with the plasma membrane. In the jejunum,
expression appears to be highest in the mucosal epithelial cells, although lower levels
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are seen in the epithelial cells lining the crypts of the large intestine (Crawford et al,
1991). In rat intestine, CFTR shows decreasing gradients of expression along both
the crypt-villus and proximal-distal axes (Trezise and Buchwald, 1991).
1.1.10.2 The pancreas
CFTR protein is expressed in epithelial cells of the pancreatic secretory ducts. This
expression is restricted to the smaller of the secretory ducts, and to the luminal
portion of these cells (Crawford et al, 1991).
1.1.10.3 The respiratory system
It has been difficult to characterise the CFTR expression profile in the lung: such
studies have been frustrated by high levels of background staining when performing
immunohistochemistry on this tissue. RT-PCR has demonstrated that CFTR is
expressed at ~ 1-2 mRNA copies per cell in human nasal, tracheal, and bronchial
epithelium, in contrast to pharyngeal epithelium, where levels are 100-fold lower
(Trapnell et al, 1991b).
Submucosal glands are the main site of CFTR expression in the lung (Engelhardt et
al, 1992). Fig. 1.5 shows a cartoon of the lung, including a diagram of the
submucosal gland and the pseudostratified airway epithelium. Staining was seen in
both the serous components of the secretory tubules (where almost every cell showed
high levels of CFTR protein localizing to the apical surface) and in subpopulations of
both columnar and basal cells in the ciliated ducts. Expression was not as marked in
the surface respiratory epithelium of the proximal airways, and was restricted to a
small population of non-columnar cells.
A later study (Engelhardt et al, 1994) detected lower levels of CFTR expression in
the more distal airways (including the proximal, terminal, and respiratory
bronchioles, and alveoli). In the proximal bronchioles, this expression was localised
to the apical surface in a population of non-ciliated ceils (these co-localise with the
Clara cell marker CC10). Expression was more random in the more distal airways
and alveoli.
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1.1.10.4 Other organs
The infertility in CF males and reduced fertility in CF females would predict a role
for CFTR in the reproductive system. Indeed, CFTR expression has been detected in
the seminiferous tubules of males and the uterus epithelial lining in females, in rat
tissues (Trezise and Buchwald, 1991).
CFTR protein is abundant in epithelial cells lining the sweat ducts (Crawford, 1991).
Kidney tubules show a high level of CFTR protein, despite the fact that the kidney is
not affected in CF (Crawford, 1991).
CFTR mRNA is expressed in the heart, and CFTR appears to have a function as a Cl-
channel in this tissue (Levesque et al, 1992), although the heart does not appear to be
affected in CF. There is an epicardial to endocardial gradient of CFTR expression in
the left ventricle of the rabbit heart (Wong et al, 1999), which may represent an
alternatively spliced form of CFTR (Horowitz et al, 1993).
1.1.10.5 Non-epithelial cells
Early investigations suggested that CFTR expression was restricted to epithelial cells
(Crawford et al, 1991). However, there is now some evidence of expression in other
cell types (Yoshimura et al, 1991a; Tousson et al, 1998). There is evidence of CFTR
expression in lymphocytes, Sertoli cells, heart muscle cells, non-epithelial cells of the
submucosal gland, and hypothalamic neurons. CFTR expression has been
demonstrated in mast cells, and it seems likely that CFTR may be involved in mast-
cell activation and secretion, through its CI- transport function (Kulka et al, 2002).
CFTR expression appears to be regulated during development. Studies of fetal tissue
from pancreas, intestine, and vas deferens of CF patients show developmental
abnormalities For example, dilation or destruction of the pancreatic glands and ducts,
and abnormalities or absence of the epididymus and vas deferens in males (Zuelzer
and Newton, 1969; Thomaisis and Arey, 1963; Valman and France, 1969, Ornoy et
al, 1987).
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CFTR is expressed in the bronchial epithelium during the first and second trimesters,
with a gradient of expression diminishing from the bronchi, to the bronchioles, to the
pre-alveolar tubes. This expression appears to be uniform in the first trimester, but
becomes restricted to patches in the second trimester, perhaps reflecting cell
differentiation (McCray et al, 1992). The fetal pulmonary lung secretes fluid: this
process is thought to be driven by CI- secretion and to be involved in development.
Thus, there is potential for CFTR to have a role in lung development. One study has
claimed to reverse the phenotype in a CF mouse model by in utero gene therapy
(Larson et al, 1997). In this study an adenovirus vector was administered to the CF
mouse in utero. This appeared to drive CFTR expression during development, but
expression became switched off after birth. They claimed that this completely
rescued the intestinal phenotype of the S489X CF mouse; this would suggest that it is
CFTR's role in development that causes the gut phenotype. However, this data is
controversial. In addition, the lack of obvious morphology in CF neonate lungs casts
doubt on the hypothesis that it is CFTR's role in development that is responsible for
the respiratory phenotype in CF patients.
1.1.10.6 AF508 CFTR expression in CF
mRNA levels were found to be similar in the respiratory epithelium from normal and
AF508 CF patients (Trapnell et al, 1991a). However, in vitro studies (Lukacs, 1993),
and later, in vivo studies (Kartner et al, 1992) have shown that the AF508 protein
fails to localise to the apical membrane. In addition, at the protein level, AF508
shows a different distribution to wt CFTR: while similar levels of protein are seen in
respiratory and intestinal tracts, AF508 protein is undetectable in the sweat gland
(Kiilin et al, 1999).
1.1.11 Animal models of CF
Animal models are important tools in biological research. The possibility of creating
knockouts and transgenics in the mouse has opened new doors of understanding for
many diseases.
Several groups have generated mouse models of CF (Table !. I) (reviewed in
Davidson and Dorin, 2001). These can be broadly separated into three classes: (1)
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compete knockouts, (2) 'leaky' knockouts (where a low level of functional CFTR is
produced, for example, due to alternative splicing of insertion mutants), and (3)
models of specific clinical mutations, for example, AF508 and G551D (interestingly,
all but one of the 60 clinical missense mutations are in sequences conserved between
the human and mouse).
Table 1.1. Mouse models of CF.
Mouse Model Class Lesion Reference
CFTRtm ^ 1 Exon 10 replacement Snouwaert et al, 1995
CFTRtm' 1 Exon 10 replacement Ratcliff et al, 1993
t in3 B3y 1 Exon 2 replacement Hastv et al, 1991
I Hsc
1 Exon 1 replacement Rozmahel et al, 1996
CFTRtm ^ 2 Exon 10 insertional Dorin et al, 1992
j^tni 1 Bay 2 Exon 3 insertional duplication O'Neal et al, 1993
jprjp t m2Cam 3 AF508 by exon 10 replacement Col ledge et al, 1995
CFTRtm ^ 3 AF508 by exon 10 replacement Zeiher et al, 1995
cri'R1111' 3 AF508 by exon 10 "hit and run' Doominek et al, 1995
CFTRtm' ^ 3 G55ID by exon ! 1 replacement Delaney et al, 1996
^pf-p 11n2 H Cj U 3 G480C by exon 10 'hit and run' Dickinson et al, 1998
(This table has been adapted from Davidson and Dorin, 2001)
All of these mice show a defect in CI- transport in epithelial ceils, characteristic of
CF (Clarke et al, 2.002). Varying degrees of intestinal phenotype are displayed,
according to the genetic lesion, and the mouse strain. However, none of the mouse
models shows convincing evidence of lung disease under normal housing conditions.
The sterile living environment, short life span, and possibly the presence of an
amiloride-insensitive, electrogenic Na-f-glucose transport system in the mouse
airway (which is not present in humans) (Joris and Quinton, 1989) may account for
the failure ot the mouse to develop a spontaneous morbid lung phenotype. At least
two groups have been successful in demonstrating a differential immune response
and bacterial clearance between CF mutant mice and their wild-type littermates,
following a forced infection with pathogens commonly found in CF patients
(Heeckeren et al, 1997; Davidson et al, 1995).
YAC transgenics have also been informative. A transgenic mouse, carrying a YAC
containing the intact human CFTR locus was made (Manson et al, 1997). This YAC
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transgenic shows an expression pattern similar to endogenous CFTR (where there is
a difference in expression patterns between mouse and human CFTR, the transgene
appears to follow the mouse pattern). This YAC transgene is capable of rescuing the
intestinal phenotype of the CFTR"nl( 1111 knockout: YAC transgenic x CFTRlnilCam
mice appear phenotypically normal and breed well, in contrast to the null mice, 50%
of which die perinatally. To test the effects of the intron 1 element upon expression,
A YAC was generated where the intron 1 DHS element had been deleted: this YAC
was used to create another transgenic mouse. Deletion of the intron 1 DHS was
shown to reduce expression in the intestine by 60%, in contrast to the YAC
transgenic with intact intron 1, while expression in the lung was similar between the
two constructs (Rowntree et al, 2001). This provides further evidence that the intron
1 DHS element accomplishes upregulation of CFTR expression in the gut.
Although the inbred strains used to make transgenics may be a poor model of the
heterogeneous CF population, these mouse strains have proved useful in the
dissection of modifier genes. A major modifier locus has been mapped in the mouse
near the centromere of chromosome 7, which produces a 'prolonged survival'
phenotype in CFTRlllllHsL null mice (Rozmahel et al, 1906), by strain interbreeding.
1.1.12 Larger model organisms
Larger mammals may provide better models for CF studies. The sheep, in particular,
has a number of advantages (Harris, 1997; Traber and Traber, 1989):
• Sheep are of similar size to humans.
• Sheep have a life span close to that of humans, this may be necessary for the
development ot the complex respiratory phenotype seen in human CF. The
longer lite span will also allow long-term studies to be performed.
• Sheep and humans have a similar cardiopulmonary system (Harris, 1997).
• The cloning of Dolly the sheep (Wilmut et al, 1997) and genetic engineering
of Polly, a transgenic sheep, (Schnieke et al, 1997) have opened up the
possibility of creating a sheep model of CF by targeting the CFTR gene for
knockout or mutation.
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• Because of their similarity to humans, the sheep may develop a lung
phenotype that closely mimics CF, where the mouse has not.
Flowever, the sheep has a number of disadvantages as a model organism, as well:
• Sheep are more expensive to keep, and larger volumes of reagents will be
required to treat the larger sheep tissues.
• Inbred sheep strains do not exist and one would expect modifier genes to be
present in the outbred population (in contrast to the genetically homogenous
mouse strains). While this may provide a more realistic model of the human
condition, these modifier genes may complicate the phenotype and increase
the variability of experimental results.
• Conversely, the longer life span of the sheep means that scientists will have
to wait longer for animals to reach maturity, in order to set up breeding
programs and utilise these adult animals for experiments. For example,
humans with CF are usually diagnosed at four years of age, thus once the first
CF sheep is produced it may be four years before we can establish whether it
displays a respiratory phenotype.
• The non-sterile living conditions in which sheep are currently housed may
lead to complications.
• There are additional ethical issues in sheep experiments, and it is more
difficult to obtain a license for such experiments.
It seems likely that both the traditional mouse models and larger mammal models
will play a role in future studies of Cystic Fibrosis.
1.2 Gene Therapy for Cystic Fibrosis
1.2.1 Rationale behind gene therapy for CF
One possibility for the treatment of cystic fibrosis is gene therapy: by introducing a
normal copy of the CFTR gene into epithelial cells of the lung, it may be possible to
direct expression of f unctional CFTR protein, and thus correct the respiratory defect
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(Beardsley, 1990). Several features of CF make this disease particularly amenable to
gene therapy (Douglas and Curiel, 1998; Alton et al, 1993). CF represents a
significant cause of mortality, for which there is no known cure, justifying the
development of additional therapies (Gaiso, 1998). The disease is monogenetic and
the genetic lesion is well defined, providing a clear target: augmenting cells with a
normal copy of the CFTR gene should be sufficient for a cure.
The human lung has a surface of 1-2 square meters, with successively branching
'fractal-like' structure (Fig. 1.5). The stem cells of the respiratory epithelium have
not been precisely identified, and it will undoubtedly be difficult to access these cells
for removal. Flence, an ex vivo approach would probably not be suitable (Rosenteld
et al, 1992; Midleton and Alton, 1998; Flotte et al, 2001). However, the airway is
relatively accessible for in vivo transfer: aerosol delivery of medicines successfully
treats respiratory diseases such as asthma. Nebulisation of the lung is an alternative
delivery method that may produce more efficient gene transfer to the respiratory
epithelium (Flotte et al, 2001).
The precise mechanisms by which CFTR mutations cause the debilitating lung
phenotype in CF remain unclear (see Section 1.1.6). It seems unlikely that the alveoli
will be the therapeutic target (Korst et al, 1995). The submucosal glands are the
predominant site of expression in the lung. However, high levels of expression do not
guarantee that these are the affected cell types: both the kidney and the heart express
high levels of CFTR, but do not display a phenotype (see Section 1.1.9). If
submucosal glands turn out to be the required target for CF gene therapy, it is
unlikely that airway administration will be successful: these cells might be more
successfully transfected by intravenous administration coupled with a method to
target this cell type (Middleton et al, 1998). However, the surface respiratory
epithelium of the proximal airways is the current focus as a target for gene therapy
studies, and these cells are relatively accessible for airway administration.
1.2.2 Gene Therapy vectors
The vectors used in gene therapy fall into two classes: viral and non-viral. Both
approaches have been considered to treat CF (reviewed in Davies et al, 1998).
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1.2.2.1 Viral vectors
Viral vectors exploit the natural ability of viruses to infect cells and drive expression
of their genetic material. For safety reasons, most viral vectors are made replication-
deficient, by removing some, or all of the viral genes required tor replication. The
first gene therapy vectors were based on retrovirus. However, these vectors only
infect dividing cells, and the respiratory epithelium displays a low level of
proliferation. In addition, retroviral vectors are unstable in the presence of serum and
it is difficult to produce these vectors in high titres. Thus, retroviral vectors may be a
poor choice for CF gene therapy.
More promising viral vectors are based on adenoviruses, which can infect cells that
are not proliferating, and have a natural tropism for the respiratory epithelium
(Rosenfeld et al, 1992; Crystal et al, 1994; Imleret al, 1996; Davies et al, 1998).
Adenovirus is thought to enter the cell by receptor-mediated endocytosis. The virion
then ruptures the endosome, gaining entry into the cytoplasm. Adenovirus infection
is not associated with malignancy, as the viral DNA docs not integrate into the host
genome, eliminating the risk of insertional mutagenesis. Natural adenovirus produces
an immune response, which could be particularly problematic for CF patients. In
addition, infection is usually short lived, often resulting in attenuation, thus
preventing administration of the same vector twice. Finally, adenovirus does not
infect columnar, and more differentiated cells of the airway: these may turn out to be
the therapeutic targets for CF. In first-generation adenoviral vectors, the early
immediate genes El a, El b and E3 were deleted, to prevent viral replication, these
vectors produced an immune response (see Section 1.2.5). In second-generation
adenoviral vectors, the E2a and E4 regions have been deleted, this appears to reduce
the immune response and may produce longer-lived expression. In third generation
adenoviral vectors, no viral genes remain: this should combat the issue of cell-related
immune responses. However, the problem of humoral immune response to the viral
caspid remains (Flotte et al, 2001).
Adeno-associated viruses (AAVs) might also be used as gene therapy vectors
(Douglas and Curiel, 1998). These share many of the advantages of adenoviruses, for
example, the tropism for the respiratory tract and the ability to infect non-dividing
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cells. Unlike adenovirus, AAVs may transduce multiple cell types. This type of
vector allows integration of DNA into the host genome, which may allow for longer-
lived expression, but conversely produces the possibility of insertional mutagenesis.
AAV virus requires adenovirus or herpes virus to replicate, and thus AAV vectors
should be naturally replication deficient (Flotte et al, 2001). Like retrovirus, AAV
can only be produced in low titers, and AAV transgene accommodation is limited
(4.5 kb maximum). AAV may not induce the immune response seen with adenovirus.
1.2.2.2 Non-Viral Vectors for gene therapy
Non-viral vectors, such as cationic liposomes, provide an alternative vehicle with
increased safety and reduced immunogenicity in contrast to viral vectors (Douglas
and Curiel, 1998; Goddard, 1997). These vectors accomplish DNA transfer by
membrane fusion, endocytosis, or other mechanisms. Non-viral vectors do not have
the advantage of millions of years of evolution to maximise entry into the cell, but
conversely, the cell has not had millions of years of evolution to adapt to preventing
their entry.
Bacterial plasmids are the primary vehicle used in non-viral gene therapy research.
These circular DNA molecules can be engineered to carry the gene of interest and
can be produced in bulk. In most circumstances, plasmids would remain episomal
following gene transfer. The plasmid will not undergo replication, thus repeat
administrations will be required as the therapeutic gene is diluted with successive
cell cycles. However, alternative approaches are being considered. For example,
several groups are investigating a 'gene correction' approach, where the endogenous
CFTR gene is targeted for repair through recombination with a primer, short DNA
fragment, or RNA/DNA hybrid 'chimeroplast' (Thorpe et al, 2002). Another
alternative is to create a human artificial chromosome (HAC) as a gene therapy
vector. This would be maintained in a similar fashion to an endogenous chromosome
(Saffery and Choo, 2002).
Initial experiments testing transfection of naked plasmid DNA into epithelial cells
have met with limited success (Holmes et al, 1999) Transfection reagents have the
potential to increase the efficiency of gene transfer. For example, liposomes (such as
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DOTAP), Saint-Mix™, Polyethylenimine, or the LID method may enhance
transfection (see Section 4.1 for more on these reagents).
In vivo, expression from plasmid vectors appears to be short-lived, beyond that
accounted for by dilution of the transgene through the cell cycle. This may be due to
inactivation of the transgene, exclusion of the transgene from the cell, or shedding of
transfected cells. This may be a specific response following recognition of certain
bacterial DNA sequences in the plasmid. Preliminary experiments have shown a lack
of attenuation to cationic liposome-DNA complexes, allowing the possibility of
repeat administration to prolong expression.
1.2.3 In vitro and ex vivo Experiments
In vitro experiments as early as 1990 have shown that introducing the normal human
CFTR cDNA into cultured cells drives cAMP-mediated CI- secretion. Drumm and
colleagues (Drumm et al, 1990) used amphotrophic retrovirus to transform CFTR
cDNA into the CFPAC-1 cell line (a pancreatic adenocarcinoma line from a CF
patient, which does not express CFTR). cAMP-dependent CI- secretion was
demonstrated by measuring intracellular I125 efflux, and whole-cell patch-clamp
technique, in transformed cells; this activity was not present in untransformed
controls. Gel blot hybridisation showed the presence of CFTR DNA in these cells,
and RNA blot hybridisation demonstrated the presence of CFTR mRNA. Hence, it
seems likely that expression of CFTR from the vector produced a functional CFTR
channel, responsible for the restoration of normal ion transport properties to the cells.
In addition, Rich and colleagues (Rich et al, 1990) showed that vaccinia-viral
mediated transfer of normal CFTR cDNA, but not AF508 CFTR cDNA, to cultured
CF airway cells restored normal electrolyte transport properties, as assayed by the
patch-clamp technique.
In order to study the percentage of cells that must express normal CFTR to achieve
functional correction, Johnson and colleagues (Johnson et al, 1992) transfected CF
airway cells with either CFTR or a reporter gene and mixed the cells in different
proportions, before seeding them to form confluent epithelial sheets. They found that
epithelial sheets containing only 6-10% corrected cells (expressing CFTR) had Cl-
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transport properties similar to sheets containing 100% corrected cells. They
speculated that this might be due to movement of CI- between cells in the epithelial
sheet, through gap junctions. This suggests that it might be possible to restore normal
lung function by correcting only a proportion of the cells in the lung with gene
therapy.
Finally, Zhang and colleagues (Zhang et al, 1998b) compared a recombinant
adenoviral vector with liposomal transfection of a plasmid expressing CFTR, to asses
the correction of two defects in a CF bronchial xenograft model: CI- transport and
mucous sulfation (see Section 1.1.6). They found that the adenoviral vector
efficiently transduced cells, driving a high level of CFTR transgene expression, and
correcting the CI- transport defect to 91% of non-CF levels. However, the mucous
sulfation defects were not corrected, apparently because adenovirus does not target
goblet cells. In contrast, liposomal transfection of a CFTR-encoding plasmid
produced lower expression levels, and only corrected CI- transport to 7.4% of non-
CF levels. However, liposomal transfection efficiently reduced mucous sulfation.
These findings reveal that different vectors have different complementation profiles,
and that a low level of CFTR expression may suffice to correct some of the CF
airway defects.
1.2.4 Animal experiments
The development of CF mouse models has been a watershed in the study of CF, and
these models have played a key role as an intermediary between in vitro experiments
and human trials of gene therapy (see Section l. I. I I). Delivery of a CFTR
plasmid/liposome complex to the respiratory epithelium of mice resulted in CFTR
mRNA expression in the lung (including large and small airways). Delivery of this
complex to the airways of CFTRtnl2Cani mice restored the defect in cAMP-stimulated
CI- secretion in the tracheae of these mice (Hyde et al, 1993). In a similar fashion,
the DOTAP liposomal reagent was successful in restoring the electrophysiological
defect in CF mutant mice (McLachlan et al, 1996). Alton (Alton et al, 1993) showed
that delivery of human CFTR cDNA-DC-Chol/DOPE liposomal complex by
nebulisation to the airways of the CFTR,mlHGU mouse restored the presence of CFTR
mRNA, at a range of levels (averaging 50% of wt levels). This was superior to
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instillation of the complex, which only produced modest correction. A restoration of
CI- transport properties was also demonstrated in the nasal and tracheal epithelium,
by measuring potential difference (PD)1.
Dorin and colleagues (Dorin et al, 1996) crossed mice with the CFTRlmlL NC allele
and the cprpRtmlHGU allele, to produce mice that expressed different levels of CFTR.
The cp-pRtmlUNC/ CFTR11"1 hgu compound heterozygote expressed 5% of normal
levels, while CFTRtmlUNC/wt, expressed 50%, and CFTRtmlHGU/wt expressed 55%.
This experiment demonstrated a non-linear relationship between phenotype and gene
activity: they found that 5% of the normal levels of CFTR mRNA were sufficient to
restore 50% of the normal CI- transport, and essentially rescue the intestinal disease
phenotype. This further justifies human gene therapy trials, as it lends strength to the
hypothesis that only a fraction of gene activity must be restored to the lung to
achieve normal lung function. In sum, these experiments have provided a strong
premise for gene therapy trials in CF patients.
1.2.5 Clinical Trials
Human gene therapy trials for CF include three successive phases: phase I trials test
the safety of the therapy, phase II trials test efficacy in a small groups and phase III
trials show efficacy in a larger group, confirming the suitability of the therapy for
regular use. CFTR delivery has been tested in phase I trials in the nasal and lung
epithelia.
'
PD measures the change in voltage, which is affected by the flow of ions across the
cell membrane. cAMP-dependent chloride secretion can be measured by first
administering amiloride, which blocks sodium channel activity, causing a reduction
in the levels of potential, then administering forskolin, which stimulates cAMP, and
thus acts as an agonist for CFTR CI- secretion (see Section l. 1.4). In CF cells, there
is no response in PD following the administration of forskolin, as no chloride flow
through CFTR can be induced, whereas normal cells respond with an increase in
potential difference.
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A trial by Zabner and colleagues (Zabner et al, 1993) demonstrated transfer of a
replication deficient adenovirus to the nasal epithelium of CF patients. This tissue
was chosen for the trial because it had a morphology and function similar to the lung
epithelia and manifested the CF CI- transport defect. In addition, the nasal epithelium
was more accessible than the lung and minimised the risk to the patient if an adverse
reaction should occur. Gene delivery resulted in a partial restoration of CI- transport,
as measured by nasal voltage change following the addition of amiloride and then
cAMP agonists. In addition, CFTR transcripts were detected by RT-PCR. In this
trial, there was no evidence of viral replication or virus-associated adverse effects.
In another study by Crystal and colleagues (Crystal et al, 1994), adenoviral vector
expressing the CFTR cDNA sequence was introduced into the nasal and bronchial
epithelium of CF patients. Preliminary experiments in animals had demonstrated no
change in clinical safety parameters, although there was a moderate inflammatory
response. Nasal administration to CF patients produced no adverse response.
Adenoviral CFTR DNA and mRNA were detected in nasal brushings, and CFTR
protein was detected in some cells by antibody staining. However, following
bronchial administration to CF patients, a substantial transient systemic and
pulmonary syndrome was observed. This serious side effect has cast doubt on the
suitability of viral vectors for C.F gene therapy.
Many CF gene therapy investigators have responded to this adenoviral-induced
immune response by switching to a non-viral vector. Caplen and colleagues (Caplen
et al, 1995) attempted to deliver a liposome/CFTR complex to the nasal epithelium.
PCR products (specific to the introduced CFTR copy) were amplified from nasal
biopsies. RT-PCR confirmed I he presence of a CFTR transcript specific to the vector
in samples from several patients. In vivo nasal PD demonstrated some restoration of
normal ion transport properties, with some measurements reaching the non-CF range.
Most importantly, there was no evidence of treatment-related toxicity. Similar
studies by Gill and colleagues (Gill et al, 1997), and Porteous and colleagues
(Porteous et al, 1997) have demonstrated transgene expression and restored Cl-
transport in the nasal epithelium following treatment with liposome/CFTR plasmid
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complexes, with no related immune response. Hence, non-viral vectors may provide
a better prospect for further gene therapy trials.
However, in a later trial by Alton and colleagues (Alton et al, 1999), administration
of a CFTR-cDNA/GL-67 liposomal complex to the nasal or bronchial epithelium of
CF patients caused mild, influenza-like symptoms in seven out of eight patients
receiving the treatment, and six out of eight patients in both the treatment and
placebo groups reported mild airway symptoms. While both effects were mild and
resolved spontaneously, this underlines the need to investigate safety parameters and
refine gene therapy treatments to non-toxic formulations, even amongst non-viral
therapies. The CFTR-cDNA/GL-67 treatment produced a significant correction in
the CI- transport properties (as measured by PD and chloride efflux ) and bacterial
adherence was reduced.
1.2.6 Hurdles to CF gene therapy
Early studies have identified a number of difficulties directly relating to gene transfer
(Davies et al, 1998; Flotte et al, 2001). The cell has evolved multiple barriers to
prevent entry of foreign particles. A successful vector for gene therapy must show
proficiency in:
• Crossing the mucus at the cell surface
• Crossing complex cell surface structures such as cilia
• Achieving cell entry (e.g. by endocytosis)
• Escaping the endosome, to enter the cytoplasm, if necessary
• Entering the nucleus
• Driving CFTR expression
If gene therapy for cystic fibrosis is to become a reality, several issues will need to be
resolved. Most importantly, there is the issue of safety: the vector must not induce an
adverse immune or other morbid response in the patient. In addition, if a viral vector
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is used, the possibility that this vector may somehow reproduce and infect other
tissues in the patient or other individuals, especially the germ-line, must be guarded
against. Clinical studies of CF gene therapy are facilitated by the fact that CF males
are infertile (see Section 1.1.2), thus germ-line gene transfer is not as problematic. As
most current vectors for gene therapy show only transient expression, it will be
necessary to alter the vector for more prolonged expression, or design a vector which
is suitable for repeat administration. Attenuation to re-infection is a feature of viral
vectors, however, Goddard and colleagues have shown that a repeat dose of liposome
is as affective as the first in delivering CFTR cDNA to the mouse trachea, and in
correcting cAMP-dependent CI- secretion in this tissue (Goddard et al, 1997).
Although low levels of expression and expression in a small portion of the cells may
be sufficient to correct the defect in CI- secretion, a complete restoration of the ion
transport properties (e.g. correction of the sodium hyperabsorption characteristics)
may require a more comprehensive restoration of gene activity (Douglas and Curiel,
1998). Thus, the efficiency of transgene delivery and expression may have to be
increased by the development of improved vectors and delivery systems. Finally,
there is evidence that expression of CFTR at excess levels (Stutts et al, 1993; Wei et
al, 1995; Schiavi et al, 1996, Mohammed-Panah et al, 1998), or in inappropriate cell
types (Ye et al, 2001) is deleterious. More research is required to elucidate the
affected cells that cause CF lung disease, and to target these cells in gene therapy,
either at the level of cell entry or at the level of gene expression. A logical solution
would be to use sequences from the natural CFTR promoter to drive gene expression,
as opposed to the heterologous constitutive promoters (usually derived from a virus),
which have been used in most gene therapy trials so far (Boyd et al, 1999b): this is
the rationale behind 'genomic context vectors' (GCVs) for CF gene therapy.
In the quest for better gene therapy vectors, it will be necessary to use reporter genes
to monitor expression. This report investigates one such reporter gene: Enhanced
Green Fluorescent Protein (EGFP).
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1.3 EGFP as a reporter gene
Previously, reporter genes such as LacZ (Imler, 1996; Boyd et al, 1999a), luciferase
(Smith, AN et al, 1996a; Mogayzel and Ashlock, 2000), and CAT (Chou et al, 1991)
have been used to assay expression from the CFTR promoter. New reporter gene
constructs, based on the Green Fluorescent Protein (GFP) may prove to be a valuable
supplement to this list.
1.3.1 The GFP gene
Green Fluorescent Protein was isolated from the jellyfish Aquorea victoria and is a
naturally fluorescing protein, which absorbs light in the blue region of the spectrum
(-470 nm), and emits light in the green region of the spectrum (with a peak at -509
nm, and a shoulder at -540 nm). The spectral properties of GFP are achieved by a
hexapeptide repeat, which starts at the 64th amino acid of the GFP protein. The
primary sequence of the protein in this region results in cyclisation of serine-
dehydrotyrosine-glycine, producing an active chromophore (or fluorophore), which
produces the fluorescence (Stauber et al, 1998). The protein forms a cylinder, made
up of i 1 strands of (3-sheet on the outside, and an a-helix on the inside; GFP was the
first protein to be identified with this novel arrangement of domains, named a '(3-can'
(see Fig. 1.6). The fluorophore is contained on the inside of the cylinder (Yang et al,
1996).
GFP offers several advantages over more traditional reporter genes (Chalfie et al,
1994; Marshall et al, 1995; Albano, 1998; Lo et al, 1998). Because GFP fluorescence
does not require any cofactors or substrates, complicated assay procedures are
avoided. In addition, the protein is very stable, creating a lasting signal for detection,
and background signal is low. GFP can be visualised without fixing or
permeabilising cells, thus expression can be studied in live cells, along a time-course,
or with a change in conditions (Albano, 1998; Persons et al, 1998). One report
provides evidence that GFP might evoke an immune response (Stripecke et al, 1999).
However, transgenic animals expressing GFP are viable, suggesting that this reporter
gene is suitable for in vivo studies (Chiocchetti et al, 1997).
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Figure 1.6. The Structure of Green Fluorescent Protein.
Eleven p-sheets (green) form the outside of the cylinder, with a-
helices (blue) on the inside, in a 'P-can' arrangement. The
fluorophore (yellow) lies at the center of the cylinder. This
diagram was adapted from Yang et al, 1996.
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Generation of enhanced GFP mutants, with increased fluorescence intensity, and
mutants with shifted emissions spectra (to make red, yellow, and blue fluorescent
proteins) have expanded the applications of this reporter gene (Anderson et al, 1996;
Stauber et al, 1998; Clontech website). Several reports have demonstrated N- and C-
termina! protein fusions with GFP, without compromising the spectral properties of
GFP, or the localisation or functional properties of the fused protein (Kain et al,
1995; Marshall et al, 1995; Pines, 1995; Lo et al, 1998).
Alternatively, transcriptional fusions may be created where the genes are separated
by an internal ribososme entry site (IRES), to allow separate translation of proteins
from a single mRNA. IRES function was originally identified in picornvirus RNA
translation (Jackson et al, 1990). The long length and predicted secondary structure
of the picornvirus 5' UTR appears to be incompatible with the traditional ribosome
scanning mechanism (where the ribosome binds at the 5' end of the mRNA). Thus,
an alternative method must be employed to initiate translation. A 450-bp sequence
from picornvirus 5' UTR was shown to confer IRES function, allowing ribosomes to
bind to an internal RNA segment to initiate translation.
This IRES has practical uses in molecular biology. For example, Levenson and
colleagues (Levenson et al, 1998) successfully used an IRES to drive GFP
expression. They created a dicistronic construct encoding a regulated gene cassette
followed by an IRES and then GFP. As the two genes were transcribed in a single
mRNA before being translated separately, they were able to use GFP fluorescence to
accurately model the expression pattern of the upstream gene. This would not have
been feasible if these genes had been included in separate operons.
The Clontech promoterless enhanced green fluorescent protein (EGFP) vector
pEGFP-l was designed to test regulatory elements by cloning them into the multiple
cloning site (MCS) upstream of the EGFP reporter gene. This approach will allow us
to analyse the regulatory effects of CFTR 5' sequences. In addition, the
pIRES2EGFP vector will allow the assembly of transcriptional fusions with CFTR,
allowing the inclusion of intronic regulatory elements, in their natural context
(Clontech website).
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Several other reports strengthen the rationale for using GFP as a reporter gene in
studying CFTR promoter elements. Dunn and Handelsman (Dunn and Handelsman,
1999) demonstrated the use of a promoter-trapping EGFP reporter plasmid, to
identify regulatory regions. Kolossov and colleagues (Kolossov et al, 1998)
demonstrated tissue-specific expression of GFP, driven by the chicken alpha-actin
and beta-actin promoters. This confirms that it is appropriate to use the GFP reporter
to study the effects of regulatory elements. Marshall demonstrated co-transfection of
a GFP-expressing plasmid with a plasmid encoding an ion channel (Marshall et al,
1995). This facilitated identification of transfected cells; GFP did not seem to alter
the properties of the co-expressed ion channels. Moyer and colleagues (Moyer et al,
1998) transfected cells with a vector encoding a GFP-CFTR fusion protein: GFP
retained its fluorescent properties and CFTR appeared to retain its ion transport
properties. Thus, transfection with a GFP-expressing vector in itself should not alter
the ion transport properties of transfected cells.
The suitability of GFP vectors for CF gene therapy studies must be assessed. One
report (Bartlett and Samulski, 1998) discussed the use of fluorescently labelled
vectors for gene therapy, to identify the types of cells that are being transfected. A
GFP-expressing vector under the control of a CFTR promoter could go even further
in demonstrating whether the correct cell types can be targeted and signaled to
express a transgene following administration to the lungs.
1.3.2 FACS analysis
Fluorescence activated cell sorting (FACS) is a powerful tool for analsying
expression of the GFP gene. In this method, cells are passed through a cytometer. As
each cell enters the chamber, a laser is shone upon it, and the forward scatter (FSC) -
a measure of cell size, side or orthogonal scatter (SSC) - a measure of cell
complexity or granularity, and fluorescent emissions FLl-H (530-560 nm; green
fluorescence), FL2-H (570-610 nm; orange fluorescence) and FL3-H (610 nm +; red
fluorescence) are measured (Stanford 5-minute guide to Flow cytometry website;
Cancer Research UK FACS laboratory website). The data for all ceils may then be
assembled to produce histograms or dot-plots based on the FSC, SSC and FL-H
parameters. Thus, a detailed profile is generated for the sample population.
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Traditionally, histogram analysis has been used to dissect the proportion of cells
expressing GFP, and the average fluorescence intensity of the transfected population,
which is a measure of the level of GFP expression (this is discussed this in greater
detail in Chapter 3). FACS has also been used to detect fluorescent antibody staining.
1.4 Project aim: Towards gene therapy for cystic fibrosis: Enhanced
Green Fluorescent protein as a reporter of CFTR promoter activity.
The aim of the project was to analyse the suitability of Green Fluorescent Protein as
a reporter of CFTR promoter activity. The enhanced Green Fluorescent Protein
(EGFP) version was selected: this GFP variant produces brighter fluorescence than
the original GFP. EGFP corresponds to the GFPmutl variant, which contains a
double-AA substitution (Phe -> Leu at residue 64, Ser -> Thr at residue 65), as well
as silent basepair changes that optimise EGFP for human codon usage (Cormack et
al, 1997; Clontech website). EGFP is ~35-foId brighter than wtGFP. This choice was
primarily dictated by the availability of the Ciontech pEGFP-l and pfRES2EGFP
plasmids, which allow easy assembly of reporter constructs (Clontech website).
Towards this end, a series of constructs have been assembled, incorporating proximal
or distal CFTR 5' regions, and/or the CFTR intron I region, and the EGFP reporter
gene. A foldout diagram has been included in Appendix E, for easy reference while
reading this thesis. A full description of these vectors is given in Chapter 3. Briefly,
p I kbcfproEGFP contains 797 bp of the region 5' of the CFTR gene, driving EGFP
reporter gene expression; PAc65kbcfproEGFP contains 65 kb of CFTR 5' region
driving EGFP expression: these vectors were created to allow us to assess the effects
of proximal and distal 5' regulatory elements upon expression. The pacRC l iresEGFP
and PAcRC2iresEGFP vectors both contain 65 kb of 5' region and the coding
sequence of CFTR, followed by an IRES and then EGFP. The latter contains CFTR
intron I whilst the former does not; this allows us to assess the effects of intron l
upon expression. The vectors pCFTRiresEGFP and PAcRC2cmvEGFP were created
as controls. These vectors allowed us to investigate the ways in which initiating
transcription from an IRES, or including the reporter gene in a large PAC vector will
influence expression.
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The small plasmids were made by conventional cloning, while the large PAC vectors
were created by a double recombination method (Boyd et al, 1999b, described in
Chapter 3) incorporating both Cre/loxP and homologous recombination. Cre is a 38
kDa protein, derived from bacteriophage PI, which catalyses site-specific
recombination between two loxP sites. This recombination may be intramolecular,
e.g. between two loxP sites within a single DNA molecule or intermolecular, e.g.
between two loxP sites on separate DNA molecules (the latter is employed in the
double recombination method). The loxP site is comprised of two 13-bp inverted
repeats (ATAACTTCGTATA), separated by an 8-bp asymmetric spacer region
(ATGTATGC), which determines the directionality of the loxP site. Two molecules
of Cre bind at each loxP site (one per inverted repeat), these catalyse a recombination
event in the 8-bp spacer region (Sauer, 1993).
In order to facilitate transfection studies, several transfection reagents were
compared. The liposome DOTAP has met with previous success during in vitro and
in vivo studies (McLachlan et al, 1995 and 1996) and in a clinical trial (Porteous et
al, 1997). The Saint-Mix™ reagent, which combines synthetic amphiphile with
DOPE, has been purported to demonstrate low cytotoxicity and a high efficiency of
gene transfer (Saint B.V. website). A Polyethylenimine (PEI) method condenses
DNA for efficient delivery to cells (Personal communication from Matt Cotton;
Thorpe et al, 2002). The LID method, described by Dr. Steve Hart, Institute of Child
Health, London incorporates the liposome Lipofectin and the integrin-targeting
peptide P6 (Hart et al, 1995). Linally, a new method was developed for this study;
the 'SID' method combines the Saint-Mix™ reagent with the integrin-targeting
peptide used in the LID method. Hence, a panel of very different transfection
reagents was compared to optimise transfection efficiency in the COS-7, MDCK-
iowa, Caco-2, T84, and HBE cell lines (this is discussed in Chapter 4). EGLP
expression was detected by LACS: a dotplot analysis method was found to be
superior to the traditional histogram analysis method for the needs of this study.
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Following these optimisation studies, the LID transfection reagent was used to
transfect EGFP vectors into permanent cell lines, in order to dissect the effects of the
various CFTR genomic context elements upon expression (see Chapter 5). The large
PAcRC2cmvEGFP vector was compared to the small pEGFP-N plasmid, to dissect
the effects of vector size upon expression. This led to an investigation of the effects
of vector copy number and plasmid mixing upon expression, with some surprising
results.
Cell lines form a good starting point for gene therapy studies but are not an ideal
model for CF gene therapy. Thus an ex vivo culture system was chosen as a more
realistic model for these studies (Chapter 6). Primary sheep tracheal cells were
cultured at air-interface. These cultures were characterised by transepithelial
resistance, and scanning and transmission electron microscopy, and demonstrated
features of the native trachea. The SID and LID methods were compared for
transfecting these predominantly epithelial cultures. Finally, some of the EGFP
vectors were transfected into these primary culture using the LID method.
This thesis will demonstrate that EGFP is an excellent reporter gene for studying
CFTR promoter elements. The ability to detect EGFP with FACS opens new doors in
analysing expression. With FACS it is possible to dissect the number of cells
expressing EGFP and quantitatively measure the average fluorescence intensity of
this population, which appears to be a linear measure of the level of EGFP
expression (Subramanian and Srienc, 1996). A dual dotplot analysis, based on
comparing a cell's FL1-H and FL2-H fluorescence, increases FACS sensitivity:
allowing detection of a single fluorescent cell in a sample of 10,000 cells, or greater.
This is superior to detection of the (3galactosidase reporter gene: protein assays
measure the amount of (3galactosidase in a cell lysate sample, which does not
distinguish between the numbers of cells expressing and the expression levels per
cell, while staining assays show only the number of cells expressing the transgene
but do not give a quantitative measure of the levels of expression. Other reporter
genes are limited by assays with similar weaknesses. In addition, protein and staining
assays for reporter genes such as [3galactosida.se may be frustrated by a high
background, while the FACS dual dotplot analysis provides a fairly robust distinction
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of transfected cells expressing all but the lowest levels of EGFP. This is particularly
useful for studies of weak CFTR promoter activity, where expression levels are
likely to be low. In sum, EGFP has shown unique strengths as a reporter gene in
these transfection studies and will be a suitable reporter for future experiments
studying CFTR promoter elements and the mechanics of gene transfer.
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2.1 General methods
2.1.1 Handling PAC DNA
PAC DNA was always pipetted through cut-off tips (pipettman tips which had been
widened by cutting approximately 0.5 cm off the end with a scalpel). PAC DNA was
never vortexed or heated above 50 °C as this could shear or denature the delicate
PAC molecule.
2.1.2 Measuring DNA concentration on a spectrometer
l pi of the DNA sample was diluted with 99 pi of water, and placed in a Pharmica
GeneQuant 100-pl cuvette. The OD26o was measured on a Pharmica GeneQuant
RNA/DNA calculator spectrometer. The DNA concentration of the original
(undiluted) sample was calculated with the formula:
Concentration in mg/ml = 5000 x OD260
The DNA concentration was roughly confirmed by electrophoresis down an agarose
gel, next to known masses of DNA.
2.1.3 Restriction enzyme reaction
1 pg of DNA was mixed with 2 pi of the appropriate I OX buffer (provided by Roche
or NEB, with the restriction enzyme), 0.2 pi of BSA, if required, and water, to make
a final volume of 19 pi, in a 1.5-ml microcentrifuge tube (Sarstedt Ltd. cat# 72.690).
The tube was flicked to mix the contents, and the liquid was spun down in a
picocentrifuge. 1 pi of the appropriate restriction enzyme (Roche or NEB; containing
3 to 10 U/pl, depending on the enzyme) was then added to the DNA/buffer mixture.
The enzyme was aspirated and dispensed gently just under the liquid surface to avoid
denaturing the delicate protein. The tube was gently flicked to mix the contents and
the liquid was spun down in a picocentrifuge. The mixture was incubated at 37 °C
for 24 hours. The ingredients were scaled up to digest larger masses of DNA.
2.1.4 Phosphatase
Digested DNA was treated with HK Phosphatase enzyme (IU/pl, Cambio, cat
#H92050) according to the manufacturers instructions.
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2.1.5 Ligation
Linearised plasmid was mixed with the insert fragment in the desired ratio, in a l .5-
ml microcentrifuge tube. I jul of 10X T4 ligase buffer (Roche) was added, and water
was added to make a final volume of 9 pi. The tube was flicked to mix the contents,
and the liquid was spun down in a picocentrifuge. I pi of T4 ligase enzyme (l U/|ll,
Roche cat#716 359) was added to this mixture; the enzyme was aspirated and
dispensed gently just under the liquid surface to avoid denaturing the delicate
protein. The mixture was incubated in a 4 °C water bath for 24 hours.
2.1.6 Cre/LoxP reaction
PAC DNA was mixed with the insert fragment in the desired ratio, in a l ,5-ml
microcentrifuge tube. I pi of buffer M (Roche, see Recipes) was added, and then
water was added to make a final volume of 9.5 pi. The tube was flicked to mix the
contents, and the liquid was spun down in a picocentrifuge. 0.5 pi of Cre enzyme
was added to this mixture. The enzyme was aspirated and dispensed gently just under
the liquid surface to avoid denaturing the delicate protein. The mixture was incubated
in a 30 °C water bath for one hour to allow recombination to occur.
2.1.7 Disk dialysis
A petri dish was filled with distilled water. A 0.025 pm, 25 mm white nitrocellulose
filter (Millipore, cat #VSWP02500) was floated on the water. 1-5 pi aliquots of
DNA were gently dispensed onto the membrane. Dialysis was allowed to proceed
for 5-15 minutes; the DNA was then gently removed from the membrane with a
pipettman.
2.1.8 Pouring agarose gels for electrophoresis
The required mass of agarose (Agarose type II, medium EEO, Sigma, cat # A-6877;
or LMP agarose, GIBCO BRL, cat # 15517-022) was mixed with 50 ml of TBE or
TAE buffer (see Recipes) in a 200-ml conical flask. The solution was microwaved at
50% power until the agar had completely dissolved. The flask containing the agar
solution was cooled in a 50 °C water bath for 10 minutes. 2 pi of ethidium bromide
solution (lOmg/ml BioRad 161-0433) was added to the agar, if required, and swirled
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to mix. The gel was then poured into a tray (tape was placed over the top and bottom
edges of the tray, to contain the gel), and a comb was inserted; the gel was allowed to
set at 4 °C, to expedite the cooling process. Once the gel had set, the tape was
removed from the top and bottom edges of the tray (to allow current to contact the
gel) and the comb was gently removed to produce sample wells. The mixture was
scaled up when necessary, to make larger gels.
2.1.9 Electrophoresis
Drops of Ficoll loading buffer (approximately 1 |ll of buffer per 5 jil sample volume)
were dispensed onto parafilm. Each DNA sample was applied to a drop of loading
buffer, and pipetted up and down to mix. The sample was then carefully loaded into
a well in the agarose gel. DNA size markers were loaded alongside the samples, to
provide a size reference.
The gel was placed into an electrophoresis tank containing enough buffer (TBE or
TAE, corresponding to the buffer in the gel) to just cover the gel. Positive and
negative electrodes were connected to a power pack (negative at the top, next to the
sample wells in the agarose gel, and positive at the bottom), and a current of between
20 and 100 V was applied to the apparatus, until the DNA had run a sufficient
distance down the gel.
2.1.10 Ethidium bromide staining
The agarose gel was placed in a shaking bath containing ethidium bromide solution
(2 jul of Bio-Rad lOmg/ml ethidium bromide stock in 50 ml of water). The gel was
stained at room temperature for 15 minutes, with gentle agitation. The gel was then
transferred to a shaking bath containing water, and de-stained for five minutes, with
gentle agitation, before transferring the gel to the EfV transilluminator.
2.1.11 Southern Blot
PCR products were electrophoresed on an agarose gel and stained with ethidium
bromide, as described above. The migrated DNA bands were visualised under the
UV transilluminator, to document migration of the size markers for later reference.
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The gel was placed in a shaking bath of Denature solution (see Recipes) for 15
minutes, then in a shaking bath of Neutraliser solution (see Recipes) for 15 minutes.
The gel was briefly washed in water, then 2X SSC solution. Subsequently, the gel
was placed on top of two pieces of thick blotting paper on a glass plate suspended
above a tank. The edges of the lower piece of paper dipped into the 20X SSC in the
tank below, to act as a wick. A piece of Hybond-like filter (React Scientific, cat
#NOOHYA0010) was cut to the size of the gel, dipped in 2X SSC and placed on top
of the gel (care was taken to remove any bubbles). Three pieces of thin blotting
paper (cut to size, also dipped in 2X SSC), and then a thick layer of dry paper towels
followed this. Finally, a second glass plate was placed on top and two 500-ml bottles
full of water were used to weigh this down. Fig. 2.1 shows a diagram of the Southern
Blot apparatus.
The apparatus was left overnight to allow the DNA in the gel to migrate through the
resulting SSC gradient into the Flybond-like filter. The filter was removed and
allowed to air-dry, then auto-cross linked in a Stratagene UVStratalinker 2400.
2.1.12 Hybridisation with32P-A TP labelled oligonucleotides
All radioactive work was performed in a designated area; monitoring and disposal of
radioactivity was performed according to the guidelines set out by the UK National
Radiological Protection Board.
Hybond-like filters from a Southern Blot were placed between pieces of gauze in a
hybridisation bottle. 15 ml of Hybridisation mix (see Recipes) was added, and the
bottle was pre-warmed in a rotating oven to the desired temperature for hybridisation
(usually 5°C below the oligonucleotide annealing temperature).
Polynucleotide Kinase (PNK) (Roche, cat #174645) was used to label
oligonucleotides with 3~P-ATP. 20-50 ng of oligonucleotide was mixed with 2 pi of
PNK buffer, I pi of PNK (lOU/pl ) and water to make a final volume of 20 pi, in a
1.5-ml microcentrifuge tube. 1-3 pi (10-30 pCi) of 32P-ATP was added to this
mixture at a designated radiation workstation. The mixture was incubated at 37°C
for 30-40 minutes and then added to the bottle containing the Hybaid filters. The
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bottle was returned to the rotating oven, and incubated for approximately 24 hours to
allow hybridisation to occur.
The following day, the hybridisation mix (containing oligonucleotides that had not
hybridised to the filters) was poured down the sink. The filters were washed in a
0.1 % SDS, 2X SSC solution for 5 minutes. Subsequent washes were performed with
solutions containing decreasing concentrations of SSC, until distinct signals of
radioactivity could be discriminated from background on the filters, as determined by
a Geiger counter.
The filters were placed between layers of saran wrap in a lead-lined X-ray cassette
for exposure of X-ray films, or in a lead-lined phosphoimager cassette.
2.1.13 Hybridisation with 32P-CTP labelled PCR products
Nitrocellulose filters from colony lifts were placed between pieces of gauze in a
hybridisation bottle and 15 ml of Hybridisation mix (see Recipes) was added. The
bottle was pre-warmed in a rotating oven at 68 °C.
50-100 ng of PCR product was mixed with water to make a final volume of I 1 pi, in
a 1.5-ml microcentrifuge tube. A hole was made in the top of the microcentrifuge
tube with a needle, to prevent the tube from opening due to increasing pressure
during the subsequent heating procedures. The tube was placed in a hot block at
100°C for 10 minutes to denature the PCR product.
3 pi (30 pCi) of 3"P-CTP and 4 pi of High Prime (Roche, cat #1585592) were added
to the tube containing the PCR product, at a designated radiation workstation. The
tube was then transferred to a 37 °C water bath and incubated for 20 minutes to allow
High Prime labelling of the PCR product.
To ensure that the PCR product had been labelled, approximately 0.5 pi of the
mixture was applied to a Whatmann GF/B 25mm filter (SLS, cat #FIL4204). The
filter was then monitored with a Geiger counter, washed with 5% trichloroacetic acid
(TCA), and then monitored again: if >50% of the radioactive signal remained after
the wash, this indicated successful High Prime labelling.
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Next, 100 |il of TNE (see Recipes) was added to the radioactively-labelled PCR
product. The mixture was transferred to a hot block at 100 °C, to denature the PCR
product, for 10 minutes. Subsequently, the mixture was added to the bottle
containing the nitrocellulose filters, and incubated in a rotating oven at 68 °C
overnight, to allow the PCR product to hybridise to the nitrocellulose filters.
The following day, the hybridisation mix (containing PCR product that had not
hybridised to the filter) was poured down the sink. The filters were washed in a 0.1 %
SDS, 2X SSC solution for 5 minutes. Subsequent washes were performed with
solutions containing decreasing concentrations of SSC, until distinct signals of
radioactivity could be discriminated from background on the filters, as determined by
a Geiger counter.
The filters were placed between layers of saran wrap in a lead-lined X-ray cassette
for exposure of X-ray films, or in a lead-lined phosphoimager cassette.
2.1.14 GELase digestion of agarose gel slices
DNA was electrophoresed down an LMP gel (made with TAE buffer and containing
ethidium bromide). Slices containing the desired DNA bands were excised from the
gel under a UV transilluminator. Agarose gel slices were digested with GELase
enzyme (0.2U/(il; Epicentre Technologies, cat #G3l 100) according to the
manufacturer's instructions, with the following modifications: gel slices were melted
at a temperature of 68 °C, and digestion was performed at a temperature of 42 °C.
2.1.15 Plasmid-safe DNase
Plasmid-safe ATP-dependent DNase (10U/|il; Epicentre Technologies, cat #E3l0lK)
digestion was performed according to the manufacturer's instructions. Incubation
was performed overnight at 37°C. The enzyme was either inactivated by heat
denaturising (as per packet instructions) or removed by phenol-chloroform extraction
(for PAC DNA only phenol-chloroform extraction was used as large PAC DNA
would have been destroyed by heat inactivation). Following phenol-chloroform
extraction, the DNA was ethanol precipitated to ensure the complete removal of
residual phenol.
Chapter 2: Materials and Methods 30
2.1.16 Polymerase chain reaction (PCR)
Reagents were mixed in the following proportions:
DNA template l to lOOng
dNTPs(lOmM) I pi
l OX Buffer 10 pi
DMSO 10 pi
Primer #1 (100 ng/pl) 1.5 pi
Primer #2 (100 ng/pl) 1.5 pi
Taq polymerase 0.2 pi
Water to make a final volume of 50 pi
Sigma Taq DNA polymerase (5 U/pl; Sigma, cat #D-6677) was used for most
reactions; the Expand™ High Fidelity PCR system (3.5 U/pl; Boehringer Mannheim,
cat #1732650) was used where specified. The template was added last to prevent
contamination of negative controls. When multiple reactions were being set up, the
mixture was made up in bulk, and then aliquoted. Reactions were set up in either 0.5-
ml microcentrifuge tubes (Sarstedt Ltd. cat# 72.735.002), or 96-well plates (96-well
plate covers were washed with ethanol and water, then sterilised by 15 minutes of
UV exposure in the Stratagene UVStratalinker 2400).
PCR was performed on an MJ Research PTC-225 or PTC-200 Peltier thermal cycler.
The following programs were used:
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'CF5491PCR'
(for construction of papRCI iresEGFP, pApRC2iresEGFP and pArRC2cmvEGFP)
STEP 1 94°C - 0:10
STEP 2 55°C - 1:00
STEP 3 72°C - 2:00
STEP 4 go to step 2, 29 times
STEP 5 94°C 3:00
STEP 6 4°C for ever
'65PCR' (for colony PCRs)
STEP1: 95°C - 1:30
STEP 2: 95°C - 0:30
STEP 3: 65°C - 1:00
STEP 4: 72°C - 1:00
STEP 5: go to step 2, 29 times
STEP 6: 4°C for ever
'60PCR' (for colony PCRs)
STEP1: 95°C - 1:30
STEP 2: 95°C - 0:30
STEP 3: 60°C - 1:00
STEP 4: 72°C - 1:00
STEP 5: go to step 2, 29 times
STEP 6: 4°C for ever
'(3gaF (for ftgalactosidase and GAPDH RT-PCRs)
STEP 1 94°C - 5:00
STEP 2 95°C - 0:30
STEP 3 50°C - 0:10
STEP 4 72°C - 4:00
STEP 5 go to step 2, 29 times
STEP 6 4°C for ever
'GFP' (for GFP RT-PCRs and colony PCRs)
STEP 1 96°C - 1:30
STEP 2 94°C - 0:30
STEP 3 52°C- 1:00
STEP 4 72°C - 1:00
STEP 5 go to step 2, 29 times
STEP 6 4°C for ever
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2.1.17 Hot-start PCR
The hot-start PCR protocol was designed to enhance amplification from small
amounts of DNA (Chou et al, 1992). Heating the template DNA and primers
separately, then combining them for PCR while they are still hot reduces mispriming
and primer dimersiation. This protocol is useful to amplify DNA from large PAC
templates where the possibility of mispriming may be enhanced, due to the presence
of sequences similar to the primer-annealing site in this larger template molecule.
This protocol may also be useful when using large primers, or primers with a
predicted secondary structure (e.g. the loxP primer), to prevent annealing between or
within primers.
For hot-start PCR, a reaction mixture was made up as described above, omitting the
template DNA, and reducing the amount of water, to make a final volume of 25 pi
per reaction. This mixture was made up in bulk in a 0.5-ml microcentrifuge tube. For
each reaction, I0-100 ng template DNA was mixed with water to make a final
volume of 25 pi per reaction in a 0.5-ml microcentrifuge tube. The individual tubes
of template DNA (one per reaction) and tubes containing the bulk reaction mixture
were placed in the PCR block, and the following program was run:
'HOTSTART' (for construction of pi kbcfproEGFP)
STEP l 94°C - 3:30*
STEP 2 94°C - 0:10
STEP 3 55°C - l :00
STEP 4 72°C - 2:00
STEP 5 go to step 2, 2 times
STEP 6 94°C - 0:10
STEP 7 65°C - 1:00
STEP 8 72°C - 2:00
STEP 9 go to step 6, 26 times
STEP 10: 94°C - 3:00
STEP l : 4°C for ever
*After two minutes at 94°C (during the first step), the tubes in the PCR block were
opened, and 25 pi of the bulk reaction mixture was added to each tube containing
template. This procedure was completed quickly, before the first step had ended. The
tubes were then closed, and the PCR program was allowed to run to completion.
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2.1.18 Colony PCR
For colony PCRs, the PCR reaction mixture was inoculated with bacteria from a
single colony or streak, using a toothpick (in place of the template DNA). Otherwise,
colony PCRs were performed with the methods and programs described above.
2.1.19 DEPC treatment of water
100 pi of DEPC (SIGMA, cat #D5758) was added to 1L of UHP dH20 water. This
solution was mixed, and left in a fume cupboard overnight to allow DEPC to break
down any RNase present in the water. The solution was autoclaved before use, to
break down the remaining DEPC.
2.1.20 RNA extraction
RNAzol cell lysates were collected in 1.5-ml screw-top microcentrifuge tubes (see
Tissue Culture Methods). Samples were prepared in an Envair class II
microbiological safety cabinet, to prevent contamination of the prep with DNA or
RNase.
100 pi of chloroform was added to each sample. The mixture was vortexed for 10
seconds, and incubated on ice for 5 minutes. The aqueous and organic phases were
separated by spinning in a refrigerated microcentrifuge at 13,000 RPM for 15
minutes. 450 pi of the top (aqueous) phase was transferred to a new tube.
To precipitate the RNA, 450 pi of isopropanol and 4 pi of glycogen (to act as a
carrier) were added to each tube. Samples were left on ice for 15 minutes to
precipitate the RNA, and then spun in a refrigerated microcentrifuge for 30 minutes
at 13,000 RPM. The supernatant was removed and the pellet was washed by adding
1 ml 75% ethanol and vortexing for 10 seconds. RNA was pelleted as before in a
refrigerated microcentrifuge for 15 minutes.
The supernatant was completely removed and the RNA pellet was re-suspended in
49 pi of DEPC-treated water.
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2.1.21 DNase Treatment
Samples were prepared in an Envair class II microbiological safety cabinet, to
prevent contamination of the prep with DNA or RNase.
RNA samples were prepared in a volume of 49 pi. The following reagents were then
added:
Samples were mixed by flicking and then spun down for 30 seconds in a
microcentrifuge. The mixture was incubated at 37 °C for 60 minutes.
Phenol-chloroform extraction was performed to remove residual enzymes: 60 pi of a
I: I mixture of phenol: chloroform was added to each tube and the samples were
vortexed for 10 seconds. The samples were spun in a refrigerated microcentrifuge at
13, 000 RPM for 15 minutes, to separate the organic and aqueous phases, and
approximately 55 pi of the top (aqueous) phase was transferred to a new tube on ice.
55 pi of chloroform was then added (to remove any residual phenol); the samples
were again vortexed and spun for an additional 15 minutes. Approximately 50 pi of
the top (aqueous) layer was transferred to a new tube.
5 pi of 3M NaOAc (pH 5.6) and 120 pi of ethanol were added to each sample.
Samples were transferred to dry ice for 15 minutes (or placed in a -70 °C freezer
overnight) to precipitate the RNA. RNA was pelleted in a refrigerated
microcentrifuge for 30 minutes at 13,000 RPM. Samples were transferred
immediately to ice.
The supernatant was removed and the pellet was washed with 1 ml of 75% ethanol
and vortexing. RNA was pelleted by an additional 15-minute spin in the
microcentrifuge. The supernatant was completely removed and the pellet was re-
suspended in 20 to 50 pi of DEPC-treated water.
DNase 1 (RNase free) 10 U/pl (Roche)
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RNA was stored in a -70 °C freezer before cDNA synthesis, if necessary.
2.1.22 cDNA synthesis
A first strand cDNA synthesis kit (Roche, cat #1483188) was used.
Samples were prepared in an Envair class II microbiological safety cabinet, to
prevent contamination of the prep with DNA or RNa.se.
The RNA samples were thawed on ice if necessary. 2-5 pi of each RNA sample was
aliquoted into a 1.5-ml screw top microcentrifuge tube (duplicates were included for
each sample to provide a control without AMV-RT - see below). DEPC-treated
water was added to make a total volume of 7.8 pi (negative controls of water only
were also included). These samples were denatured at 65 °C for 15 minutes and then
chilled on ice.
A bulk reaction mixture was prepared containing the following quantities of reagents
for each sample:
1 OX buffer 2 pi (Tube 1)
MgCE 4 pi (Tube 2)
dNTPs 2 pi (Tube 3)
Gelatine 0.4 pi (Tube 4)
P(dN)6 primer 2 pi (Tube 6)
RNaseln 1 pi (Tube 7)
AMY -RT 0.8 pi (Tube 8)
A duplicate mixture was made up with water in place of the AMV-RT, to ensure that
any signal in the subsequent RT-PCR was due to cDNA created from the RNA rather
than a background signal from genomic/plasmid DNA (which is a common artefact
due to incomplete DNase I digestion).
The heat-denatured RNA was spun down for 30 seconds. 12.2 pi of the mixture
containing AMV -RT was added to each RNA sample, and 12.2 pi of the mixture
without AMV -RT was added to the duplicate RNA samples. The mixture was
pipetted up and down several times to mix.
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The samples were incubated at room temperature for 10 minutes to allow the primers
to anneal, then at 42 °C for 60 minutes.
The sample was spun down and kept on ice while preparing for RT-PCR, or frozen at
-70 °C.
2.1.23 Reverse transcription polymerase chain reaction (RT-PCR)
Samples were prepared in an Envair class II microbiological safety cabinet, to
prevent contamination of the prep with DNA.
5 pi of each cDNA sample was aliquoted into a labelled 0.5-ml microcentrifuge tube.
Samples + AMV-RT and -AMV-RT were included for each RNA sample, in
addition, negative controls (containing water in place of RNA) and positive controls
(containing plasmid DNA) were included.
A bulk mixture was prepared containing the following quantities of reagents for each
sample:
10 X buffer (Roche): 5 pi
DMSO .5 pi
lOmMdNTPs I pi
Primer 1 (100 ng/pl) 1 pi
Primer 2 (100 ng/pl) 1 pi
Sigma Taq polymerase 5 U/pl 0.5 pi
DEPC water 31.5 pi
45 pi of this bulk mixture was added to each sample, and mixed by pipetting.
PCR was performed on an MJ Research PTC-225 or PTC-200 Peltier thermal cycler,
as described above.
2.1.24 ExoSAP-IT™
5 pi (containing approximately 50 ng) of PCR product was mixed with l pi of
ExoSAP-IT™ (E1SB, cat #78201) in a 96-well plate. The plate was heated on an MJ
Research PTC-225 Peltier Thermal Cycler at 37°C for one hour, and then the enzyme
was denatured at 80°C for 20 minutes.
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2.1.25 Qiaquick PCR purification
Qiaquick PCR purification was performed according to the kit protocol. DNA was
eluted from the column in a 30-pl volume, to increase DNA concentration in the
eluate. Water was used to elute the DNA, as salts in the kit elution buffer might have
interfered with the subsequent sequencing procedure.
2.1.26 Sequencing
6 pi (containing approximately lOng) of template DNA was combined with 6 pi of
primer (10 ng/pl), 4 pi of Rhodamine reaction mixture, and 4 pi of half-term buffer
in a 96-well plate. Cycle-sequencing was performed on an MJ Research PTC-225
Peltier Thermal Cycler with the following program:
STEPl: 95 °C, 30 seconds
STEP2: 53 °C, 20 seconds
STEP3: 60 °C, 3 minutes
GOTO step 1, 40 X
2.1.27 PCR sequencing
PCR sequencing was performed as above, but 6 pi of ExoSapIT™ reaction mixture
(containing PCR product) was used in place of the template DNA.
2.1.28 Cleaning up sequencing reactions
Reagents were mixed in the following proportions:
95% ethanol (sequencing grade) 50 pi
3M sodium acetate (NaOAc), pH 4.6 2 pi
Pellet Paint co-precipitant (Novagen, cat# 69049) 0.5 pi
A bulk mixture was made up and 52.5 pi of this was added to each 20-pl sequencing
reaction in a 0.5-ml microcentrifuge tube. The mixture was vortexed for 10 seconds
and incubated at room temperature for one hour to precipitate extension products.
The extension products were pelleted in a microcentrifuge for 30 minutes at 13,000
RPM. The supernatant was removed and the pellet was washed with 250 pi of 70 %
ethanol. The tube was vortexed to fully wash the pellet and centrifuged for 15
minutes at 13,000 RPM in a microcentrifuge. The washing step was then repeated.
Chapter 2: Materials and Methods 58
Following this, the supernatant was completely removed and the pellet was allowed
to air-dry for I minute. Pellets were stored at 4 °C until rehydration and
electrophoresis. The sequences were run on an ABI Prism DNA sequencher as a
service by Angie Fawkes in the Clinical Genetics Section, MMC University of
Edinburgh.
The sequencing results were viewed, and a Contig was created from the sequences
for each clone, using the 'Consed' software package. The Human Genome Mapping
Project (HGMP) GCG software 'BestfiF was used to compare this Contig sequence
to the expected sequence.
2.1.29 Ethanol precipitation
DNA was mixed with one half-volume of 3M Sodium Acetate (NaOAC) pH 4.6 and
four new volumes of 100 % ethanol. The mixture was vortexed to mix (for PAC
DNA the mixture was flicked to mix, as vortexing would have sheared the large PAC
DNA molecule). The mixture was then spun for 30 minutes at 13,000 RPM in a
microcentrifuge to pellet the DNA. The supernatant was removed and the pellet was
washed in 70% ethanol and vortexed or flicked to mix. The pellet was then re-
centrifuged at 13,000 RPM for 15 minutes. The supernatant was removed
completely and the pellet was allowed to air-dry for one minute. DNA was then re-
suspended in a suitable volume of I X TE (pH 8.0) or water.
2.1.30 Phenol: chloroform extraction
An equal volume of PCI (see Recipes) was added to the aqueous solution in a l ,5-ml
microcentrifuge tube. The mixture was vortexed or inverted to mix. The mixture was
spun at 13,000 RPM in a microcentrifuge for one minute, to separate the organic and
aqueous phases. The top (aqueous) phase was removed to a fresh 1,5-ml
microcentrifuge tube; care was taken to avoid debris at the phase interface. If
necessary, a chloroform extraction was then performed to remove any traces of
phenol (e.g. the procedure was repeated, using neat chloroform in place of PCI).
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2.2 Bacterial Methods
2.2.1 Making competent cells
Soap-free glassware was used throughout the protocol to improve cell transformation
competence.
A plate was poured containing 0.4 g of DIFCO Bacto agar (SLS, cat#0140 - 01) in
35 ml SOB -Mg (see Recipes), containing IPTG (626 pg/ml) if required. The
competent cell stock was streaked out on this plate and grown in a 37°C incubator
overnight to obtain single colonies.
4 X 800-ml cultures were set up containing SOB -Mg and IPTG (625 |lg/ml), if
required. A single colony was inoculated into each culture. These cultures were
grown at 30°C in a shaking incubator for approximately 15 hours until an OD^o of
0.75 - 1 was reached.
16 X 50-ml Falcon tubes were filled with the contents of one 800-ml culture. The
cells were spun down at 4,000 RPM for 15 minutes in a Jouan centrifuge and the
supernatant was discarded. The process was repeated with the other three 800-ml
cultures, pouring them into the same 16 tubes to pool the cells.
The cells were re-suspended in 50 ml of cold GYT (see Recipes) to wash, and
pelleted by centrifugation. This step was repeated. The cells were then re-suspended
in a small volume of GYT, and pooled into eight falcons; 50 ml of cold GYT was
added to wash and the cells were again pelleted by centrifugation. This process was
repeated to pool the cells into four, and then two falcons with a GYT wash between
each consolidation. After the final spin, most of the GYT supernatant was poured off
from the pellet, leaving a thin layer. The cell pellet was re-suspended in the
remaining GYT to produce a thick suspension. 140-|il aliquots of the cell suspension
were snap-frozen by dispensing into 1,5-ml microcentrifuge tubes on dry ice.
Competent cell aliquots were stored at -70°C. A test transformation was performed
on each batch prior to use, to confirm competence and rule out bacteriophage
contamination.
Chapter 2: Materials and Methods 60
2.2.2 Electroporation
Aliquots of competent cells were thawed on wet ice. 20 - 30 (0.1 of the competent cell
suspension was combined with the DNA (usually between 10 and 200 ng) in a 1,5-ml
microcentrifuge tube. This mixture was flicked to mix, then transferred to a chilled 1
mm cuvette and tapped down to ensure the mixture had entered the well between the
electrode contacts in the cuvette. A pulse of 1.25 V at 100 Q, 25 |iF was applied to
the cells with a BioRad Gene Pulser™ electroporator. 0.5 - 1 ml of recovery medium
(10 pl/ml glucose in L-broth) was immediately added to the cells, and then the
mixture was transferred to a sterile 5-ml polystyrene tube with vent-cap (Greiner,
cat# 120180). The cells were allowed to recover for 1 hour in a 37°C shaking
incubator. Aliquots of the transformed cells were spread on L-agar plates (containing
antibiotics at 50 mg/ml, IPTG at 625 fig/ml, and XGal at 625 (ig/ml, if required), and
incubated at 37°C overnight to allow colony growth.
When IPTG/Xgal staining was used to identify colonies expressing (3galactosida.se,
the plates were incubated at 4°C for two hours, to allow the blue colour to develop,
prior to scoring the plates.
2.2.3 Streaking out bacteria for single colonies
An L-agar plate was prepared containing the appropriate antibiotics (50|ig/ml) and
IPTG/XGal (each at 625 jLLg/ml), if required.
A plastic loop was used to collect a sample from a bacterial colony or frozen stock.
This was streaked across the L-agar plate. A new loop was used to make a second
streak from the end of the first. The process was repeated to create a pattern of
streaks with decreasing concentration of bacteria. The plates were incubated at 37°C
overnight to allow colony growth: a portion of the plate would then contain single
colonies.
2.2.4 Patching colonies in grid formation
A plate of L-agar (containing the appropriate antibiotics at 50 Jig/ml and IPTG/Xgal
at 625 jig/ml, if necessary) was prepared, and laid on top of a 96-square grid. The
plate was marked to confirm orientation. A small sample of the bacterial colony was
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collected onto a plastic loop, and streaked diagonally across one of the boxes in the
grid. This process was repeated for each colony. The plate was incubated at 37°C
overnight, to allow colony growth.
2.2.5 Preparing frozen stocks of transformed bacteria
A single colony was inoculated into L-broth containing the appropriate antibiotics
(50 pg/ml) in a conical flask. The culture was grown overnight at 37°C in a shaking
incubator. The next day, 1 ml of the culture was mixed with 1 ml freezing mix (60%
SOB, 40% Glycerol) in a cryotube. The stock was stored at -70°C.
2.2.6 Crude DNA minipreps
Bacterial colonies were inoculated into 2-ml aliquots of L-broth containing the
appropriate antibiotics (50 mg/ml), in 5-ml Bijoux tubes (the caps were loosened to
allow air circulation). The Bijoux tubes were placed in a basket in the 37°C shaking
incubator, and incubated overnight.
1.5 ml of each cell suspension was poured into a 1.5-ml microcentrifuge tube. The
cells were spun down in a microcentrifuge for five minutes at 13,000 RPM. The
supernatant was removed and the pellet was re-suspended in 100 pi GTE (see
Recipes). This suspension was vortexed to mix, and incubated at room temperature
for five minutes.
200 pi of 0.2M NaOH, 1% SDS solution was added; the tube was inverted to mix
and incubated for five minutes at room temperature.
150 pi of 3M KAc was added; the tube was inverted to mix and was incubated on ice
for five minutes.
The tube was then spun in a microcentrifuge at 13,000 RPM for 10 minutes to
precipitate proteins. The supernatant was transferred to a fresh 1.5-ml
microcentrifuge tube.
400 pi of PCI (see Recipes) was added to the sample. The mixture was vortexed and
spun in a microcentrifuge at 13,000 RPM for one minute, to separate the aqueous and
organic phases.
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400 pi of the top (aqueous) phase was removed to a new 1,5-ml microcentrifuge tube
(avoiding any debris at the interface).
1 ml of ethanol was added to the solution; the mixture was flicked to mix and spun in
a microcentrifuge at 13,000 RPM for 30 minutes to precipitate DNA.
The supernatant was removed and 1 ml of 70% ethanol was added to wash the DNA
pellet. The pellet was then re-centrifuged for 15 minutes.
The supernatant was removed with a pipettman, and the pellet was left to air-dry for
five minutes. The pellet was then re-suspended in a small volume of TE pH 8.0, or
water.
2.2.7 Qiagen Midipreps and Maxipreps
QIAGEN midipreps (Qiagen, cat # 12143) and maxipreps (Qiagen, cat #12163) were
performed according to the kit instructions with the following exceptions:
After incubation with buffer P3, the solution was centrifuged only once then passed
through gauze to ensure complete removal of particulate material before adding this
solution to the QIAGEN-tip.
Isopropanol precipitation was performed in 50-ml Falcon tubes. The DNA pellet was
precipitated by centrifugation in a Jouan centrifuge for one hour at 4,000 RPM. The
DNA pellet was washed with 70% ethanol and a second spin was performed at 4,000
RPM for 30 minutes. The pellet was re-suspended in a small volume of TE pH8.0, or
water.
When PAC DNA was prepared, the media volumes were altered. A larger volume of
culture was set up for each QIAGEN-tip: 50 ml for each midiprep tip and 200 ml for
each maxiprep tip. A larger volume of PI, P2, and P3 were used: 5 ml of each
solution per 50 ml culture volume. In addition, QIAGEN-tips were washed three
times with QC buffer, before the elution step. These alterations were based on an
optimised protocol for the preparation of PAC DNA, developed by Ann Doherty and
Heather Davidson (members of the MMC Medical Genetics group, University of
Edinburgh).
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A Beckman Coultier Avanti J20 I centrifuge with JA25 rotor was used to pellet the
bacteria and bacterial debris, prior to applying the supernatant to the QIAGEN-tip. A
Jouan CR3i centrifuge was used for DNA precipitation.
2.2.8 Colony lifts
Colonies were patched in grid formation and grown overnight. A round
nitrocellulose filter (Protran BA 85/20 0.45 mm, 82 mm filter, Schleicher and
Schuell) was labelled and marked for orientation. This membrane was laid on top of
the agar plate containing the patched bacterial colonies. The filter was left for a few
seconds, to allow the colonies to adhere.
The nitrocellulose filter was then laid colony side-up, on top of pieces of blotting
paper soaked in the following solutions, for the specified periods:
10% SDS - 5 min.
Denature - 5 min.
Neutraliser - 5 min.
0.4M NaOH - 20 min.
The membrane was then rinsed twice in 2 X SSC, 0.1% SDS solution, then once in 2
X SSC solution, with gentle agitation to remove colony debris. The membrane was
then cross-linked in the Stratagene UVStratalinker 2400, to permanently bind the
bacterial DNA.
2.3 Tissue culture Methods
2.3.1 Culture of immortalised cell lines
Immortalised cell lines were handled in an Envair class II microbiological safety
cabinet, to prevent contamination with microorganisms.
2.3.2 Splitting cells
Growth medium was removed from a flask of cells (Greiner 75 cm flasks with
vented caps, cat #658175 and 25cm flasks with vented caps, cat #690175, were
used). A 1:1 mixture of PBS and Versine was added to the flask (10 ml for a 75cm
flask, 5 ml for a 25cm flask) to wash away remaining medium and inactivate any
residual serum. This mixture was removed and an equal volume of a 1:1 mixture of
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Trypsin and Versine was added to the flask. The flask was placed in a humidified
37°C, 5% CO2 incubator for approximately 10 minutes until cells had detached from
the plastic and dissociated (confirmed by visual examination under the microscope).
It was often necessary to pipette the cells several times through a fine-tipped pastette
to produce a single-cell suspension.
New flasks of cells were set up as follows:
Table 2.1. Seeding flasks with permanent cell lines.







The appropriate fraction of the cell suspension was transferred to a new flask and
growth medium was added (30 ml for a 75cm flask, 10 ml for a 25cm flask).
Cells were grown in a humidified 37°C, 5% CO2 incubator. The growth media was
changed twice a week and the cells were split once a week.
2.3.3 Collagen-coating Transwell inserts
25 mg of human placental collagen type VI, acid soluble (Sigma, cat # C-7521) was
mixed with 50 ml tissue culture tested deionised H20 and 100 pi of glacial acetic
acid. This mixture was heated in a 37°C water bath until the collagen dissolved, then
an additional 450 ml FFO was added. This solution was filtered through a 0.2 jam
acrodisc prior to use.
100 pi of collagen solution was added to each Costar Transwell Clear insert (6.5mm
diameter, 0.4 mm pore, Costar C3470) in a 24-weIl plate. This was left in the laminar
hood to coat for 6 to 24 hours. Before use, any remaining liquid collagen was
removed from the insert and the membrane was washed inside and out with PBS.
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2.3.4 Establishing sheep primary tracheal air-interface cultures
Intact sheep tracheae were obtained from the Moredun Research Facility at Easter
Bush, Edinburgh. The tracheae were transferred to PBS + 1% Penicillin
/Streptomycin (Stock 10,000 u/ml, 10,000 pg/ml, G1BCO, cat # 15140-122),
Amphotericin B (0.25 |ig/ml) and Vancomycin (100 pg/ml) for transport to the
laboratory.
(Day 1) As much fat and connective tissue were removed from the outside of the
trachea as possible, and an incision was made along the length of the trachea on the
posterior side, between the extremities of the cartilage rings. Muscle and membrane
at the border of the cartilage rings were trimmed away. The trachea was sliced
between the cartilage rings at intervals of two to three rings; these pieces were then
cut into squares of roughly 1 cm2. The pieces of trachea were added to 50 ml of
Dissociation media (see Recipes) in a 50-m! falcon, and incubated overnight at 4°C,
to allow the cells to dissociate.
(Day 2) The Falcon tubes were inverted gently 6X and the dissociated cell
suspension was poured off the tracheal husks. The tracheal husks were washed with
50 ml of Airway media (see Recipes) to harvest additional cells, and this was
combined with the first cell suspension. FCS was added to a final volume of 10%.
Cells were spun down from the suspension, and then re-suspended in 10 ml of PBS.
To lyse any blood cells in the preparation, 20 ml of tissue culture treated dHBO was
added. After 30 seconds, 2 ml of 10X PBS was added to restore isotonicity.
The mixture was again spun down, and cells were re-suspended in 48 ml of Airway
media per trachea. 12-ml aliquots were added to 10 cm tissue-culture plates
(Primeria; Falcon cat #3803). These were incubated for 4-5 hours to remove any
fibroblasts, which adhere preferentially to the plastic.
The remaining cell suspension containing predominantly epithelial cells was
collected and four 12-ml aliquots were pooled into a 50-ml Falcon tube. A 100-pl
aliquot of the cells was mixed with 100 pi of tryphan blue, to stain dead cells. The
mixture was then applied to a haemocytometer slide and visualised under the light
Chapter 2: Materials and Methods 66
microscope, to assess cell viability and quantify live cells. The cells were spun down
and then re-suspended in 200 pi of Airway media per 1X106 cells. A 200-pl volume
of the cell suspension was seeded on the inside of each collagen coated Costar insert
and 600 pi of Airway media was placed below the insert to feed the cells from
below. The cells were cultured in a 37°C humidified incubator with 6% CCA.
(Day 3) Media below the insert was replaced with 600 pi USG media (see Recipes)
and media inside the insert was removed, creating an air-interface. Cells were
cultured for up to 5 weeks. The USG growth media was replaced twice a week.
Visual examination was used to evaluate trie presence of ciliated cells. When
focusing just above the plain of the cells, a shimmering effect could be seen above
some cells in the culture. This was indicative of beating cilia (personal
communication from Donald Davidson).
A System EVOM Epithelial Voltohmeter + STX2 Electrode Set (World Precision
Instruments, Inc) was used to monitor electrical resistance across the membrane.
Growth media below the insert was replaced with 600 pi PBS and 200 pi PBS was
placed above the insert. One prong on a set of electrodes was lowered into the PBS
below the insert, and the other into the PBS above the insert, and the resistance
reading was taken. A high resistance reading (above 1,000 Q/membrane) indicated
the presence of tight junctions between the celts. Readings were taken every few
days to assess the presence of tight junctions throughout the culture period
2.3.5 Transfection
Permanent cell lines were seeded as follows:
Table 2,2. Seeding permanent cell lines for transfection.
Cell line Number of cells per well (24-well plate)
COS7 5X10*
MDCK-IOWA 5 xW
CaC02 1 X 10'
HBE 1 X iO5"
T84 5 XIO'
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The appropriate number of cells was added to each well in a 24-weil plate. 2 ml of
growth media was added to each well. The cells were transfected at 60-80%
confluence (this density was usually achieved 24 hours after seeding). Cells were
washed once with 2 ml of serum-free growth medium, prior to transfection.
2.3.5.1 Dotap Transfection
12 pi of DOTAP liposomal transfection reagent (Boerhinger-Manheim, cat #
1202375) was mixed with 88 pi of Optimem 1 in a sterile 5-ml polystyrene tube
(Falcon #352054). In a separate tube, 1 |ig of DNA was mixed with Optimem 1 to
make a total volume of 100 pi. The two solutions were combined and shaken
vigorously to mix. The mixture was left for 20 minutes to allow a complex to form.
300 pi of Optimem I was added to the complex, to make a final volume of 500 pi;
this 500-pl volume was applied to a single well in a 24-well plate. For duplicate and
triplicate transfection, the mixture was scaled up and made in bulk.
After a five-hour transfection period, the transfection complex was removed and 2 ml
of growth media was added to each well.
2.3.5.2 Saint Mix Transfection
20 pi of Saint-Mix™ (Saint B.V.) was mixed with 80 pi of Optimem 1 (GIBCO, cat
#319-047) in a sterile 5-mi polystyrene tube. In a separate tube, 1 pg of DNA was
mixed with Optimem 1 to make a total volume of 100 pi. The two solutions were
then combined and pipetted several times to mix (with PAC DNA, the tubes were
shaken in preference to pipetting, to prevent shearing of the DNA). The mixture was
used immediately.
For transfection of permanent cell lines, 300 pi of Optimem 1 was added to the
complex, to make a final volume of 500 pi; this 500-pl volume was applied to a
single well in a 24-well plate. For primary cultures, the complex was used undiluted;
the 200-pl volume was applied to a single primary culture insert (see below). For
duplicate and triplicate transfections, the mixture was scaled up and made in bulk.
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After a four-hour transfection period, 2 ml of growth media was added to each well
without removing the complex. 24 hours later, the growth media was replaced. For
primary cultures, the transfection complex was simply removed from the cell surface
after four hours.
2.3.5.3 PEI transfection
3 |ig of DNA was mixed with HBS to make a 125-pl final volume, in a sterile 1,5-ml
microcentrifuge tube. In a separate tube, 2.5 pi of PEI (2K) was mixed with HBS to
make a I25-pl final volume; this mixture was then combined with the DNA/HBS.
The mixture was flicked to mix then contents, then incubated at room temperature
for 15 minutes.
In a separate tube, 4.5 jllI of PEI (25K) was mixed with HBS to make a 125-pl final
volume. This mixture was then added to the DNA/ PEI (2K) mixture. The tube was
flicked to mix the contents, and then incubated at room temperature for 15 minutes.
500 jil of serum-free media was added to each well in a 24-well plate. 120 pi of
complex (containing 1 jig DNA) was added to each well, the plate was gently
swirled to mix. After a four-hour incubation at 37 °C, the transfection complex was
removed and 2 ml of growth media was added.
The mixture was not scaled up or down, as this appears to compromise transfection
efficiency (personal communication, Matt Cotton).
2.3.5.4 LID transfection
0.75 pi of Lipofectin reagent (GIBCO BRL, cat #18297-01 1) was mixed with 40 pi
of P6 integrin-targeting peptide (lOOng/pl in Optimem 1) and 60 pi of Optimem 1 in
a sterile 5-ml polystyrene tube. 1 pg of DNA was mixed with Optimem 1 to make a
final volume of 100 pi. The two solutions were then combined. The mixture was
used immediately.
For transfection of permanent cell lines, 300 pi of Optimem 1 was added to the
complex, to make a final volume of 500 pi; this 500-pl volume was applied to a
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single well in a 24-well plate. For primary cultures, the complex was used undiluted;
the 200-pl volume was applied to a single primary culture insert (see below).
After a five-hour transfection period, the transfection complex was removed and 2 ml
of growth media was added to each well. For primary cultures, the transfection
complex was simply removed from the cell surface after five hours. For duplicate
and triplicate transfections, the mixture was scaled up and made in bulk.
2.3.5.5 SID transfection
20 pi of Saint-Mix™ (Saint B.V.) was mixed with 10 - 40 pi of P6 integrin- targeting
peptide (lOOng/pl in Optimem 1) and Optimem 1 to make a final volume of 100 pi,
in a sterile 5-ml polystyrene tube. In a separate tube, 1 pg of DNA was mixed with
Optimem 1 to make a final volume of 100 pi. The two solutions were then combined
and pipetted several times to mix (with PAC DNA, the tubes were shaken in
preference to pipetting, to prevent shearing of the DNA). The mixture was used
immediately.
For transfection of permanent cell lines, 300 pi of Optimem 1 was added to the
complex, to make a final volume of 500 pi; this 500-pl volume was applied to a
single well in a 24-well plate. For primary cultures, the complex was used undiluted;
the 200-pl volume was applied to a single primary culture insert (see below).
After a five-hour transfection period, the transfection complex was removed and 2 ml
of growth media was added to each well. For primary cultures, the transfection
complex was simply removed from the cell surface after five hours. For duplicate
and triplicate transfections, the mixture was scaled up and made in bulk.
2.3.6 Procedure for transfection of primary cultures
The resistance across the membrane was measured with a voltohmeter before
transfection to assess the presence of tight junctions (see above); only cultures with a
resistance > 1,000 were accepted for transfection. Cultures of relatively higher and
lower resistances were spread evenly between transfection conditions, to prevent a
bias in the results.
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Tight junctions were disrupted by applying 200 pi of 6 rnM EGTA (pH 7.0) above
the membrane, and 600 pi below. The cultures were incubated at 37 °C for 20
minutes, then the new resistance readings were measured: a resistance < 350
Q/membrane indicated successful disruption of tight junctions. The PBS used to
measure resistance also served to wash serum away from the cells before
transfection.
As described above, 200 pi of transfection mix (containing 1 pg DNA) was placed
above each insert, and 600 pi of Optimem 1 was placed below each insert.
Transfection was performed according to the methods described above.
2.3.7 Harvesting cells for FACS
For 24-well plates:
Cells were washed once with 1 ml PBS per well. 1 ml of a 1:1 Trypsin: Versine
mixture was added to each well. The plate was then placed in a humidified 37°C, 5%
CO2 incubator for approximately 10 minutes, until cells had detached from the
plastic and dissociated (confirmed by visual examination under the microscope). It
was often necessary to pipette the cells through a fine tipped pastette to achieve a
single-cell suspension. The suspension was transferred to a 15-ml Falcon tube.
1 ml of Fetal Calf Serum was added to each tube of cells, to inactivate the Trypsin.
The cells were spun down in a Jouan centrifuge for 5 minutes at 1,000 RPM.
The supernatant was removed, taking care not to disturb the pellet of cells. 1 ml of
PBS was added to each 15-ml Falcon tube to wash the cells and the tube was flicked
several times to roughly re-suspend the pellet. The cells were centrifuged again as
above. The cells were then re-suspended in 0.5 - 1 ml of PBS, and transferred to a
sterile 5-ml polystyrene tube.
For air interface primary tracheal cultures:
600 pi of PBS was placed below the insert and 200 pi of PBS was placed above the
insert. Electrical resistance readings were taken before harvesting cells for FACS
(see above).
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600 pi of a 1:1 Trypsin: Versine mixture was placed below the insert and 200 pi was
placed above the insert. The cells were then incubated, harvested, and processed as
described above for 24-well plates (see above).
2.3.8 FACS










FLH-1, FLH-2 and FLH-3:
Data Mode: Logarithmic
Detector level: 438
10,000 cells were counted for each sample, unless otherwise stated.
2.3.9 Pgalactosidase luminometer assay
Cells in a 24-well plate were washed twice with 500 jil of PBS. 150 ft I of Lysis
buffer (see Recipes) was added to each well, and incubated for one to two minutes at
room temperature to allow lysis to proceed. The solution was then transferred to a
96-well plate, and spun in a Jouan CR422 centrifuge, with plate buckets, at 1200
RPM for 5 minutes, to pellet debris. The supernatant (containing pgalactosidase)
forms the sample for the subsequent assay (it was sometimes necessary to dilute the
sample 1/10 or 1/20 in Lysis buffer to prevent an overload reading in the assay).
Pgalactosidase enzyme was diluted in Lysis buffer, to make a series of twofold
dilutions (from 12,500 ng/ml to 390.63 pg/ml), for use as controls.
200 pi of Reaction buffer (see Recipes) was added to a set of 5-ml polystyrene tubes.
40 pi of sample (or Pgalactosidase dilution control) was added to each tube. In
addition, negative controls (containing 40 ul lysis buffer, in place of the sample)
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were included. The mixtures were shaken and incubated in the dark at room
temperature for one hour.
An EG+G Berthold Lumat LB 9507 luminometer was used to assay the
pgalactosidase concentration. A program was created to direct the luminometer to
inject 300 jllI of Accelerator buffer (see Recipes) into the sample, and then read the
absorbance of the solution at 530nm. The concentration of Bgalactosidase in each
sample was calculated by plotting the readings for the controls of known
concentration.
2.3.10 j3Galactosidase ELISA
The (3-Gal ELISA colorimetric enzyme immunoassay kit (Boehringer-Mannheim, cat
# I 539 426) was used according to the manufacturers instructions.
2.3.11 Obtaining RNazol lysates for RT-PCR
Cells in a 24-well plate were washed once with ! ml of PBS, and then I ml of RNazol
(Ambion, cat #C5l04) was added to each well. The plate was incubated for 5
minutes, then the RNazol was pipetted up and down to ensure complete lysis of the
cells and collection of the total DNA content. The samples were transferred to 1.5-ml
screw-top microcentrifuge tubes and stored in a-70 °C freezer.
2.3.12 Preparing samples for electron microscopy
The Costar inserts were washed 5X in PBS. 200 pi of Fix (2.5% gluteraldehyde in
PBS) was applied above the membrane, and 600 pi below. The cells were fixed for at
least two hours. The inserts were washed with PBS three times, and then the
membrane (with the cell monolayer still attached) was carefully removed from the
plastic insert support with a scalpel. The remainder of the processing was done as a
service by Steve Mitchell at the Department of Veterinary Medicine, University of
Edinburgh.
2.3.13 Statistics
In order to determine the significance of any differences between treatments,
statistical tests were employed.
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2.3.13.1 T-Test
For phosphoimager analysis of RT-PCR results, Pgalactosidase assays, and FACS
analysis, a two-tailed T-test was employed. This statistic tests the null hypothesis:
|ll=]j.2, in other words, the probability that there is no significant difference in the
observed values for two treatments, by measuring signal/noise (the T-test is
appropriate due to small sample size). The T-value is calculated according to the
formula:
T = (|ir |i2)/SE(|ii- |l2)




n = sample number
degrees freedom = n-1
A statistical table (SurfStat statistical tables website) was then used to calculate the
probability (P-value) that the null hypothesis is correct from this T-value. If the P-
value was less than 0.05 (e.g. less than 5% probability that the means are the same),
then the difference was considered to be significant, and the null hypothesis was
rejected. Only significant differences are reported in the text (along with their
corresponding P-values). The T-va!ues for these calculations can be found in
Appendix F.
2.3.13.2 Test statistic plp4 = p2p3
A more complex statistical analysis was performed by Dr. Naomi Wray (Statistician,
MMC, University of Edinburgh), in order to determine whether the observed
difference in the average fluorescence intensity following transfection with the
PAc65kbcfproEGFP vector and the pikbcfproEGFP vector was proportional to the
difference between the PAcRC2cmvEGFP vector and the pEGFP-N vector.
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We want to test the null hypothesis: pl/|J,2 = |i3|l4, where:
jil = the average fluorescence intensity of pEGFP-N
jl2 = the average fluorescence intensity of PAcRC2cmvEGFP
p3 = the average fluorescence intensity of pi khcfproEGFP
|l4 = the average fluorescence intensity of pAc65kbcfproEGFP
However, this hypothesis is non-trivial. The null hypothesis: |llp4 = (L2p3 is
equivalent and is easier to test. The triplicate (or duplicate) samples are treated as
random effects, as they are sampled from separate populations (e.g. wells) and we
therefore expect real differences in the sample means.
The test statistic is calculated according to the formula:
T = X,X4-XiX3
v/( L1 /nin4][ X42<3|2 + X i2G42 + g |2 g42] + [ l/n2n3][ X22 g32 + X32 g22 + g22 g3
where:
n = number of sample replicates
X = the mean of the average fluorescence intensity
G






The results of this analysis are discussed in Chapter 4, and the original T-values are
reported in Appendix F.
















(adjust pH to 4.5/5 with concentrated HCI)
50 X TAE
121 Og Tris Base






400ml 0.5M EDTA (pH 8.0)
H20 5L
TE
5ml IM Tris (pH 8.0)
100fj.l 0.5 MEDTA
H20 500ml





(adjust pH to 7.0 with a few drops of NaOH)
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10XTNE




































(adjust pH to 7.2 with NaOH)
aliquot 400ml + 6g Bacto Agar to each bottle
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GTE (minipreps)
0.5g glucose









2.5g Bacto yeast extract
5ml lMNaCl
1.25 ml 1M KC1
H20 -> 500ml
2.4.3 Tissue Culture Recipes
COS7 Growth Media
DMEM (GIBCO, cat #41965-039)
10% Fetal Bovine Serum (GIBCO, cat# 10106-151)
1% PenniciIlin/ Streptomycin (Stock 10,000u/ml, 10,000|ig/ml GIBCO, cat#15140-
122)
MDCK-IOWA Growth Media
1:1 DMEM: HAM's F12 (GIBCO, cat#21765-029)
10% Fetal Bovine Serum
1 % Pennici I lin/ Streptomycin
T84 Growth Media
1:1 Vitacell Modified DMEM (ATCC, cat # 30-2002): Ham's F12
10% Fetal Bovine Serum
1% Pennicillin/ Streptomycin
HBE Growth Media
MEM (GIBCO, cat# 31095-029)




2mM Glutamine (200mM stock. GIBCO, Cat #25030-024)
1 X non-essential amino acids (100X stock, GIBCO, cat # 1 1 140-035)
1% Pennicillin/ Streptomycin





(adjust pH to 7.4, filter sterilise in sterile safety cabinet)







1lOpg Sodium Pyrivate (SIGMA, cat#58636)
15mg Phenol Red
12ml Penn/Strep (Stock 5,000u/ml, 5,000pg/ml)
pH to 7/5 with a few drops of concentrated hydrochloric acid. Store at 4°C and filter
through a 0.2 pm filter before use.
Dissociation Media
60 ml Ca2+ Mg2+ free MEM
84 mg Pronase (Boeringer-Mannheim 165121)
6 mg DNase (~3,000u)(Sigma DN-25)
Filter through a 0.2pm filter before use, then add 0.25 jig/ml Amphotericin B and
100 pg/ml Vancomycin.
Airway Media
1:1 DMEM: (GIBCO 41966-029) to HAM's F12 (GIBCO 21765-029)
5% FCS
2% Penicillin/ Streptomycin Stock (Stock 5,000 u/ml, 5,000 pg/ml)
600 pi Human Actrapid Insulin (Stock lOOiu/ml)
Store in flasks with vented caps in a 37 °C, 6% C02 tissue culture incubator, to
allow the media to breathe for C02 exposure. Before use add 0.25 pg/ml
Amphotericin B.
USG Media
233 ml DMEM(GIBCO 41966-029): 247 ml HAM's F12 (GIBCO 21765-029)
10 ml Lyophilised Ultroser G serum substitute (GIBCO 15950-017)
10 ml Penn/Strep (Stock 5,000u/ml, 5,000pg/ml)
Store at 4°C. Before use, add 0.25 pg/m! Amphotericin B.
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Bgal luminometer assay Lysis buffer
9.15 ml 100 mMK2HP04
0.85 ml 100 mM KH2P04
20 |!l Triton X (SIGMA, cat#T-9284)
10 JJ.1 DTT




100 (0.1 Tropix Galacton (Tropix, cat #GC020)
Bgal luminometer assay Accelerator
1 ml Tropix Emerald (Tropix, cat#LAE250)
2 ml 1M NaOH (stock must be made up fresh)
7 ml H20
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3.1 Introduction:
The first generation of vectors designed for CF gene therapy contained the CFTR
reporter gene, coupled to a strong promoter (e.g. the Pcmv viral promoter/enhancer).
However, a more elegant design may be ultimately required for gene therapy vectors,
incorporating regulatory elements to restrict expression to the correct levels and to
the correct cell types. Our approach is to utilise the endogenous CFTR control
elements in genomic context vectors (GCVs), to regulate expression (see Section
1.2).
In order to test the effects of such regulatory elements in a gene therapy context, a
series of vectors was created, coupling different portions of the CFTR genomic
region to the EGFP reporter gene. Regions 5' of the CFTR gene were included in
some of these vectors, to test the effects of proximal and distal upstream regulatory
elements upon expression. CFTR intron 1 was included in one vector, to test the
effects of the intron 1 DHS upon expression, as previous reports have demonstrated
that this element upregulates CFTR expression in cells of the gut epithelium (Smith,
AN et al, 1996; Rowntree et al, 2001). These regions were linked to the EGFP
reporter gene either directly, or by an internal ribosome entry site (IRES). An IRES
allows translation to initiate from an internal site, rather than the 5' end of the
mRNA. A previous report (Vassaux and Huxley, 1997) has demonstrated that CFTR
transcriptional activity can be accurately monitored by inserting an IRES and
reporter gene downstream of the CFTR coding sequence.
Two small plasmids, plkbcfproEGFP and pCFTRiresEGFP, were generated by
conventional restriction/1 igation reactions. However, it is not easy to manipulate
large PAC constructs by such conventional cloning procedures, and thus a
recombinogenic method was used to create the PAC constructs PAc65kbcfproEGFP,
PAcRC2cmvEGFP, pacRC 1 iresEGFP, and pAcRC2iresEGFP. The foldout Appendix
E shows a diagram of the expression cassette in each of these vectors (and some
control constructs), for easy reference. The predicted sequence of each vector was
assembled using the HGMP GCG 'assemble' and 'seqed' software.
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Recombinant clones were detected by plasmid restriction, colony PCR, or Southern
Blot. These plasmids were then characterised by restriction analysis, to confirm their
structure. When a PCR step was included in the construction process, the appropriate
region was sequenced, to ensure that a deleterious mutation had not been introduced.
In sum, a panel of vectors was created, to provide the tools for subsequent
transfection studies. Upon transfection into mammalian cells, these vectors will
report upon the effects of CFTR 5' and intron 1 elements on EGFP transgene
expression.
3.2 Recombinogenic method (Fig. 3.1):
A PCR product was generated with a loxP site at the 3' end and a region homologous
to the site of vector insertion at the 5' end. These features can theoretically be
introduced by primer-directed mutagenesis if they are not already present in the
region to be amplified, making the system highly flexible'.
Two recombination events were used to fuse the PCR product with the vector
(Fig. 3.1):
1. Cre/loxP recombination. The Cre enzyme was used to catalyse a
recombination event between loxP sites in the parent vector and PCR product
in vitro. This generates a linear molecule.
2. Homologous recombination. This was accomplished by transforming the
linear molecule into DHl OB-u/pSpRecGam cells. The DHlOB-u/pSpRecGam
strain exhibits a high frequency of homologous recombination, and was made
from the E. coli strain DHlOB-u by introducing a plasmid (pSpRecGam)
' This method is sound in principle, however it may not prove possible to incorporate
the loxP site by primer-directed mutagenesis, as this sequence is palindromic and is
predicted to form a strong secondary structure in the primer. The practicality of this
approach must be tested.
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encoding RecET and Gain. The RecET protein complex promotes RecA-
independent homologous recombination. Gam increases the efficiency of
recombination by repressing recBCD, which digests linear DNA. Replication of
the pSpRecGam plasmid is dependent on the presence of IPTG (which represses
Laclq and thus derepresses pSpRecGam replication), thus the high frequency of
homologous recombination can be turned off after the plasmid is introduced by
exclusion of IPTG to prevent further aberrant recombination events. The use of
RecET for plasmid construction was reported by Zhang (Zhang et al, 1998a).
This event circularises the recombinant vector.
This double-recombination method was reported by Boyd and colleagues (Boyd et
al, 1999b). The use of a PCR product in lieu of a restriction fragment for insertion,
and the use of primer-directed mutagenesis to incorporate a loxP site for
recombination, are refinements made for this work.
3.3 Results
3.3.1 p1kbcfproEGFP
The small plasmid pi kbcfproEGFP contains 797 bp of CFTR 5' region, upstream of
the EGFP reporter gene (see fold out Appendix E). This vector will report upon the
effect of proximal CFTR 5' promoter elements on transgene expression. A
conventional cloning procedure was used to make this plasmid (Fig. 3.2.1).
797 bp of sequence 5' of the ATG start site of the CFTR gene was amplified from
pac3 (Boyd and Porteous, 1997), by PCR. The primers used in this reaction, 5'cfpro
and 3'cfpro, were designed to introduce restriction sites BamHI and Sstll,
respectively, onto the ends of the PCR product, allowing subsequent
restriction/ligation reaction (see Appendix A for primer sequences). A hot-start
program was used to enhance amplification from the PAC template (Chou et al,
1992; see Methods). The Expand™ High Fidelity PCR system (Roche) was used in
this reaction; this enzyme blend has proofreading (3'-5' exonuclease) activity,
minimising the possibility of PCR mutagenesis (Roche website). The PCR product
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Figure 3.2. Vector construction. This figure shows the schematics of vector
construction for (3.2.1) plkbcfproEGFP, (3.2.2) pCFTRiresEGFP, (3.2.3)
PAc65kbcfproEGFP, (3.2.4) PACRC2cmvEGFP, (3.2.5) PAcRC1iresEGFP, and
(3.2.6) PAcRC2iresEGFP. Represents CFTR 5' region,
mmm represents EGFP, i i represents CFTR, ■■■ represents figal.































































































3.2.6 Construction of pAcRC2iresEGFP
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was digested with Sstll and BamHI, and purified by ethanol precipitation (see
Methods).
pEGFP-1 is a promoterless vector, designed to monitor transcription from different
promoter/enhancer combinations inserted into the multiple cloning site (MCS)
located upstream of the EGFP coding sequence (see Appendix D, and Clontech
website). This vector was digested with Sstll and BamHI (proximal restriction sites
in the multiple cloning site), and treated with phosphatase to prevent re-ligation of
the parent vector (see Methods).
Sstll produces a 3' overhang (GC), while BamHI produces a 5' overhang (CTAG).
Thus, the vector and insert will have compatible 'sticky ends', allowing the two to be
joined by ligation (see Methods). A series of ligation reactions were set up with
different ratios of plasmid DNA to PGR product (Table 3.1 - p. 124).
A 2 pi aliquot of each reaction was disk dialysed and transformed by electroporation
into a 20 pi aliquot of DH lOB-u E. coli competent cells (see Methods). The time
constants were between 1.9 and 2.0 ms. Cells were plated out on L-agar plates
containing Kanamycin and grown overnight (see Methods). The following day the
plates were scored for colony growth. (Table 3.3a - p. 125).
40 colonies were chosen at random and patched onto a new plate, and then crude
DNA minipreps were performed (see Methods- two of these, samples #19 and 30,
did not grow, and were excluded from further analysis). Dral and BssHII digests
were performed to identify recombinant clones.
Six colonies (# 3,23,25,33,34 and 37) showed the correct digest pattern for the
recombinant plasmid with both enzymes (Fig. 3.3). 24 of the remaining colonies
showed the correct digest pattern for the parent vector. Three colonies (# 26,28 and
29) showed the correct digest pattern for the recombinant plasmid, except for an
extra faint band in the BssHII digest. Although this band could have been an artifact,
these clones were excluded from further analysis. Five colonies (# 2,6,21,36 and 38)
presented unusual digest patterns with one, or both enzymes, no further analysis was
performed on these errant clones.
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Qiagen maxiprep DNA was prepared from the six clones #3, 23, 25, 33, 34, and 37.
This DNA was used as a template to sequence across the insertion site, in order to
check for mutations derived from the PCR primers, or introduced in the PCR
reaction. The vector DNA was sequenced directly using a Rhodamine-sequencing kit
(see Methods); the primers seqF, seqR, seqF2, and seqR2 were used in this reaction
(see Appendix A for primer sequences). The sequences were run on an ABI-Prism
sequencher as a service, by Angie Fawkes in the Clinical Genetics Section, MMC,
University of Edinburgh. The Consed software package was used to assemble
contigs from the original sequences for each clone, and then the HGMP GCG
'bestfit' software was used to compare these contigs to the predicted vector
sequence.
Surprisingly, mutations were identified in several of the clones, despite the use of
HPLC-purified primers and the Expand™ High Fidelity PCR system during vector
construction. Colony #34 was free from mutations in the inserted region (see
Appendix B1 for the sequencing results); this clone was named pi kbcfproEGFP.
3.3.2 pCFTRiresEGFP
The small plasmid pCFTRiresEGFP contains the coding sequence of both CFTR and
EGFP. An internal ribosome entry site is located between the genes, allowing them
to be translated as separate proteins from a single mRNA (Clontech website). A Pcmv
promoter drives expression (see fold-out Appendix E). This construct acted a control
for transfection studies and was instrumental in the creation of further vectors.
pCFTRiresEGFP was created by a simple restriction-ligation reaction (Fig. 3.2.2).
The region containing the CFTR coding sequence was excised from the pCMV-
CFTRint6ab vector (Boyd et al, 1999a) by restriction with Sail, then gel purified.
The Clontech vector pIRES2EGFP (Clontech website) was designed to make
transcriptional fusions with EGFP. A multiple cloning site has been incorporated
upstream of an internal ribosome entry site (IRES) for easy insertion of a transgene
coding sequence (Clontech website); Appendix D shows a diagram of this vector.
The EGFP gene is located downstream of the IRES. This vector was linearised by
restriction with Sail, which cuts in the multiple cloning site. Linear vector was gel
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purified and treated with phosphatase to prevent re-ligation of the parent vector (see
Methods).
-125 ng linearised pIRES2EGFP vector and - 250 ng of the Sail fragment from
pCMV-CFTRint6ab were ligated in 10 p.] volume (see Methods). A 2 pi aliquot was
disk dialysed and electroporated into 30 pi of DHlOB-u competent E. coli cells. The
time constant was 2.2 ms. Cells were plated out on L-agar plates containing
Kanamycin and grown overnight (see Methods).
The plates were scored for growth the next day. Every plate had approximately 1,800
colonies. 1,000 of these colonies were chosen at random and patched onto a new
plate in grid formation. A colony lift was performed (see Methods) and the filters
were probed with a mixture of 32P radioactively-labelled PCR products Ex4-9 and
Ex 19-24 (see Appendix A, and Methods). Three colonies (#349, 501 and 703)
showed a strong, positive signal (Fig. 3.4).
Qiagen DNA maxipreps were prepared from these colonies. Diagnostic restriction
digests were performed to identify colonies where the CFTR fragment had inserted
in the correct orientation (the insert could have attached in either orientation, due to
the identical restriction ends).
One of these (colony #501) showed the correct restriction digest pattern with
enzymes A////, BamHI, and Xbal (Fig. 3.5). This plasmid was named
pCFTRiresEGFP.
3.3.3 PAc65kbcfproEGFP
The PAC vector PAc65kbcfproEGFP contains 65 kb of CFTR 5' region upstream of
the EGFP reporter gene. This vector will report upon the effects of distal CFTR 5'
elements on expression (see fold-out Appendix E). A double recombination method
was used to create PAc65kbcfproEGFP (Fig. 3.2.3).
A region containing the 797 bp of CFTR 5' region and the EGFP gene was amplified
from pikbcfproEGFP by PCR (see Methods). The primers 5'cfpro and loxP were
used in this reaction (see Appendix A). The loxP primer anneals downstream of the











Figure 3.4 pCFTRiresEGFP colony hybridisation. pCFTRiresEGFP clones
were patched in a grid formation, along with a positive control (pCMV-
CFTRint6ab colonies) and a negative control (plRES2EGFP colonies - as
labelled). A colony lift was performed, and the filters were probed with a
mixture of PCR products Ex4-9 and Ex19-24, labelled with 32P-CTP (see
Methods). This figure shows an X-ray film, exposed to the filters for 5-hours. A
distinct signal can be seen in three colonies (circled): #349, 501 and 703, and








Figure 3.5. Diagnostic digest of pCFTRiresEGFP. Maxiprep
DNA from pCFTRiresEGFP colony #501 was digested and
run down an agarose gel (see methods). (1) Aflll digestion
produced the expected doublet of size 5746/5208 bp (2) BamHI
digestion produced the expected bands of size 7811, 2540, 387
and 216 bp (3) Xbal digestion produced the expected bands of
size 10234 and 720 bp.
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EGFP gene and introduces a loxP site onto the end of the PGR product. The
Expand™ High fidelity PCR system was used in this reaction (see Methods). The
PCR product was gel purified to minimise vector contamination, and purified by
ethanol precipitation (see Methods).
An in vitro Cre reaction was used to catalyse a recombination event between the loxP
sites in the PCR product and PAcRClb vector (this vector is described in Appendix
D). Cre reactions (see Methods) were set up with different ratios of vector to PCR
product; controls with no PCR product and no Cre were also included (see Table 3.2a
-p. 124).
2 pi aliquots of these reactions were disk dialysed and transformed by
electroporation into 30 pi DHIOB-u/pSpRecGam competent E. coli cells (see
Methods - three aliquots were transformed for reactions 1 - 3, and one aliquot for
control reactions 4 + 5). In addition, a 2 pi aliquot of each reaction was transformed
into DHlOB-u cells as a control. The time constants were between 2.0 and 2.2 ms.
Sample 2c was lost.
The cells were plated on L-agar plates containing Kanamycin, IPTG, and Xgal and
grown overnight (see Methods). The next day, the plates were incubated at 4 °C for
several hours to enhance IPTG/Xgal staining for [3galactosidase. As the
recombination event removes the (3galactosidase cassette from the pAcRClb parent
vector, recombinant colonies will be white, in contrast to blue pAcRClb colonies.
The plates were scored for growth and colony colour (Table 3.3b - p. 126). The Cre
reaction plates from DHIOB-u/pSpRecGam transformations contained both white
and blue colonies, while the DHlOB-u plates and Cre controls contained only blue
colonies. The 77 white colonies were picked and patched onto a fresh L-Agar plate
containing Kanamycin, IPTG, and Xgal (see Methods).
28 of the 77 colonies acquired a blue colour after patching; this could have resulted
from misidentification of the original colony colour (small colonies were often a very
faint blue colour, easily mistaken for white), or contamination with adjacent blue
colonies during the picking process.
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Colony PCR was performed on the remaining 49 white colonies, to identify correct
clones, using the primers GFPs and GFPas (see Appendix A), which amplify a 442
bp fragment of the EGFP sequence. The products were electrophoresed down a 1 %
TBE gel (Fig. 3.6). 19 colonies (#3, 13, 18, 24, 30, 36, 39, 41, 48, 49, 50, 53, 54, 56,
59, 61, 62, 63, +75) showed a 442 bp band, suggesting that the EGFP gene was
present.
To confirm that these were recombinant colonies (and not, for example, recovered
pikbcfproEGFP template from the PCR reaction) additional colony PCRs were
performed. To confirm that the entire insert was present; primer sets 1F/2R and
3F/4R were used (see Appendix A); the resulting PCR products overlap and together
span the site of insertion. The products were electrophoresed down a 1% gel (Fig.
3.7). All of the colonies showed the correct size bands for both PCR reactions - a
1038 bp band for 1F/2R and a 1014bp band for 3F/4R (the colony #18 1F/2R sample
was lost in this experiment, but this colony produced a band of the correct size in a
repeat experiment - results not shown).
Crude DNA minipreps were made from these 19 colonies (see Methods). Clal and
EagI digests were set up on the miniprep DNA (see Methods); the digests were
electrophoresed down a 1% TBE gel. All 19 colonies showed the correct digest
pattern for the recombinant clone, in contrast to the HAcRClb parent clone (Fig. 3.8).
Qiagen DNA Maxipreps were performed on three of these colonies - #13,18 and 24.
Bulk reactions of the 1F/2R and 3F/4R PCR products were generated using the
maxiprep DNA as template. These PCR products were purified with a Qiaquick
PCR-purification kit (see Methods). Primers IF, 1 R, 2F, 2R, 3F, 3R, 4F and 4R (see
Appendix A) were used to sequence the PCR product with a Rhodamine-sequencing
kit (see Methods). It was paramount to sequence the recombinant region to check for
mutations introduced by the polymerase chain reaction or small insertions, deletions,
or rearrangements resulting from imperfect recombination events.
The sequencing of clones #13 and 18 was stopped when mutations were discovered.
Clone #24 was free from mutations in the sequenced region (the sequencing results
are included in Appendix B2); this clone was named PAc65kbcfproEGFP.
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Figure 3.6. GFPs/GFPas PCR on PAC65kbcfproEGFP colonies.
Colony PCR was performed on PAC65kbcfproEGFP colonies 3-76, or
a positive or negative control (as labelled), using the primers GFPs
and GFPas (Appendix A). Colonies 3, 13, 18, 24, 30, 36, 39, 41, 48,
49, 50, 53, 54, 56, 59, 61, 62, 63 and 75 and the positive control
produced a PCR product of size 422 bp, indicating that the EGFP
gene is present in these colonies.
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Figure 3.8. Diagnostic digests of PAC65kbcfproEGFP colonies. Miniprep DNA from
PAC65kbcfproEGFP colonies (3-75) and PACRC1b (as labelled) was digested and run
down an agarose gel (see Methods), (a) Clal digestion of every PAC65kbcfproEGFP
colony produced a single band of the correct size for the recombinant clone (81047
bp). In contrast digestion of pacRC1 b produced two bands (78290 bp and 11908 bp)
(b) Eagl digestion of every PAC65kbcfproEGFP colony produced a single band
(representing a doublet of 66878/13838 bp): the correct pattern for the recombinant
colony. In contrast, digestion of PACRC1b produced three bands; a large band
(representing the 71105/13576 bp doublet) and two smaller bands (3474 and 1412
bp). The Eagl digest for both PAC65kbcfproEGFP and PACRC1 b should also produce a
331 bp band, which is too small to be visualised on this gel.
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Finally, restriction digests of PAc65kbcfproEGFP were run down a pulse field gel
(see Methods). A pulse field gel will separate bands of a larger size, allowing us to
confirm that the large PAC vector has not suffered any gross rearrangements. SacII
and Pmel digestion of PAc65kbcfproEGFP produced the correct pattern for the
recombinant vector, in contrast to the PAcRClb parent vector (Fig 3.9).
3.3.4 PAcRC2cmvEGFP
The PAC vector PAcRC2cmvEGFP contains the EGFP gene under the control of a
Pcmv promoter (see fold-out Appendix E). This is an essential control for
transfection studies, as it reports on the effects of vector size upon expression from
the Pcmv promoter.
PAcRC2cmvEGFP was produced in a similar manner to PAc65kbcfproEGFP (Fig.
3.2.4). A region containing a portion of the Pcmv promoter and the EGFP gene was
amplified from the vector pEGFP-N (described in Appendix D), using the primers
cmvl and loxP (see Appendix A) and the Expand™ high fidelity PCR system. The
PCR product was purified as described above. The pEGFP-N vector was linearised
with Drall before PCR amplification, to minimise recovery of this vector in the
subsequent cloning reaction.
A Cre reaction was used to catalyse a recombination event between the loxP sites in
the PCR product and the PAcRC2b vector. The PAcRC2b vector (described in
Appendix D) is similar to the PAcRClb vector: as above, the recombination method
will delete the (3galactosidase cassette, changing the colony colour in the presence of
IPTG/Xgal. Different ratios of vector to PCR product were used in the Cre reactions
and controls with no PCR product, no PAcRC2b vector, or no Cre were included
(Table 3.2b-p. 124).
2 jllI aliquots of these reactions were disk dialysed and electroporated into 30 (i!
DHlOB-u/pSpRecGam competent E. coli cells (see Methods - two aliquots each for
reactions 1-3, one each for reactions 4 - 6). In addition, a 2 p.1 aliquot of each reaction
was transformed into DHlOB-u competent E. coli cells as a control, and 100 ng of
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Figure 3.9. Diagnostic digests of PAC65kbcfproEGFP
and PACRC1b, run down a pulse field gel. The vectors
were digested with Sacll and Pmel and run down a pulse
field gel. Sacll digestion of (1) PAC65kbcfproEGFP
produced bands of size 74 and 7 kb and (3) PACRC1b
produced bands of size 74, 5.6 and 3.5 kb. Pmel digestion
of (2) PAC65kbcfproEGFP produced a band of size 81 kb
and (4) PACRC1b produced a band of size 90.2 kb
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PAcRC2b was transformed into a 30 fj 1 aliquot of each E. coli strain as an additional
control. The time constants were between 2.0 and 2.2 ms. The time constant for
transforming DHlOB-u with ligation #1 was slightly lower (1.4 ms), but this did not
seem to have a major effect on the subsequent colony growth. The time constant for
transforming ligation #6 into DHlOB-u was much lower (0.5 ms) and a popping
sound accompanied the electroporation. This indicated that the electroporation was
faulty; this could have been due to salt in the electroporation mix, or a bubble in the
cuvette. No colonies grew on plates from this transformation.
Cells were plated on L-agar plates containing Kanamycin, 1PTG, and Xgal and
grown overnight (see Methods). The next day, the plates were scored for growth and
colony colour (Table 3.3c - p. 127).
The presence of white colonies on the control plates, at a similar frequency to the Cre
reaction plates, suggested that most of the white colonies in the Cre reaction plates
were not true recombinants. These colonies could have been the result of
contamination of the transformation with another Kanamycin resistant vector.
Alternatively, they could have been satellite colonies, or Pgalactosidase expressing
cells that had not yet developed blue colour due to their small size or insufficient
Xgal/IPTG in the plate.
Nevertheless, 100 white colonies from the DH1 Ob-u/pSpRecGarn transformation
plates la-c, 2a-c, and 3a-c (see Table 3.3c) were patched onto a new plate for further
analysis. Three white colonies from the PAcRC2b DHlOB-u transformation were also
patched for further investigation of these aberrant white colonies.
Of the 100 patched colonies from the DH lOB-u/pSpRecGam transformation plates
la-3c, only 56 appeared white after patching; the rest appeared blue. All three
'white' colonies from the PAcRC2b plate appeared blue after patching. This suggests
that the original colony colour was not a good indicator of [3galactosidase expression.
Colony PCR was performed to identify recombinant clones amongst these colonies.
The primers cmvseq and 4R flank the insertion site, and PCR should produce a band
of 1.3 kb for the recombinant clone. Because the Pgalactosidase cassette that is
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removed from the vector during the recombination event is not very large, we found
that it was also possible for to amplify a band from the parent vector with these
primers. However, this band was larger (4 kb); thus, we were able to distinguish
between the parental vector and recombinant clone by the size of the PCR product.
This PCR was performed on the 56 colonies that appeared white and 16 colonies that
appeared blue from the patches of DHlOB-u/pSpRecGam transformation plates la-
3c. In addition, a PCR was performed on PAcRC2b DNA as a control. The products
were electrophoresed down a 1% TBE gel (Fig. 3.10).
Surprisingly, one of the blue patched colonies (#22) derived from the plates la - 3c
produced a band of size 1.3 kb, while none of the white patched colonies from these
plates produced bands. Amplification of PAcRC2b DNA failed to produce the 4 kb
band in this experiment; perhaps the conditions were too stringent in this experiment
to allow the generation of this large product.
Colony #22 was investigated further. One possible explanation for the colour
discrepancy would be if this colony were a composite of the recombinant vector and
the parent vector PAcRC2b, thus showing blue colour. To test this theory, the patch
was restreaked for single colonies. Indeed, both white and blue colonies were
derived. Colony PCR showed that the white colonies derived from this streak
produced a band of size 1.3 kb for the recombinant, while blue colonies derived from
this streak and PACRC2b colonies produced a band of size 4 kb (Fig. 3.1 I). Thus, a
recombinant clone (designated clone #22W) was rescued from the composite colony
#22.
A DNA maxiprep of colony #22W was prepared, and restriction analysis was
performed to characterise this plasmid. Notl and SacII digestion of clone #22W
produced the correct digest patterns for PACRC2cmvEGFP in contrast to the parent
plasmid PAcRC2b (Fig. 3.12).
Cmvseq/4R PCR product was amplified from colony #22W DNA, and the product
was purified with a Qiaquick PCR purification kit (see Methods). PCR sequencing
was performed with a Rhodamine kit. using the primers cmvseq, 2R, 3F, 3R, 4F and
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Figure 3.10. cmvseq/4R PCR on PACRC2cmvEGFP colonies.
Colony PCR was performed on PACRC2cmvEGFP white colonies 54
- 95, blue colonies 2 - 33, PACRC2b colonies, or a negative control
(as labelled), using the primers cmvseq and 4R (Appendix A). None
of the white colonies or PACRC2b produced a band of the expected
size for either the recombinant or parent plasmid. However, one of
the blue colonies, #22, produced a 1.3 kb band - the expected size
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Figure 3.11. cmvseq/4R PCR on PACRC2cmvEGFP
clone #22 blue and white colonies . Colony PCR was
performed on PACRC2cmvEGFP clone #22 white and blue
colonies, a PACRC2b colony,or a negative control (as
labelled), using the primers cmvseq and 4R (Appendix A).
The two white colonies produced a 1.3 kb band - the
expected size for the recombinant plasmid, while the two




Figure 3.12. Diagnostic digests of PACRC2cmvEGFP clone #22W and
PACRC2b. Maxiprep DNA was digested with Notl and Sacll and run down
an agarose gel (see Methods). Notl digestion of (1) PACRC2b produced
two bands: a large band (a predicted doublet of sizes 96624 and 14207
bp), and a small band of size 3474 bp; (3) PACRC2cmvEGFP clone #22W
produced a single large band (a predicted doublet of sizes 14169 and
97172 bp). Sacll digestion of (2) PACRC2b produced three bands: a large
band (a predicted doublet of sizes 73956 and 31236 bp) and two smaller
bands of sizes 5636 and 3480 bp; (4) PACRC2cmvEGFP clone #22W
produced two bands: a large band (a predicted doublet of sizes 73953 and
31035 bp) and a smaller band of size 6353 bp.
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4R (see Appendix A). No mutations were found in the recombinant region (the
sequencing results are reported in Appendix B3). Thus, clone #22W was named
PAcRC2cmvEGFP.
Finally, diagnostic restriction digests were performed and run down a pulse-field gel
(see Methods) to confirm that the PACRC2cmvEGFP plasmid does not contain any
gross rearrangements (Fig. 3.13). SacII, Sbfl, and NotI digestion of
pacRC2citivEGFP produced the correct pattern for the recombinant clone, which was
similar to the pattern obtained for the PAcRC2b parent vector.
3.3.5 PAcRCHresEGFP
pacRC 1 iresEGFP is a PAC containing the coding sequences of both CFTR and
EGFP, separated by an IRES, as in pCFTRiresEGFP. 65 kb of CFTR 5' region is
present upstream of the CFTR sequence, to drive expression (see fold-out Appendix
E).
pacRC 1 iresEGFP was made in a similar manner to PAc65kbcfproEGFP (Fig. 3.2.5).
A region containing a portion of CFTR exon 24, the internal ribosome entry site, and
the EGFP gene was amplified from pCFTRiresEGFP, using the primers CFTR5491
and loxP, which introduces the loxP site into the PGR product (Appendix A). The
vector pCFTRiresEGFP was linearised with SnaBl before amplification, to prevent
recovery of this plasmid during the subsequent cloning reaction. A Cre reaction was
then used to catalyse recombination between the loxP sites in this PCR product and
pacRC lb (see Methods). Vector and insert were mixed in different ratios in the Cre
reactions (Table 3.2c - p. 124).
2 pi aliquots of these Cre reactions were disk dialysed, and electroporated into
DHlOB-u/pSpRecGam E. coli cells (two aliquots each for reactions 1+ 2 and one
aliquot for reactions 3-5). In addition, a 2 pi aliquot of each reaction was transformed
into DHlOB-u E. coli cells. The time constants were between 1.8 and 2.0 ins. The
cells were plated on L-agar plates containing Kanamycin, IPTG, and Xgal, and
grown overnight (see Methods). The following day, growth and colony colour were
scored (Table 3.3d - p. 128).













Figure 3.13. Diagnostic digests of PACRC2cmvEGFP and PACRC2b, run down
a pulse field gel. The vectors were digested with Sacll, Sbfl and NotI and run
down a pulse field gel. Sacll digestion of (1) PACRC2cmvEGFP produced three
bands (73953, 31035 and 6353 bp) and (4) PACRC2b produced three similar
bands(73953, 31236 and 5636 bp). Pmel digestion of (2) PACRC2cmvEGFP
produced two bands (77436 and 29989 bp) and (5) PACRC2b produced two similar
bands (80400 and 29989 bp. NotI digestion of (3) PACRC2cmvEGFP produced two
bands (97172 and 14169 bp) and (6) PACRC2b produced two similar bands (96624
and 14207 bp). (N.B.. Sacll digestion of PACRC2b should also produce a 3480 bp
band; Sbfl digestion of PACRC2cmvEGFP and PACRC2b should also produce 2676
and 1240 bp bands, and Not! digestion of PACRC2b should also produce a 3474 bp
band: these are too small to be visualised on a pulse field gel).
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Unfortunately, Xgal/IPTG Pgalactosidase stain was unsuccessful in these plates, and
all of the colonies appeared white. Hence, 400 colonies from the DH10B-
u/pSpRecGam Cre reaction transformation plates were selected at random and
patched onto new plates. 22 of these appeared white after patching (labelled a-v).
Colony PCR was performed on these white colonies using the primers 3F and 4R
(see Appendix A) - the product of this PCR spans the 5' breakpoint of insertion. The
products were electrophoresed down a 1% TBE gel (Fig. 3.14). Six colonies (a, b, f,
h, 1 and o) produced a band of the correct size (1014 bp), in addition to the positive
control PAc65kbcfproEGFP (which has the same 5' breakpoint). Negative controls
with no template did not produce a band.
A second colony PCR product was performed on 5 of these colonies (a, b, f, h and I)
with the primers CF5420 and 4R (see Appendix A); this product spans the entire site
of insertion. The products were electrophoresed down a 1% TBE gel (Fig. 3.15).
Colonies a, b, h, and I produced an 1874 bp band in this PCR, confirming that they
contained the entire insert (in a repeat of this PCR, colony f also produced a band of
size 1874 bp - results not shown). The negative controls did not produce a band.
This CF5420/4R PCR product was amplified directly from these colonies; this
product was purified with the Qiaquick PCR purification kit and treated with
ExoSapIT™ (see Methods). PCR-sequencing was then performed with the primers
CF5420, 2R, 3F, 3R, 4F and 4R (Appendix A) using a Rhodamine kit (see Methods).
Every clone sequenced contained the mutation 71082 G -> A. We hypothesised that
this mutation derived from the original Clontech vector pIRES2EGFP. This mutation
would destroy an ApaLI restriction site at position 1145 in the pIRES2EGFP vector,
leaving a single ApaLI site at position 4937. Indeed, ApaLI digestion of the
pIRES2EGFP vector yielded a single band at -5308 bp, representing linearised
vector (Fig. 3.16). This is consistent with the hypothesis that the mutation derived
from the parent vector.

























Figure 3.14. 3F/4R PCR on pacRC1 iresEGFP colonies.
Colony PCR was performed on pacRC1 iresEGFP colonies a-v,
or a positive control (PAC65kbcfproEGFP) or negative control
(as labelled), using the primers 3F and 4R (Appendix A).
Colonies a, b, f, h, I and o, and the positive control show a
1014 bp PCR product, indicating that the correct 3' join is
present in these colonies.
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Figure 3.15. cf5420/4R PCR on pacRC1 iresEGFP
colonies. Colony PCR was performed on
pacRC1 iresEGFP colonies a-l, or a negative control (as
labelled), using the primers cf5420 and 4R (Appendix
A). Colonies a,b,h and I show a 1874 bp PCR product,
indicating that the correct 5' join is present in these
colonies (unfortunately there was no positive control













Figure 3.16. ApaLI digestion of
plRES2EGFP. plRES2EGFP DNA was
digested with ApaLI (as labelled). A single
5308 bp band can be seen (representing
linearised vector), suggesting that only one
ApaLI site is present in the vector.
Sequencing showed that clone 1 also contained a single base pair deletion in the
region between the polyadenylation site of EGFP and the downstream loxP site
(72127 AT), however this mutation is in an unimportant region, and will not affect
expression; otherwise this clone was free from mutations (The sequencing results are
reported in Appendix B4). Hence, clone 1 was named PAcRC1 iresEGFP.
Restriction digests were performed to further characterise this vector (Fig. 3.17).
NotI and SacII digestion of the pacRCI iresEGFP vector produced the correct pattern
of bands in contrast to the pacRC lb parent vector.
In addition, some diagnostic digests were run down a pulse field gel, to confirm that
there were no gross rearrangements in the vector (Fig. 3.18). BsiWI and Sbfl digests
produced the correct pattern for PAcRC1 iresEGFP, which was similar to the pattern
obtained for the parent vector pacRC 1 b.
3.3.6 PAcRC2iresEGFP
PAcRC2iresEGFP is identical to PAcRCl iresEGFP with the exception that it contains
intron 1 of CFTR in its natural context (see fold-out Appendix E). Thus, these twin
vectors can be used to dissect the influence of intron 1 upon expression.
This clone was made in the same way as pacRCI iresEGFP except that the
CFTR5491/loxP PGR product (retained from pRCl iresEGFP construction - see
above) was recombined with the vector PAcRC2b instead of pacRC lb (Fig. 3.2.6).
Table 3.2d (p. 124) shows the ratios of PGR product to vector used in the Cre
reactions.
3 Jul aliquots of the Cre reactions were disk dialysed and electroporated into DH10B-
u/pSpRecGam cells (two aliquots each for reactions 1 and 2 and one each for
reactions 3 and 4). In addition, a 3 pi aliquot of each reaction was transformed into
DHlOB-u cells as a control. The time constants were generally between 1.9 and 2.0
ms (the time constant of transformation 1 a was only 1.6 ms, and fewer colonies grew
on plates from this transformation).












Figure 3.17. Diagnostic digests of pacRC1 iresEGFP and PACRC1b.
Maxiprep DNA was digested with Notl and Sacll and run down an agarose
gel (see Methods). Notl digestion of (1) pacRC1 iresEGFP produced a
single large band (a predicted doublet of sizes 71941 and 14160 bp); (2)
PACRC1b produced two bands: a large band (a predicted doublet of sizes
72517 and 14207 bp) and a smaller band (3474 bp). Sacll digestion of (3)
PACRC1 iresEGFP produced three bands: a large band (predicted size
73953 bp) and two smaller bands (6928 and 5229 bp); (4) PACRC1b
produced four bands: a large band (predicted size 73953) and three
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Figure 3.18. Diagnostic digests of PACRC1iresEGFP and PACRC1b, run
down a pulse field gel. Maxiprep DNA was digested with BsiWI and Sbfl
and run down a pulse field gel (see Methods). BsiWI digestion of (1)
PACRC1iresEGFP produced a single band (86110 bp) (2) PACRC1b
produced two bands (61876 and 28322 bp). Sbfl digestion of (3)
PACRC1iresEGFP produced three bands (52205, 29989 and 2676) (4)
PACRC1bproduced three similar bands (56293,29989 and 2676 bp).
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Cells were plated on L-agar plated containing Kanamycin, IPTG, and Xgal and
grown overnight (see Methods). Table 3.3e (p. 128) shows the score of colony
growth. The 58 white colonies were patched onto a new plate.
Colony PCR was performed on the patched colonies using the primers CF5420 and
4R (see Appendix A - this PCR spans the entire site of insertion). Nine colonies (#
10,11,15,16,17,18,19,22 and 23) produced a band of the correct size for the
recombinant clone (1874 bp). Six colonies (#13, 14, 20, 21, 24 and 27) produced a
band of -600 bp size; one might speculate that these were colonies where an aberrant
recombination has deleted the pgalactosidase cassette without inserting the ires-
EGFP fragment, but these colonies were not investigated further. PAcRCliresEGFP
was included as a positive control - this also produced an 1874 bp band, while the
negative control did not produce a band (Fig. 3.19).
The CF5420/4R colony PCR product was amplified directly from the colonies, then
purified with the Qiaquick PCR purification kit and treated with ExoSapIT™ (see
Methods). PCR-sequencing was then performed with the primers CF5420, 2R. 3F,
3R, 4F and 4R (see Apppendix A) using a Rhodantine kit (see Methods). The
mutation 95187 G ^ A was identified in every clone sequenced; this is identical to
the mutation seen in the PAcRCl iresEGFP clone, and is consistent with the
hypothesis that this sequence was derived from the parent vector.
Clone #18 also contained a mutation in the region between the polyadenylation site
of EGFP and the downstream loxP site (96232 AT). This mutation was identical to
the mutation found in the PAcRC1 iresEGFP vector (which is in an unimportant region
of the vector)- a striking coincidence that will be considered in the Discussion.
Otherwise, clone #18 was mutation-free (the sequencing results are included in
Appendix B5). This clone was named PACRC2iresEGFP.
Finally, restriction digests were performed on PACRC2iresEGFP, to confirm that the
vector structure was correct (Fig. 3.20). The NotI and SacII digestion of
PAcRC2iresEGFP produced the correct pattern for the recombinant clone, in contrast
to the PAcRC2b parent vector.
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Figure 3.20. Diagnostic digests of PACRC2iresEGFP and PACRC2b.
Maxiprep DNA was digested with A/of/and Sacll and run down an agarose
gel (see Methods). NotI digestion of (1) PACRC2iresEGFP produced a
single large band (a predicted doublet of sizes 96046 and 14169 bp); (2)
PACRC2b produced two bands: a large band (a predicted doublet of sizes
96624 and 14207 bp) and a smaller band (3474 bp). Sacll digestion of (3)
PACRC2iresEGFP produced two bands: a large band (a predicted doublet
of sizes 73953 and 29334 bp) and a smaller band (6928 bp); (4) PACRC2b
produced three bands; a large band (a predicted doublet of sizes 73953
and 31236) and two smaller bands (5636 and 3480 bp).
I 19
In addition, some PAcRC2iresEGFP diagnostic digests were run down a pulse field
gel to confirm that there were no gross rearrangements in the vector (Fig. 3.21).
BsiWI and Sbfl digestion of pACRC2iresEGFP produced the correct pattern for the
recombinant vector, which was similar to the pAcRC2b parent vector.
3.4 Discussion
The successful creation of the vectors PAc65kbcfproEGFP, PAcRC2cmvEGFP,
PAcRC 1 iresEGFP and pACRC2iresEGFP validates some theoretical concepts of vector
design. Firstly, the creation of these vectors demonstrates that it is possible to use a
PCR product in the established double recombination method (Boyd et al, 1999b).
Secondly, it has proved possible to incorporate a loxP site onto the end of a PCR
product by primer-directed mutagenesis.
Colony PCR is a powerful tool for identifying recombinant clones generated by the
double-recombination method. A large number of white colonies were generated
during the production of pAcRC2cmvEGFP (56 white colonies) that were not true
recombinants. In addition, there were many repeats of the cloning experiments which
generated no recombinant clones whatsoever, despite the presence of many white
colonies (data not shown). Because true recombinants were very rare in some cloning
reactions, it would have been laborious to identify these clones by making crude
DNA minipreps and performing restriction analysis.
During the analysis of PAcRC1 iresEGFP and PAcRC2iresEGFP vectors, PCR
sequencing was successfully performed using the product of a colony PCR as
template. This is much less laborious (and expensive) than performing a DNA
maxiprep on every colony prior to PCR-sequencing. Bacterial residue is removed
from the colony PCR during the Qiaquick purification and ExoSapIT™ treatment to
a sufficient degree to facilitate subsequent sequencing reactions.
The PAcRC2cmvEGFP recombinant clone was rescued from a mixed colony. The
blue colour derived from the parent plasmid (pacRC1 b) in colony #22 masked the
presence of the recombinant clone, which would otherwise produce white bacteria.
















Figure 3.21. Diagnostic digests of PACRC2iresEGFP and PACRC2b, run
down a pulse field gel. Maxiprep DNA was digested with BsiWI and Sbfl
and run down a pulse field gel (see Methods). BsiWI digestion of (1)
PACRC2iresEGFP produced a single band (110215 bp); (2) PACRC2b
produced two bands (85983 and 28322 bp). Sbfl digestion of (3)
PACRC2iresEGFP produced two bands (76310 and 29989); (4) PACRC2b
produced two similar bands (80400 and 29989). Sbfl digestion of both
PACRC2iresEGFP and PACRC2b also produced a band of size 2676 bp,
which is too faint to see on the scanned photo.
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Through the sequencing of daughter clones, a probable variation from the published
sequence was uncovered for the vector pIRES2EGFP. This variation would destroy
one of two predicted ApaLI restriction sites in the pIRES2EGFP vector. ApaLI
restriction linearised this vector, rather than producing two fragments, supporting the
hypothesis that the sequence variation derived from the Clontech vector. In other
words, the reported sequence for the pIRES2EGFP plasmid appears to be incorrect.
The PAcRCliresEGFP and PAcRC2iresEGFP clones contained an identical mutation
(AT) between the polyadenylation site of EGFP and the loxP site. This region was
derived from the loxP primer. Several clones that were sequenced (but disqualified
due to other mutations) did not contain the AT mutation. However, the presence of
this identical mutation in both vectors is an uncanny coincidence, and may still
reflect an aberrant synthesis of the loxP primer, such that a proportion of primers
contain this divergent sequence. Fortunately, this mutation does not alter a functional
region of the vector and is therefore inconsequential.
Different ratios of vector to PCR product to insert were included in the Cre reactions
in an attempt to identify the optimum ratio for generating recombinant clones. For
example, in the construction of PAc65kbcfproEGFP, Table 3.3b (p. 126) correlates the
patched colony number with the transformation from which it was derived; Fig. 3.6
shows the results of colony PCR on these patched colonies. By analysing this case in
point, we can consider whether the insert to vector ratio determines the success of
generating recombinant clones.
• The three DHlOB-u/pSpRecGam electroporations from Cre reaction 1
produced three colonies that initially appeared white; only one of these
proved to be a true white colony after patching. This colony was shown to be
a true recombinant in the colony PCR.
• The two electroporations from reaction 2 produced 20 colonies that initially
appeared white, although only 13 of these appeared white after patching. Two
of these colonies were shown to be true recombinants by colony PCR.
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• The three electroporations from reaction 3 produced 54 colonies that initially
appeared white. After patching, only 35 of these colonies appeared white.
Sixteen of these colonies were shown to be true recombinants by colony
PCR.
Thus, the average number of white colonies generated per plate was 0.11 with
reaction 1 (1:5 ratio of insert: vector), 3.33 with reaction 2(1:1 ratio), and 3.89 with
reaction 3 (5:1 ratio). It seems that there is a correlation between the insert to vector
ratio and the number of white colonies produced. This trend is confirmed by the
PAcRC2iresEGFP results (see Table 3.3e - p. 128) where reaction 1(1:1 ratio of insert
to vector) produced an average of 1.33 white colonies per plate, while reaction 2 (5:1
ratio) produced an average of 8.33 white colonies per plate.
One may also consider the proportion of white colonies that turned out to be true
recombinants instead of aberrant white colonies (as determined by colony PCR) and
test whether this is affected by the ratio of insert to vector. When we analyse the
population of white clones for PAc65kbcfproEGFP, we see that 1/1 (frequency = 1)
white colonies is a true recombinant with reaction 1 (1:5 ratio of insert: vector), 2/13
(frequency = 0.154) white clones are true recombinants with reaction 2(1:1 ratio),
and 16/35 (frequency = 0.457) white clones are true recombinants with reaction 3
(5:1 ratio). Thus, there is no recognisable trend in the frequency of true recombinants
vs. aberrant white colonies, in relation to the insert to vector ratio. Taking both of
these factors into account, the largest number of true recombinant clones was derived
by using a high ratio of insert to vector.
To sum up, six vectors were created, coupling CFTR genomic context elements to
the EGFP reporter gene. These constructs can be used in tranfection studies to
investigate the influence of proximal and distal CFTR 5' region and intron 1
elements upon EGFP expression. Four of these vectors were created by a
recombinogenic method utilising both Cre/loxP and homologous recombination.
Two innovations of vector design were validated through the creation of these
constructs: (1) the use of a PCR-generated fragment in the recombinogenic method,
and (2) the incorporation of a loxP site onto the end of the PCR product by primer-
directed mutagenesis.
Chapter 3: Vector design and construction 123
Table 3.1. Ligations. This table describes the amount of insert and vector used in the
p I kbcfproEGFP ligation reaction:
Reaction # 1 2 3
Digested PCR product 75 ng 50 ng 30 ng
Digested pEGFP-1 62.5 ng 62.5 ng 62.5 ng
10X buffer 1 pi lpl i m
Ligase 1 pi 1 pi i pi
H20 ^ 10 pi -» lOpI -» 10 pi
Table 3.2. CRE reactions. This table describes the amounts of insert and vector used in
the Cre reactions during the construction of (a) PAc65kbcfproEGFP, (b)
PAcRC2cmvEGFP, (c) pacRC 1 iresEGFP, and (d) PAcRC2iresEGFP.
(a) PAc65kbcfproEGFP
Reaction# 1 2 3 4 5
RClb 500ng 500ng lOOng 500ng 500ng
PCR product 100 ng 500 ng 500 ng - 500 ng
Buffer M 1 pi 1 pi 1 pi lpl 1 pi
CRE 0.5 pi 0.5 pi 0.5 pi 0.5 pi -
H20 -» 10 pi lOpl lOpl -» 10 pi -> 10 pi
(b) PAcRC2cmvEGFP
1 2 3 4 5 6
RC2b 500 ng 500 ng 100 ng 500 ng 500 ng -
cmv 1/loxP
PCR
500 ng 2.5 pg 500 ng 500 ng - 500 ng
Buffer M 1.5 pi 1.5 pi 1.5 pi 1.5 pi 1.5 pi 1.5 pi
CRE 0.5 pi 0.5 pi 0.5 pi - 0.5 pi 0.5 pi
H:Q -> 15 pi -> 15 pi 15 pi -> 15 pi -» 15 pi -» 15 pi
(c) pacRC 1 iresEGFP
1 2 3 4 5
Rc 1 b lOOng 100 ng 100 ng 100 ng -
PCR product lOOng 500 ng - lOOng 100 ng
Buffer M 1 pi lp! Hal 1 pi i m
CRE 0.5 pi 0.5 pi 0.5 pi - 0.5 pi
H20 -4 10 pi -» 10 pi 10 pi -» 10 pi 10 pi
(d) PACRC2iresEGFP
1 2 3 4 5
Rc2b 500 ng 500 ng 500 ng 500 ng -
PCR product 500 ng 2.5 pg - 500 ng 500 ng
Buffer M 1 pi 1 fh 1 pi 1 Ul 1 Pi
CRE 0.5 pi 0.5 pi 0.5 pi 0.5 pi
h2o -4 10 pi -» 10 pi -> 10 pi 10 pi 10 pi
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Table 3.3. Scores of colony growth. This table shows the score of colony growth from
transformations of (a) pi kbcfproEGFP, (b) PAc65kbcfproEGFP, (c) PACRC2cmvEGFP,
(d) PACRCliresEGFP, and (e) PACRC2iresEGFP. Where colony colour was scored.
B=blue, W=white.
(a) p 1 kbcfproEGFP
Ligation # plate Volume plated # colonies
1 A 100 19
B 200 34
C 200 43
2 A 100 14
B 200 47
C 200 34
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4 100 pi -300B
OW
5 100 pi -600B
OW
DHlOB-u 1 100 pi ~4,000B
OW
2 100 pi ~3,500B
OW
3 100 pi ~3,000B
OW
4 100 pi -5.500B
OW
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RC2b 50 Lawn blue,
5W
(d) pacRC 1 iresEGFP
E. coli strain reaction Volume
Plated
Plate 1 Plate 2 Plate 3
DH10B-u/
pSpRecGam
la 200 -4,000 -5,000 -5,000
lb 200 -7,000 -7,000 -1,000
2a 200 -1,500 -3,000 -900
2b 200 -5.000 -6,000 -2,000
3 50 -800 - -
4 50 -1,500 - -
5 50 0 - -
DHlOB-u 1 50 34 - -
2 50 0 - -
3 50 409 - -
4 50 31 - -
5 50 0 - -
(e) PAcRC2iresEGFP
E. coli strain reaction Volume
Plated
Plate 1 Plate 2 Plate 3
DHIOB-u/
pSpRecGam
la 200 71B, OW 69B, OW 74B, OW
lb 200 488B, 2W 52IB, 4W 384B, 2W
2a 200 561B, 7W 482B, 14W 533B, I4W
2b 200 328B, 4W 312B.4W 230B, 7W
3 50 -400B, OW
4 50 -330B. OW
1 50 -1.800B, OW
2 50 -2.500B, OW
3 50 218B. OW
4 50 2.500B. OW
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4.1 Introduction
In order to test the effects of EGFP reporter plasmids in permanent cell lines, it was
necessary to establish a reliable and efficient method of delivering DNA to these
cells. While naked DNA may be sufficient to accomplish a low level of transfection,
the addition of transfection reagents has the potential improve delivery dramatically.
For example, transfection reagents may enhance delivery by condensing the DNA,
targeting a complex for endocytosis, protecting DNA from endosome degradation, or
by aiding DNA transport into the nucleus. To optimise transfection efficiency,
several reagents were compared:
• DOTAP: The DOTAP reagent is a liposome formulation of the cationic lipid
DOTAP (N-(l -(2,3-Dioleoyloxy)propyl)-N,N,N-trimethylammonium methyl-
sulfate) (Fig. 4.1). 12 pil DOTAP was combined with l |ig DNA in Optimem-
1, according to the optimised protocol (McLachlan et al, 1995, see Methods).
The reagent is supplied as an aqueous dispersion at 1 mg/ml. Mixing DOTAP
with DNA results in the spontaneous formation of stable complexes that are
efficiently endocytosed into eukaryotic cells, with low cytotoxicity. This
reagent can be obtained from Roche Diagnostics (Roche Diagnostics Ltd.,
Bell Lane, Lewes, East Sussex, BN7 1LG, UK, http://www.roche-applied-
science.com/). DOTAP was used as a 'gold standard' for transfection studies,
as this reagent has been extensively employed in the past for in vitro and in
vivo transfection, and has been tested in a clinical CF gene therapy trial
(McLachlan et al, 1995; McLachlan et al, 1996; Porteous et al, 1997).
However, reagents developed more recently may produce higher levels of
transfection.
• Saint-Mix™: Saint-Mix™ is a synthetic amphiphilic (non-liposomal)
delivery system, developed by Saint-B.V (now Synvolux Therapeutics).
Saint-18™ (l-methyl-4-(cis-9-dioleyl)methyl-pyridinium-chloride) (Fig. 4.1)
is a member of the pyridinium surfectant family, which effectively delivers
DNA, RNA and protein to cells, and has a favourable cytotoxicity profile.
The Saint-Mix™ reagent is comprised of Saint-18™




































Figure 4.1: Chemical structures of transfection reagents. This figure shows
the chemical structures of: (a) DOTAP (N-(1-(2,3-Dioleoyloxy)propyl)-N,N,N-
trimethylammonium methyl-sulfate) (b) DOTMA (N-(1-(2,3-dioleyloxy)propyl)-
n,n,n-trimethylammonium chloride) (c) Saint-18 (1-methyl-4-(cis-9-dioleyl)methyl-
pyridinium-chloride) and (d) DOPE (Dioleoyl-phosphatidylethanolamine).
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combined with DOPE (Dioleoyl-phosphatidylethanolamine) (Fig. 4.1) in a
1:1 ratio (weight:weight). Saint-Mix is supplied at 0.75 mM in an aqueous
solution. For optimum transfection efficiency, the company recommends
complexing 20 pi of Saint-Mix with 1 pg of DNA (see Methods). This
reagent, along with further information, can be obtained from Synvolux
Therapeutics (Synvolux Therapeutics, 'Meditech Center', F.J. Zielstraweg 1,
9713 GX Groningen, The Netherlands, http://www.synvolux.nl/).
• Polyethylenimine (PEI): PEI has been used to promote transfection in vitro
and in vivo in several studies (Baker et al, 1997, Bragonzi et al, 1999, Boussif
et al, 1995, Abdallah et al, 1996). PEI acts as a proton sponge across a wide
range of pH values, providing substantial buffering capacity: neutralising
negative charge, and condensing DNA, thus enhancing transfection. In the
PEI method used here, DNA is pre-condensed with a 22KDa PEI, then
condensed with a 25KDa PEI (Thorpe et al, 2002; this method was described
in a personal communication from Matt Cotton). The 22KDa and 25 KDa
PEIs were a kind gift from Dr. Matt Cotton, Institute for Molecular
Pathology, Vienna, Austria.
• LID: The LID method aims to enhance gene transfer by adding a targeting
ligand to the lipid-DNA complex. The integrin receptor is a particularly
attractive target for this purpose; egg-sperm fusion is integrin-mediated and
several viruses (e.g. the foot and mouth virus) bind to integrin receptors to
promote cell entry. The LID method combines 0.75 pi of the liposome
Lipofectin with 4 pg of the integrin targeting peptide P6 and 1 pg of DNA to
form a transfection complex (Hart et al, 1995 and 1998, see methods). The
Lipofectin reagent is comprised of DOTMA (N-( 1 -(2,3-dioleyloxy)propyl)-
n,n,n-trimethylammonium chloride) (see Figure 4.1) and DOPE in a 1:1 ratio
(weight:weight), and can be obtained from Invitrogen (Invitrogen Ltd., 3
Fountain Drive, Inchinnan Business Park,Paisley PA4 9Rf, UK,
http://www.invitrogen.co.uk). The P6 peptide was a kind gift from Dr. Steve
Hart, Institute of Child Health, London. P6 is comprised of the sequence
(Kift)GACRRETAWACG; this peptide acts as a ligand for the a5(3l integrin,
Chapter 4: Optimising transfection efficiency 132
which is expressed by epithelial cells of the lung. Theoretically, the P6
peptide will bind to this integrin receptor on the cell surface and the complex
will subsequently be taken up into the cell by receptor-mediated endocytosis.
LID has been successful in pulmonary gene transfer following lung
instillation delivery to the rat (Jenkins et al, 2000). Furthermore, in a slightly
different method, cationic nanoparticles incorporating an integrin-targeting
ligand sucessfully targeted tumour vasculature in vivo, resulting in a
substantial level of tissue-specific gene transfer (Hood et al, 2002).
• SID: A new transfection protocol was developed for this work, combining
the Saint-Mix™ reagent with the integrin-targeting peptide P6: this was
named the SID method.
As the project progressed, different assays were used to measure transfection
efficiency. At the start of the project, the pCMVp plasmid was transfected into cells,
and Pgalactosidase enzyme activity was measured to determine transfection
efficiency. Initially, an ELISA was used to detect Pgalactosidase expression. This
method was replaced with a Pgalactosidase luminometer assay, which was quicker
and easier, allowing more samples to be processed in parallel.
In keeping with the aims of this project, transfection studies quickly progressed to
utilise constructs expressing the EGFP reporter gene. One of the advantages of using
the EGFP reporter gene is the capacity to detect expression by fluorescence activated
cell sorting (FACS).
FACS is a powerful method. As each cell passes through a cytometer chamber, its
individual fluorescence is measured. When data from the entire population is
assembled, it is possible to determine (I) the number of cells expressing EGFP, that
is, the number of cells with a green fluorescence above background levels and (2) the
average fluorescence of this population, which is directly proportional to the level of
EGFP expression (Subramanian and Srienc, 1996). With the FACS detection system,
one can distinguish between a few cells expressing high levels of protein, and many
cells expressing low levels of protein. To obtain such a measure of Pgalactosidase
expression, it would be necessary to employ two assays: a staining method, to
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quantify the number of cells expressing the protein, and a total protein assay, to
measure the amount of protein produced.
Initially, a traditional histogram method was used to analyse the FACS output. Later
in the project, this was replaced by a dotplot analysis, which was shown to provide
improved discrimination between genuine and background fluorescence.
Because of the high level of variability in transfection studies, every experiment was
performed on at least two, and usually three separate occasions. Although the
absolute levels of transfection often varied from day to day for unknown reasons, the
trends in relative efficiency between transfection reagents were consistent between
experiments. The results of typical experiments are shown to illustrate each example.
4.2 Results
4.2.1 FACS analysis
Historically, FACS output has been analysed by creating a logarithmic histogram of
FLl-H (green) fluorescence; in other words by analysing the green fluorescence
intensity of each cell. Untransfected cells produce a single peak with a normal
distribution at low fluorescence values. This is termed background fluorescence. Fig.
4.2 shows some FLl-H logarithmic histograms of COS-7 cells with different
treatments. In the untransfected sample, there is a single peak on the histogram,
0 ^centered at -10 ' relative fluorescence units.
When cells are transfected with a construct expressing EGFP, an additional peak is
seen on the histogram. In Fig. 4.2, pIRES2EGFP shows an additional peak, which is
centered at ~103 relative fluorescent units. The additional peak represents the fraction
of cells that are expressing EGFP protein at detectable levels. It has been
demonstrated that there is a linear relationship between the cell's FLl-H fluorescence
and the amount of EGFP protein in the cell, despite complex mechanics of EGFP
processing (Subramanian and Srienc, 1996). Thus, the average fluorescence of the
transfected population will be a direct measure of the average level of EGFP
expression in this population.
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Figure 4.2. FACS histograms. COS-7 cells were either (a) left
untransfected, or transfected with (b) plRES2EGFPor (c) pS1G, complexed
with Saint-Mix™. At 48 hours FACS was performed (see Methods). This
figure shows FL1-H histograms of the FACS data. Note the logarithmic scale
of FL1-H intensity. Regions M1 and M2 were created to encompass the
approximate upper 5% and 1% of cells in the untransfected sample,
respectively. These regions were then applied to the transfected samples, for
statistical analysis.
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Several factors influence the number of cells within this additional peak and their
mean fluorescence. The promoter driving EGFP expression will influence the
amount of protein expressed per cell and thus mean fluorescence. Protein fusions
with EGFP may affect the EGFP chromophore, altering the amount of fluorescence
generated per molecule of EGFP and hence the mean fluorescence. If expression is
driven by an internal ribosome entry site, this will reduce the number of EGFP
molecules translated per mRNA molecule, as initiation of translation from an IRES is
less efficient than from the 5' end of the mRNA. In addition, the type of vector used
will affect transfection, for example, large PAC plasmids are less efficiently
transfected than small plasmids (this is discussed further in Section 5.2.6).
If such factors reduce the mean fluorescence below a certain point, the peak of
transfected cells begins to merge with the background peaks. For example in Fig. 4.2,
transfection of the pSIG vector into the COS7 cell line produces a second peak on
the FL1-H FACS histogram, that merges with the background peak (the pS 1G
plasmid encodes a CFTR-EGFP fusion protein, driven by a Pcmv promoter, and was
a gift from Barbara Stevenson, MMC, University of Edinburgh). Thus, EGFP
fluorescence becomes masked by autofluorescence: this is the Achilles heel of FACS
histogram analysis. As the CFTR promoter is very weak, and thus likely to produce
peaks with a low FF1-H mean, a traditional FACS histogram analysis is not best
suited for this study.
One possible way to dissect out the transfected population from merged peaks would
be by subtraction analysis. If the peak profile of an untransfected sample were
subtracted from the peak profile of a transfected sample, the peak of transfected cells
should remain, despite a spectral overlap between the two peaks. However, this
method is inappropriate for GCVs, due to the small number of cells that appear to be
transfected with these PAC vectors. A small number of cells with an FL1-H
fluorescence only slightly above background would not be a very convincing proof
of EGFP expression. In order to demonstrate convincing EGFP expression, there
must be a robust, qualitative difference between the untransfected and transfected
populations.
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The autofluorescence of untransfected cells is highly variable. However, the
background fluorescence appears to be consistent across the spectrum. In analysing a
dotplot of logarithmic FL1-H (green) vs. logarithmic FL2-H (orange) fluorescence
(Fig. 4.3), it appears that in any untransfected cell the green and orange fluorescence
are approximately equal: cells with low to high background fluorescence form a
diagonal line across the plot. However when cells are transfected with a plasmid
expressing EGFP, an additional population appears where FL1-H > FL2-H. This
population appears to represent cells expressing EGFP. A similar type of dotplot
analysis has been previously reported (Blaauw et al, 2000).
An RT-PCR experiment was performed to prove that the group of cells with FL1-H>
FL2-H are a population of cells expressing EGFP, and that the FL1-H fluorescence
of these cells is indicative of the amount of EGFP expressed. The COS-7 cell line
was transfected with the vector pEGFP-N, using the LID method. At 48-hours, cells
were mechanically sorted by a FACSCalibur machine. Three regions were delineated
for gating based on an FLI-H: FL2-H dotplot (Fig. 4.3). "Population 1" included
cells with FL1-H=FL2-H, "Population 2" included cells where FL1-H>FL2-H, with
low FLI-H (green) fluorescence, and "Population 3" included cells with FL1-
H>FL2-H, with high FLI-H (green) fluorescence. Cells were collected for each of
these regions; in addition, an untransfected sample was run through the FACSCalibur
and a sample of these cells with FL1-H=FL2-H was collected. At least 6,000 cells
were collected for each sample (volumes were subsequently adjusted to correct for
cell number).
The RNA was extracted from these four samples; DNase treatment and cDNA
synthesis were performed (see Methods). RT-PCR was performed in duplicate (see
Methods), for both EGFP (using the primers EGFPs and EGFPas - Appendix A) and
GAPDH (using the primers GAPDHexon 8 and GAPDFlint - Appendix A). -AMV-
RT duplicate RNA samples (where the AMV-reverse transcriptase was omitted from
the cDNA synthesis step), and water-only samples were included as negative
controls, and samples including known quantities of the pEGFP-N vector (Clontech)
were included as positive controls. The products were electrophoresed down 1%
TBE gels and a Southern Blot was performed. The filters were probed with 2P-ATP
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Figure 4.3. FACS FL1-H : FL2-H dotplot. (a) FACS dual dotplot analysis. COS-7
cells were transfected with the pEGFP-N vector, using the LID method, or left
untransfected (as labelled). At 48-hours, FACS was performed; this figure shows the
result of an FL1-H : FL2-H dotplot analysis. In the untransfected sample, all cells
have an FL1-H reading approximately equal to their FL2-H reading. However, in the
pEGFP-N transfected population, there is an additional population of cells, where
FL1-H>FL2-H, these appear to be cells expressing EGFP. (b) Gating populations of
cells. COS-7 cells were transfected with the pEGFP-N vector, using the LID method.
At 48-hours, cells were prepared for FACS (see Methods). A FACSCalibur machine
was used to analyse and mechanically sort the cells. Three regions were delineated
for gating: "Population 1", where FL1-H=FL2-H, "Population 2", where FL1-
H>FL2-H, with low fluorescence and "Population 3", where FL1-H > FL2-H, with
high fluorescence. In addition, an untransfected sample was run through the
FACSCalibur machine, and an ungated sample was collected, to act as a control (not
shown). At least 6,000 cells were collected for each sample.
138
labelled internal oligonucleotides (EGFPint for EGFP, and GAPDHint for the
GAPDH - see Appendix A.)
Semi-quantitative analysis of 32P signal was performed with a phosphoimager
cassette (Fig. 4.4). GAPDH mRNA levels were similar between the four populations
(it was not possible to perform a quantitative analysis of GAPDH levels, as no vector
containing the GAPDH sequence was available in the lab). The phosphoimager
values for the known quantities of pEGFP-N vector were plotted as a titration curve.
These values were used to predict the number of EGFP cDNA copies in the three
populations of gated cells, and in the untransfected sample (Fig. 4.4 and Fig. 4.5).
In addition, a T-test statistic was used to test whether the amount of cDNA in each
population was significantly above the background levels of untransfected cells, and
to compare the levels in "Population 2" and "Population 3" (see Appendix F1). In
"Population 1", the predicted amount of EGFP cDNA was very low (1.45 amol).
This was not significantly different from background levels. The predicted amount of
EGFP cDNA was very high in "Population 3" (8372 amol.). A lower, but still
substantial amount of EGFP cDNA was predicted in "Population 2" (16.9 amol),
despite the fact that the FL1-H reading of cells in this region was comparable to that
of untransfected cells. The amount of cDNA in "Population 3" and "Population 2"
were both significantly different from the untransfected sample (p = 0.0385 and
0.0001, respectively). In addition, the amount of cDNA in "Population 3" was
significantly different from that in "Population 2" (p = 0.0023). This shows that we
can accurately separate cells expressing EGFP by their FF1-H: FF2-H ratio, and that
there is a relationship between the FF1-H intensity of the population and the levels of
EGFP mRNA present in that population.
There is a complex relationship between mRNA and protein levels, especially as
proteins are generally more stable than their mRNAs (Carey and Smale,
Transcriptional Regulation in Eukaryotes, Chapter 5). Hence, even if the
phosphoimager results were a perfect measure of the mRNA levels, and the
fluorescence was proportional to the amount of EGFP protein, we would not expect a
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Signal 1 Signal 2 Population Signal Predicted am't
EGFP cDNA (amol.)
100 ng (32.2 fmol.) 764318.42 665096.34 Untransfected #1 786.09 0
10 ng (3.22 fmol.) 405934.20 371723.21 Untransfected #2 779.86 0
01 ng (0.322 fmol.) 132075.84 115855.00 Population 1 #1 2640.35 2.25
100 pg (0.0322 fmol.) 110630.95 111400.53 Population 1 #2 1839.26 0.64
-ve 1237.16 1028.12 Population 2 #1 10891.16 19.32
Population 2 #2 8500.46 14.49
Population 3 #1 145460.99 9016.00
Population 3 #2 136471.42 7728.00
Figure 4.4. RT-PCR of FACSorted populations: phosphoimager results. RT-PCR was performed on the
FACSorted populations shown in Fig. 4.2. The products were run down an agarose gel, and a Southern Blot
was performed. The Filter was probed with 32P-ATP labelled oligonucleotide (GAPDHint or EGFPint). A
phosphoimager scan was used to detect radioactive signal. This top panel of this figure shows a picture of
the phosphoimager scan of the filter, (a) GAPDH RT-PCR: the GAPDH signal looks similar in all of the
+AMV-RT samples, and is absent from the -AMV-RT samples and H20 controls, (b) EGFP RT-PCR: In the
+AMV-RT duplicates, a strong signal can be seen in the FLH-1>FLH-2 high samples ("population 3"), and in
the plasmid controls. A weaker signal can be seen in the FLH-1>FLH-2 low samples ("population 2"). Little or
no signal is seen in the FL1-H=FL2-H sample ("population 1") and the untransfected sample. No signal is
detected in the -AMV-RT dulpicates or H20 controls, (c) Semi-quantitiative analysis was performed with
imageQuant software. The predicted EGFP mRNA concentrations for each population were calculated
based on a plot of the signal in the plasmid controls (as 1/20 of the total sample was used for each RT-PCR,












Figure 4.5. RT-PCR of FACSorted populations: Histogram of the
phosphoimager results. Semi-quantitative RT-PCR was performed on the
FACS sorted populations (Fig.4.2): a phosphoimager was used to calculate
the predicted amount of EGFP cDNA in each population (Fig. 4.3). This
figure shows a logarithmic histogram of the predicted cDNA concentrations in
the three FACS sorted populations of the transfected sample: (1) "Population
1" (FL1-H =FL2-H) (2) "Population 2" (FL1-H>FL2-H with low FL1-H
fluorescence) (3) "Population 3" (FL1-H>FL2-H with high FL1-H
fluorescence) and (4) in the untransfected sample.
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1:1 relationship between the mRNA levels and fluorescence intensity. However,
based on these RT-PCR results, it seems likely that the FL1-H fluorescence intensity
will continue to be a linear measure of EGFP protein levels (as shown by
Subramanian and Srienc, 1996) when analysing FACS data by this dotplot method. It
appears that even in cells where the FL1-H levels are not significantly above those of
untransfected cells, the FL1-H: FL2-H ratio can be used to distinguish a population
of cells expressing EGFP.
A mixing experiment was done to confirm that the number of cells within the
delineated population (where FL1-H>FL2-H) is a consistent measure of the number
of cells with detectable EGFP expression, across a range of values. The COS-7 cell
line was transfected with the pEGFP-N plasmid, using the Saint-Mix™ reagent, or
left untransfected. At 48 hours, the concentration of cells in each sample was
quantified on a haemocytometer slide. The transfected sample was then mixed with
the untransfected sample in different proportions (0 - all untransfected sample, 0.1,
0.25, 0.5, 0.75 and I - all transfected sample) and FACS analysis was performed on
these samples. Fig. 4.6 shows a plot of dilution factor vs. the percentage of cells with
detectable EGFP expression (the original dotplot data is shown in Appendix C). A
curvilinear/linear relationship can be seen between the dilution factor and the
percentage of cells with detectable EGFP expression, as measured by the dotplot,
method. This simple experiment confirms that we can effectively measure the
number of cells with detectable EGFP expression across a range of values, using this
method.
The FL1-H: FL2-H dotplot method was used to analyse all subsequent FACS data. In
each experiment, a dotplot of an untransfected sample was analysed first, in order to
define a triangle excluding all cells in the untransfected sample (where FL1-H>FL2-
H). This triangle region was then applied to the dotplots generated for each
transfected sample. To quantify the percentage of cells with detectable EGFP
expression, the proportion of cells within the triangle region was calculated. In order
to quantify the average fluorescence of the transfected population, the mean
fluorescence of cells within the triangle region was calculated. For untransfected
samples, the mean of all cells (which fall outside the triangle region by definition)
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Figure 4.6. Dual-dotplot analysis: the effects of diluting the transfected
sample. COS-7 cells were transfected with the pEGFP-N plasmid using the
Saint-Mix™ reagent, or left untransfected. At 48-hours post-transfection,
FACS was performed (see Methods), and the data was analysed by the
dotplot method. The transfected sample was mixed with the untransfected
sample in the following proportions: 0 (all untransfected), 0.1, 0.25, 0.5, 0.75,
1 (all transfected). A curvilinear/linear correlation appears to exist between
fraction of cells that were transfected and the percentage of cells with
detectable EGFP expression. The dotplots for this graph are shown in
Appendix C.1.
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was calculated as a measure of background fluorescence. For each experiment,
duplicate or triplicate samples were processed, and the average values were
calculated, regarding the percentage of cells with detectable EGFP expression (%[f])
and the average fluorescence of the transfected population (Xf). This data is
displayed in the figures as histograms; the original dotplots are shown in
Appendix C.
4.2.2 Saint-Mix™ vs. DOTAP
Saint-Mix™ and the liposome DOTAP were compared for transfection efficiency.
Saint-Mix™ was complexed with the plasmid pCMVP in the ratios (pi Saint-Mix™:
pg plasmid) 20:1 10:1 or 5:1. DOTAP was complexed with the pCMV(3 plasmid in
the standard ratio 12 pi DOTAP: 1 pg plasmid (McLachlan et al, 1995). The
complexes were prepared according to the standard protocol, then transfected into
the COS-7 cell line (see Methods). 48 hours after transfection, the cells were lysed
and a (3-Galactosidase EL1SA was performed to quantify (3-Galactosidase protein in
the cell lysates (see Methods). The results are shown in Figure 4.7. A 20:1 ratio of
Saint-Mix™ to plasmid produced the optimum levels of transfection (352 ng/pl
pgalactosidase), although similar results were obtained following Saint-Mix
transfection at a ratio of 10:1 or 5:1 (267.23 and 206.63 ng/pl Pgalactosidase,
respectively), or DOTAP transfection (238.53 ng/pl pgalactosidase).
4.2.3 PEI vs. Saint-Mix™ vs. DOTAP
Polyethylenimine (PEI) transfection was performed according to the established
protocol (Thorpe et al, 2002). COS-7 cells were transfected with the plasmid
pCMVp using either PEI, Saint-Mix™, or DOTAP (see Methods). 48 hours after
transfection, cells were lysed and the Pgalactosidase concentration in the cell lysate
was measured with a luminometer assay (see Methods). The results are shown in Fig.
4.8. PEI produced the highest level of transfection (196.03 ng/pl pgalactosidase),
which was significantly higher than Saint mix transfection (101.37 ng/pl)
(p=0.0076), and DOTAP transfection (20.27 ng/pl)(p=0.0009). In this experiment,
Saint-Mix transfection was significantly higher than DOTAP transfection
(p=0.0095).
Chapter 4: Optimising transfection efficiency 144
Figure 4.7. Saint-Mix™ ratio and DOTAP transfection of pCMVp into the
COS-7 cell line. The COS-7 cell line was transfected with the pCMVp
plasmid, complexed with Saint-Mix™ in a 20:1, 10:1 or 5:1 ratio (pi Saint-
Mix™: pg DNA) or DOTAP in a 12:1 ratio (pi DOTAP: pg DNA)(as labelled).
48 hours after transfection, the (3galactosidase concentration was measured
with a pgalactosidase ELISA (see Methods). This figure shows a histogram
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Figure 4.8. PEI, Saint-Mix™ and DOTAP transfection of pCMVp into the
COS-7 cell line. The COS-7 cell line was transfected with the pCMV(3
plasmid, complexed with either PEI, Saint-Mix™ or DOTAP (as labelled). 48
hours after transfection, the (3galactosidase concentration was measured with
a luminometer assay (see Methods). This figure shows a histogram of the
Pgalactosidase concentration in the lysate.
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This experiment was repeated in the MDCK-iowa cell line (Fig. 4.9); these results
mirror those in the COS-7 cell line: PEI produced the optimum level of transfection
(14.06 ng/pl Pgalactosidase) which was significantly higher than Saint-Mix
tranfection (3.96 ng/pl) (p=0.0097) and DOTAP transfection (0.91 ng/pl)
(p=0.0058). Saint-Mix tranfection was significantly higher than DOTAP transfection
(p=0.0005).
The experiment was repeated with EGFP-expressing plasmids, using FACS analysis,
in order to dissect the number of transfected cells vs. the level of expression per cell.
When COS-7 cells were transfected with the p 1 kbcfproEGFP plasmid (Fig. 4.10),
Saint-Mix™ transfection produced the largest percentage of cells expressing EGFP
(%[f]= 29.18). PEI and DOTAP were significantly less efficient (%[f] = 12.58 and
9.46, respectively)(p=0.0266 and 0.0157, respectively). However, the DOTAP,
Saint-Mix™ and PEI reagents produced similar levels for the average fluorescence
of the transfected population (Xf= 1153.08, 938.56 and 643.06, respectively). These
results are at variance with those of the Pgalactosidase assay.
When MDCK-iowa cells were transfected with the pEGFP-N plasmid (Fig. 4.1 1),
again Saint-Mix™ transfection produced the largest percentage of cells expressing
EGFP (%[f| = 7.65), however, the number produced by PEI transfection (%[f) =
3.84) and DOTAP transfection (%[f] = 0.26) were not significantly lower. The
average fluorescence of the transfected population was significantly higher with PEI
(Xf = 2570.59) than with Saint-Mix™ (Xf = 391.82) (p=0.0262) and DOTAP (Xf
= 179.84)(p =0.0177).
Thus, Saint-Mix™ transfection appears to produce more cells expressing EGFP than
PEI transfection, at least in the COS-7 cell line. However, following transfection of
the MDCK-iowa cell line with the pEGFP-N plasmid, the average fluorescence of the
transfected population was much higher with PEI than with Saint-Mix™: this might
provide a clue to explain the higher readings obtained from PEI transfection in the
Pgalactosidase assay (this is considered further in the Discussion).
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Figure 4.9. PEI, Saint-Mix and DOTAP transfection of pCMVp into the
MDCK-iowa cell line. The MDCK-iowa cell line was transfected with the
pCMV(3 plasmid, complexed with either PEI, Saint-Mix or DOTAP (as
labelled). 48 hours after transfection, the [3galactosidase concentration was
measured with a luminometer assay (see Methods). This figure shows a
histogram of the pgalactosidase concentration in the lysate.
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Figure 4.10. PEI, Saint-Mix and DOTAP transfection of plkbcfproEGFP
into the COS-7 cell line. The COS-7 cell line was transfected with the
plkbcfproEGFP plasmid complexed with either PEI, Saint-Mix or DOTAP (as
labelled). At 48-hours post-transfection, cells were analysed by FACS (see
Methods). This figure shows: (a) a histogram of the percentage of cells with
detectable EGFP expression and (b) a histogram of the average
fluorescence of the transfected population. The dotplots for these histograms
are shown in Appendix C.2.
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(b) average fluorescence of the transfected population
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Figure 4.11. PEI, Saint-Mix and DOTAP transfection of pEGFP-N into the
MDCK-iowa cell line. The MDCK-iowAcell line was transfected with the
pEGFP-N plasmid complexed with either PEI, Saint-Mix or DOTAP (as
labelled). At 48-hours post-transfection, cells were analysed by FACS (see
Methods). This figure shows: (a) a histogram of the percentage of cells with
detectable EGFP expression and (b) a histogram of the average
fluorescence of the transfected population. The dotplots for these histograms
are shown in Appendix C.3.
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4.2.4 The effects of P6: Lipofectin and Saint-Mix™ vs. LID and SID
Dr. Steve Hart, Institute of Child Health, London devised the LID method, which
combines liposome, integrin-targeting peptide, and DNA for transfection (Hart et al,
1995 and 1998). Because epithelial cells of the lung express the integrin receptor that
binds the P6 motif, this method has the potential to target this cell type in gene
therapy. However, recent evidence suggests that the improved transfection efficiency
with LID vector incorporating the P6 ligand may not in fact be accomplished by such
a specific ligand-receptor interaction, as randomised P6 peptide sequences are
equally efficacious (personal communication by Dr. Steve Hart).
LID complex was prepared according to the established method (personal
communication from Dr. Steve Hart, see Methods). In addition, 20 jll of the Saint-
Mix™ reagent was complexed with 1, 2, 4 or 8 pg P6 and 1 pg DNA; this was called
the SID method. These two methods were compared to transfection with Saint-
Mix™ or Lipofectin only. Initially, cells were transfected with pCMV(3, and a
luminometer assay was used to analyse the amount of (3galactosidase in the cell
lysate. These compounds were tested for transfection in the COS-7, MDCK-iowAand
Caco-2 cell lines.
In the COS-7 cell line (Fig. 4.12), the LID reagent produced the highest level of
transfection (133.5 ng/pl (3galactosidase), which was significantly higher than SID
with 2 pg P6 (31.92 ng/pl)(p=0.0199) and Lipofectin (1.55 ng/pl)(p=0.01 15).
Amongst the SID treatments, 2 pg P6 gave the highest level of transfection, although
the levels obtained with 1 pg, 4 pg and 8 pg P6 and Saint-Mix only, were not
significantly lower (13.55, 28.4, 24.7, and 10.55 ng/pl, respectively).
In the MDCK-iowa cell line (Fig. 4.13), SID with 1 pg P6 produced the highest level
of transfection (6.8 ng/pl pgalactosidase), although this value was not significantly
different from that obtained with LID (4.25 ng/pl). SID with I pg P6 did exceed
transfection with Lipofectin (1 ng/pl) (p=0.0386). Amongst the SID treatments, SID
with 1 pg P6 was not significantly higher than SID with 2 pg P6, 4 pg P6, 8 pg P6 or
Saint-Mix only (5.9, 6.55, 5.75 and 2 ng/pl, respectively).
















Figure 4.12. SID, Saint-Mix™, LID and Lipofectin transfection of pCMVp
into the COS-7 cell line. The COS-7 cell line was transfected with the
pCMVp plasmid, complexed with SID (Saint-Mix™ +1, 2, 4, or 8 pg P6),
Saint-Mix™ only, LID or Lipofectin, or left untransfected (as labelled). 48
hours after transfection, the pgalactosidase concentration was measured with
a luminometer assay (see Methods). This figure shows a histogram of the
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Figure 4.13. SID, Saint-Mix™, LID and Lipofectin transfection of pCMVp
into the MDCK-iowa cell line. The MDCK-iowa cell line was transfected with
the pCMVp plasmid, complexed with SID (Saint-Mix™ and 1, 2, 4, or 8 pg
P6) Saint-Mix™ only, LID or Lipofectin, or left untransfected (as labelled). 48
hours after transfection, the Pgalactosidase concentration was measured with
a luminometer assay (see Methods). This figure shows a histogram of the
Pgalactosidase concentration in the cell lysate.
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In the Caco-2 cell line (Fig. 4.14), SID with I jig P6 produced the optimum levels of
tranfection, (5.53 ng/pl (3galactosidase), although the values obtained with LID and
Saint-Mix only were not significantly different (4.95, and 1.45 ng/jil pgalactosidase,
respectively). SID with 1 jig P6 transaction was, however, significantly more
efficient than Lipofectin transfection (0.11 ng/jil) (p=0.0145). Amongst the SID
treatments, SID with 1 jig P6 produced a significantly higher level of transfection
than SID with 2 |ig P6 or 4 jig P6 (2.23 and 2.24 ng/jil, respectively)(p=0.0481 and
00487, respectively).
Subsequently, cells were transfected with the pEGFP-N plasmid and FACS analysis
was used to determine the number of cells expressing EGFP and the mean
fluorescence of the transfected population. The SID method (using the optimum
amount of P6 for each line, as determined by the previous p-galactosidase assay)
was compared with the LID method, Saint-Mix™ alone, and Lipofectin alone.
In the COS-7 cell line (Fig. 4.15), LID, Saint-Mix and SID produced a similar
percentage of cells expressing EGFP (%|f| = 28.88, 22.38, 20.07, respectively); each
of these reagent produced a significantly higher percentage than Lipofectin (%[f| =
2.84)(p=0.0745, 0.0111 and 0.0011, respectively). However, Saint-Mix, LID,
Lipofectin and SID produced a similar mean fluorescence amongst the transfected
population (Xt = 4139.5, 4077.4, 3615.96 and 3550.16, respectively).
In the MDCK-iowa line (Fig. 4.16), the LID, Saint-Mix and SID methods produced a
similar percentage of cells expressing EGFP (%[f] = 6.87, 6.0, and 4.91,
respectively), while Lipofectin produced a significantly lower percentage (%[f] 1.37)
than LID (p=0.0082). The LID and SID methods produced a similar mean
fluorescence amongst the transfected population (Xf = 1888.24 and 1590.75). Lower
levels were found in the Saint Mix (X, = 215.24)(compared with SID, p=0.0325) and
lipofectin (Xt = 70.23)(compared with LID, p=0.001) transfections.
In Caco-2 (Fig. 4.17), LID transfection (%[f] = 8.03) produced a significantly higher
percentage of cells expressing EGFP than SID (%[f] = 6.11 )(p=0.0445), Saint-Mix
(%[f] = 4.67)(p=0.033), and Lipofectin (%|f| =0.55)(p=0.0037). Furthermore, SID
Chapter 4: Optimising transfection efficiency 154
Saint + 1 Saint + 2 Saint + 4 Saint + 8 Saint Mix LID lipofectin No DNA
ug P6 ug P6 ug P6 ug P6
Figure 4.14. SID, Saint-Mix™, LID and Lipofectin transfection of pCMV(3
into the Caco-2 cell line. The Caco-2 cell line was transfected with the
pCMV(3 plasmid, complexed with SID (Saint-Mix + 1, 2, 4, or 8 jig P6), Saint-
Mix™ only, LID or Lipofectin, or left untransfected (as labelled). 48 hours
after transfection, the pgalactosidase concentration was measured with a
luminometer assay (see Methods). This figure shows a histogram of the
Pgalactosidase concentration in the cell lysate.
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Figure 4.15. SID, Saint-Mix™, LID and Lipofectin transfection of pEGFP-
N into the COS-7 cell line. The COS-7 cell line was transfected with the
pEGFP-N plasmid complexed with either SID, Saint-Mix™, LID or Lipofectin
(as labelled). 48 hours after transfection, cells were analysed by FACS (see
Methods). This figure shows: (a) a histogram of the percentage of cells with
detectable EGFP expression and (b) a histogram of the average
fluorescence of the transfected population. The dotplots for these histograms
are shown in Appendix C.4.
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Figure 4.16. SID, Saint-Mix™, LID and lipofectin transfection of pEGFP-
N into the MDCK-iowa cell line. The MDCK-iowa cell line was transfected
with the pEGFP-N plasmid complexed with either SID, Saint-Mix™, LID or
Lipofectin (as labelled). 48 hours after transfection, cells were analysed by
FACS (see Methods). This figure shows: (a) a histogram of the percentage of
cells with detectable EGFP expression and (b) a histogram of the average
fluorescence of the transfected population. The dotplots for these histograms
are shown in Appendix C.5.
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Figure 4.17. SID, Saint-Mix™, LID and Lipofectin transfection of pEGFP-
N into the Caco-2 cell line. The Caco-2 cell line was transfected with the
pEGFP-N plasmid complexed with either SID, Saint-Mix, LID or Lipofectin. At
48-hours post-transfection, cells were analysed by FACS (see Methods).
This figure shows: (a) a histogram of the percentage of cells with detectable
EGFP expression and (b) a histogram of the average fluorescence of the
transfected population. The dotplots for these histograms are shown in
Appendix C.6.
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and Saint-mix produced a significantly higher percentage than Lipofectin(p=0.0078
and 0.0262, respectively). However, SID produced the highest average fluorescence
amongst the transfected population (Xf = 1406.17), which was significantly higher
than LID (Xf =937.86)(p=0.0441) and Lipofectin (Xf =305.61 )(p=0.0413), but not
significantly different from Saint-Mix (Xf =827.84).
Thus, the FACS results were not consistent with the pgalactosidase assay results.
This was probably the result of a general decrease in the efficiency of the Saint-
Mix™ reagent throughout the course of the project (see Discussion). It was evident
that the total amount of protein generated in a transfected sample derived from a
complex interaction between the number of cells expressing the protein and the level
of expression per cell. It was also apparent that each cell line had a unique profile of
transfection efficiency.
FACS was also used to compare these methods in the T84 cell line. The pEGFP-N
plasmid was transfected into this cell line using either SID (with 1 pg P6), LID,
Saint- Mix™ or DOTAP (Fig. 4.18). In this line, LID produced the highest
percentage of cells expressing EGFP (%[f] = 21.56), which was significantly higher
than SID(%|f| = 15.62)(p=0.0164), Saint-Mix (%[f] = 14.05)(p=0.0244) and DOTAP
(%[f] = 8.53)(p=0.0021); furthermore, SID produced a significantly higher level than
DOTAP (p = 0.0094). However, the average fluorescence of the transfected
population was similar for Saint-Mix, SID, LID and DOTAP (Xf = 440.65, 373.16,
365.1 and 331.63, respectively).
Finally, transfection efficiency was optimised in the HBE cell line. SID, Saint-
Mix™, LID, and DOTAP were used to transfect the pEGFP-N vector into this line
(Fig. 4.19). Saint-Mix produced the highest percentage of cells expressing EGFP
(%[f] = 13.23), which was simlar to SID and LID (%[f] =11.5 and 7.73). SID
produced a significantly higher level than DOTAP (%[f| = 2.69)(p=0.0366). The
average fluorescence of the transfected population was similar between LID, Saint-
Mix, DOTAP and SID (Xf= 1021.62, 896.9, 824.08 and 777.38, respectively).
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Figure 4.18. SID, Saint-Mix™, LID and DOTAP transfection of pEGFP-N
into the T84 cell line. The T84 cell line was transfected with the pEGFP-N
plasmid complexed with either SID, Saint-Mix™, LID or DOTAP (as labelled).
48 hours after transfection, cells were analysed by FACS (see Methods).
This figure shows: (a) a histogram of the percentage of cells with detectable
EGFP expression and (b) a histogram of the average fluorescence of the
transfected population. The dotplots for these histograms are shown in
Appendix C.7.
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Figure 4.19. SID, Saint-Mix™, LID and DOTAP transfection of pEGFP-N
into the HBE cell line. The HBE cell line was transfected with the pEGFP-N
plasmid complexed with either SID, Saint-Mix™, LID or DOTAP (as labelled).
48 hours after transfection, cells were analysed by FACS (see Methods).
This figure shows: (a) a histogram of the percentage of cells with detectable
EGFP expression and (b) a histogram of the average fluorescence of the




Experiments confirm that an FL1-H: FL2-H dotplot can be used to distinguish cells
expressing EGFP in a transfected sample. An RT-PCR experiment confirms that the
population of cells with FL1-H>FF2-H express EGFP, and that there is a positive
correlation between the FL1-H intensity and the amount of EGFP mRNA in these
cells. Mixing experiments show that the number of cells in the region where FLI-
H>FF2-H is an accurate measure of the number of cells expressing EGFP across a
range of values.
Transfection of cell lines is notoriously inconsistent. The overall efficiency of
transfection varies greatly from day to day due to a combination of factors, many
unknown. One must be careful not to over-interpret the results of these studies.
In order for a cell to express protein from a transgenic vector, DNA must be taken up
into the cell, enter the nucleus and become transcribed. Different methods
accomplish this in different ways. For example, a lipoplex achieves cell entry
through the process of endocytosis. Addition of the integrin receptor targeting
peptide allows this endocytosis to become receptor-mediated. In the PEI method,
DNA is condensed and thus is afforded some protection from endosome degradation
following cell entry. Despite much research on the subject, many facets of the
transfection process remain a mystery.
In comparing PEI, Saint-Mix™, and DOTAP (Section 4.2.3), some discrepancies
were found between the results of pCMV[3 transfection (as measured by a
luminescent assay), and EGFP transfection (as measured by FACS). One clue as to
this reason for this discrepancy may come from the experiment on MDCK-iowa cells
transfected with the pEGFP-N plasmid using either PEI, Saint-Mix™, or DOTAP
(Fig. 4.11). Although Saint-Mix™ transfected the largest number of cells, the PEI
method produced a much higher mean fluorescence amongst the transfected
population. This is likely to account for the apparent increase in transfection
efficiency with PEI over that found with Saint-Mix™, as reported by the
pgalactosidase luminometer assay.
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This result was not mirrored when the pikbcfproEGFP vector was transfected into
the COS-7 cell line (Fig. 4.10). Thus, the effect may be specific to the Pcmv
promoter. It is possible that a tightly regulated promoter, such as that of CFTR,
would not be amenable to indiscriminate upregulation of expression, whilst the
promoter of a virus, which has evolved to allow maximum expression levels, would
be amenable to such upregulation. Further study would be needed to evaluate this
hypothesis. In this instance FACS analysis of EGFP expression proved to be superior
to Pgalactosidase protein assays, as it provided a vital insight into the components of
transfection efficiency.
In comparing transfection reagents it became obvious that the overall transfection
efficiency (e.g. amount of protein expressed) is made up of a complex interaction
between the percentage of cells expressing the transgene and the level of expression
per cell. These components of transfection appear to be affected in different ways by
different transfection reagents.
The ultimate aim of comparing transfection reagents in this study was to maximise
the number of cells transfected, in order to facilitate a study of CFTR control
elements, and their effect on transgene expression. Although PEI may increase the
level of expression in certain situations, this effect may not be consistent between
promoters. This effect may be due to a change in the level of expression per
transfected cell, rather than a change in the number of cells expressing the transgene.
The aim of the GCV approach is to attempt to replicate the endogenous CFTR
expression levels, not to increase them, thus PEI may not be an appropriate
tranfection reagent for these studies.
Although the Saint-Mix™ method showed promise at the start of the project, this
reagent produced variable results, and the efficiency of transfection with this reagent
generally declined through the course of the project. For example, at the start of the
project it was possible to transfect -50% of cells in the COS-7 cell line with this
reagent (Fig. 4.2), but by the end of the project only -20-30% of cells were
transfected in the COS-7 cell line with this reagent (Fig. 4.15). In addition, a few
inconsistent batches of Saint-Mix™ were obtained, which produced little or no
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transfection at all. It is unclear whether these fluctuations were due to changes in
product quality (for example due to batch to batch variation, or changes in the
product formulation or shipping conditions), or whether they were an artifact of the
system (for example, this transfection method might be particularly sensitive to
changes in composition between batches of culture media or serum, or the COi level
in the incubator).
When Saint-Mix™ worked at its best, it produced a very high level of transfection,
and this was primarily due to an increase in the number of cells expressing the
transgene. If the causes of variation in transfection efficiency could be pinpointed
and controlled, Saint-Mix™ would be an excellent transfection reagent for this type
of study. The integrin-targeting peptide P6 may have the potential to increase
transfection efficiency even further iri concert with Saint-Mix™, in the SID method.
However, the SID method showed the same variability as Saint-Mix™ alone. The
overall decrease in Saint-Mix™ reagent efficiency probably explains the discrepancy
between the (3gaIactosidase and FACS results, when comparing the SID, Saint-
Mix™, LID and Lipofectin reagents. Whatever the cause for such variations, they are
a major barrier to using Saint-Mix™ for this project. Experiments to study the effects
of CFTR promoter elements (and ultimately gene therapy formulations) will require
a robust transfection system that produces consistent results.
The LID transfection method produced consistent results and transfected the greatest
percentage of cells in every line analysed, except HBE. It is particularly attractive to
use a method incorporating the P6 peptide, as this may generate some targeting
specificity for epithelial cells of the lung (Hart, 1999), although the equivalent results
with randomised P6 peptide call into question the mechanism by which P6 enhances
transfection (see Section 4.2.4). Another advantage of the LID method is that the
components are relatively inexpensive. In future gene therapy formulations, this
could make the difference between an affordable therapy and a prohibitively
expensive one.
To sum up, several reagents were analysed in order to optimise transfection
elticiency. It was apparent that each method produced a unique profile amongst the
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transfected population and that each method had its own strengths and weaknesses
relating to the number of cells transfected, the level of expression per transfected
cell, and consistency between experiments. The LID transfection system seems to be
best suited to the purposes of this study, and was selected for further experiments.
The FLH-1: FLH-2 dotplot method proved to be a superior way to analyse FAGS
data.
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5.1 Introduction
In order to analyse the effects of CFTR genomic context elements upon expression,
the six vectors containing portions of the CFTR 5' region and/or intron I, linked in a
transcriptional fusion to the EGFP reporter gene (see Chapter 3) were transfected
into permanent cell lines. The reader is advised to make use of the foldout vector
diagram in Appendix E, for easy reference while reading this chapter.
Several cell lines were selected for expression analysis. The project commenced with
the COS-7 cell line, due to its relative ease of transfection. This line was derived
from the CV-l cell line, isolated from African green monkey kidney (COS-7 was
created by transforming the CV-l line with an SV-40 origin-defective
mutant)(Gluzman, 1991; ATCC website). This line exhibits fibroblast-like
morphology. The COS-7 line does not express detectable levels of CFTR, and
therefore one might expect expression from CFTR genomic context vectors to be
restricted in this line.
Subsequently three cell lines that normally express CFTR were analysed. S.H. Madin
and N.B. Darby derived the MDCK cell line from canine kidney cells in 1958
(Gaush et al, 1966; ATCC website). This line has an epithelial morphology and the
MDCK-iowa variant (a kind gift from David Sheppard, University of Bristol)
expresses CFTR at high levels, thus one might expect permissive expression from
CFTR genomic context vectors in this line.
The T84 cell line was created from a human colon tumour metastasis isolated from
the lung (Dharmsathaphorn et al, 1984; ATCC website). This line expresses CFTR at
high levels and has been used to study regulation of CFTR by cAMP agonists and
PMA (Bargon et al, 1998). One might expect CFTR genomic context vectors to
exhibit higher levels of expression in this line; particularly those containing the
intron 1 DHS, which upregulates CFTR expression in gut cells (Smith, AN et al,
1996; Rowntree et al, 2001).
The Caco-2 cell line was isolated from a primary human colonic tumour, and
demonstrates epithelial morphology (Fogh et al, 1977a; Fogh et al, 1977b; ATCC
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website). As in the T84 line, one would expect upregulation of expression in
response to the CFTR intron I DHS element, as these cells are derived from the gut.
Permanent epithelial cell lines derived from the lung are available, but these lines are
comparatively difficult to propagate and transfect. Because of these difficulties, it
was only possible to perform a preliminary study on one such line. The HBE line
was derived from the human bronchus and exhibits epithelial morphology (Viallet et
al, 1994).
The pi kbcfproEGFP vector was used to investigate the effects of CFTR proximal 5'
elements upon expression. pEGFP-N is of similar structure, but the Pcmv promoter
drives EGFP expression: this vector was used as a positive control.
In order to analyse the effects of additional, distal CFTR 5' elements upon
expression, the pAc65kbcfproEGFP vector (81 kb), containing 65 kb of CFTR 5"
region, was compared to the pi kbcfproEGFP plasmid (4.9 kb). However, it would
not be prudent to directly compare expression from vectors that differ so greatly in
size and form. Preliminary experiments showed that large PACs exhibit reduced
expression in comparison to small plasmid vectors (results not shown). Expression
from the vectors PAcRC2cmvEGFP and pEGFP-N was compared, in order to
characterise and quantify the differences in transfection efficiency between small
plasmids and large PACs. These vectors both contain the Pcmv -EGFP cassette, but
PAcRC2cmvEGFP is a 1 11 Kb PAC whereas pEGFP-N is a 4.7 kb plasmid.
The twin vectors pacRCI iresEGFP and pAcRC2iresEGFP differ only in the absence
or presence of CFTR intron 1, respectively. Expression from these vectors was
compared, to determine the influence of the intron 1 DHS upon expression. EGFP
translation is initiated from an internal ribosome entry site (IRES) in both vectors.
The small plasmid pCFTRiresEGFP was included in the study as a control, to
investigate the effects of initiating translation from an IRES, rather than the 5' end of
the mRNA.
The LID method was selected for transfection of these permanent cell lines, for the
reasons described in Chapter 4. High quality, uncontaminated plasmid DNA is
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required for transfection. For these experiments, vector DNA was prepared by
Qiagen maxiprep. Plasmid-safe DNase was used to digest any DNA from bacterial
chromosomes that might be contaminating the preparation. Phenol-chloroform was
used to extract plasmid DNA from the Plasmid-safe DNase reaction, and then a
chloroform extraction was performed to remove residual phenol. Finally, the plasmid
was ethanol precipitated and resuspended in sterile TE, pFI8.0 (see Methods). When
possible, the vectors used in an experiment were prepared on the same day, to
minimise any batch-to-batch variations in transfection efficiency.
48 hours after the cells had been transfected, fluorescence activated cell sorting
(FACS) was performed, and an FL1-H: FL2-H dotplot was created to dissect the
percentage of cells expressing EGFP (%[f|) and the average FL1-H fluorescence of
the transfected population (Xf), which is a measure of the level of EGFP expression
(see Chapter 4). Triplicate samples were included in every experiment, and each
experiment was performed on at least two, and usually three separate occasions, to
confirm the results. Although the absolute levels of transfection varied between
experiments, the trends in relative transfection efficiencies were consistent between
experiments. For most samples, 10,000 cells were analysed by FACS. However,
when the transfection efficiency was very low, a larger sample was analysed to
increase the significance of the calculations. The original dotplots can be found in
Appendix C (these also give details of the numbers of cells analysed by FACS for
each sample).
An initial experiment comparing expression from pEGFP-N and pAcRC2cmvEGFP
demonstrated that large PAC vectors are less efficiently transfected than small
plasmid vectors. Further experiments were done to investigate whether this effect
was due to a difference in the vector copy number, and whether this effect could act
in trans on a co-transfected small plasmid. These studies unveiled an interesting
interaction: diluting a reporter plasmid with an anonymous plasmid did not
necessarily reduce its transfection efficiency. Further experiments were done to
investigate the mechanism of this phenomenon.
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5.2 Results
5.2.1 Transfection of the COS-7 cell line
The COS-7 cell line was selected for the first transfection experiments as this line is
easily transfected. COS-7 does not express CFTR at detectable levels, and therefore
will act as an important control, to analyse whether genomic context elements down-
regulate expression in an inappropriate cell type.
A panel of vectors was transfected into the COS-7 cell line (Fig. 5.1). Transfection of
both the p 1 kbcfproEGFP and pEGFP-N vectors produced a large percentage of cells
expressing EGFP (%[f] =37.39 and 33.7, respectively). This presumably reflects the
relative ease of transfecting the COS-7 cell line with these small vectors. However,
the average fluorescence of the transfected population was much lower with
pi kbcfproEGFP (X| =1090.52) than with pEGFP-N (Xr =4247.85). This is consistent
with previous studies, which show that the CFTR proximal 5' region exhibits weak
housekeeping-type promoter activity (Yoshimura et al, 1991b).
PAc65kbcfproEGFP-transfected cells showed a substantial reduction in both the
percentage of cells expressing EGFP (%[f| =1.86) and the average fluorescence
intensity of the transfected population (Xi =1 10.08), in comparison with
pikbcfproEGFP-transfected cells. Two hypotheses were proposed to explain this
reduction in expression: (1) the reduction might have been due to negative control
elements in the region from -lkb to -65kb, (2) the reduction might have been an
artifact of the large PAc65kbcfproEGFP vector size. pAcRC2cmvEGFP and pEGFP-N
transfections were compared, to resolve this issue.
PAcRC2cmvEGFP-transfected cells showed a reduction in both the percentage of
cells expressing EGFP (%[f| =3.48) and the average fluorescence intensity of the
transfected population (Xf = 552.62), in comparison with pEGFP-N-transfected
cells. This suggests that a reduction in expression is intrinsic to large PAC vectors.
As this reduction was comparable to that seen between the pi kbcfproEGFP and
pAc65kbcfproEGFP vector, there is no evidence that the additional region from -1 kb
to -65 kb of CFTR 5' region restricts expression in the COS-7 cell line (see
Discussion).
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Figure 5.1. Transfection of EGFP reporter constructs into the COS-7 cell
line. The COS-7 cell line was transfected with the plasmids (1) pEGFP-N,
(2) PACRC2cmvEGFP, (3) plkbcfproEGFP, (4) PAc65kbcfproEGFP,
(5) pCFTRiresEGFP, (6) PAcRC1iresEGFP, and (7) PAcRC2iresEGFP using
the LID reagent, or (8) left untransfected. 48 after transfection, cells were
analysed by FACS (see Methods). This figure shows: (a) a histogram of the
percentage of cells with detectable EGFP expression and (b) a histogram of
the average fluorescence of the transfected population. The dotplots for
these histograms are shown in Appendix C.9.
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In the COS-7 cell line, the vector size had a major effect upon both the percentage of
cells expressing EGFP and the average fluorescence of the transfected population.
The promoter present in the vector (e.g. CFTR 5' region of Pcmv) had a
comparatively minor effect upon these parameters.
Next, the pacRCI iresEGFP and pAcRC2iresEGFP transfections were compared, to
assess the effects of the intron 1 DHS in the COS-7 line. No appreciable difference
was seen between pacRC I iresEGFP (%[f] = 0.02, Xf = 33.6) and PAcRC2iresEGFP
(%[f] = 0.03, Xf = 22.08). Thus, the intron 1 element does not seem to alter
expression in this line. This is consistent with a previous report, which shows that
DNase hypersensitivity at the intron 1 site is lacking in cell lines that do not express
CFTR, and this element does not appear to upregulate CFTR expression in such lines
(Smith, AN et al, 1996).
pCFTRiresEGFP transfections showed a marked reduction in both the percentage of
cells expressing EGFP (%[f] = 9.99) and the average fluorescence intensity of the
transfected population (Xf = 131.75), in comparison to pEGFP-N. This suggests that
initiation of translation from an IRES is much less efficient than from the 5' end of
the mRNA molecule. Inefficient translation from an IRES, coupled with the effects
of large vector size and a weak CFTR promoter may explain why the
pacRCI iresEGFP and PAcRC2iresEGFP transfection efficiencies were very low.
5.2.2 Transfection of the MDCK-iowa cell line
Subsequently, the MDCK-iowa cell line was transfected with these genomic context
vectors (Fig. 5.2). Although this line is not of primary interest to CF gene therapy (as
the kidney does not show disease phenotype in CF), this line expresses CFTR at high
levels and is moderately easy to transfect. Thus, MDCK-iowa cells may prove useful
in dissecting CFTR regulatory elements.
In this line, pi kbcfproEGFP-transfected cells showed a moderate level of EGFP
expression. However, both the percentage of cells expressing EGFP and the average
fluorescence of the transfected population were reduced with pi kbcfproEGFP (%[f]
= 6.92, Xf =388.46), in comparison to pEGFP-N (%[f]= 1 1.69, Xt =2022.72). The
CFTR 5' region is acting as a weak promoter.
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Figure 5.2. Transfection of EGFP reporter constructs into the MDCK-
iowAcell line. The MDCK-iowa cell line was transfected with the plasmids
(1) pEGFP-N, (2) PACRC2cmvEGFP, (3) plkbcfproEGFP, (4)
PAc65kbcfproEGFP, (5) pCFTRiresEGFP, (6) PAcRC1iresEGFP, and (7)
PAcRC2iresEGFP using the LID reagent, or (8) left untransfected. 48 hours
after transfection, cells were analysed by FACS (see Methods). This figure
shows: (a) a histogram of the percentage of cells with detectable EGFP
expression and (b) a histogram of the average fluorescence of the
transfected population. The dotplots for these histograms are shown in
Appendix C.10.
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Again, PAc65kbcfproEGFP-transfected cells showed reduced expression (%[f]=0.5,
Xf =208.06) in comparison to pikbcfproEGFP-transfected cells. However, this effect
was mirrored when comparing pacRC2cit)vEGFP transfections (%[f]=3.09, Xt
= 1587.78) to pEGFP-N transfections, and can thus be explained as an artifact of the
large PAC vector context.
As in the COS-7 cell line, the vector size had a major effect upon the percentage of
cells expressing EGFP, while the promoter type had a lesser effect. However, in
contrast to COS-7, the vector size had only a minor effect upon the average
fluorescence of the transfected population, while the promoter had a larger effect.
This suggests that the promoter is playing a major role in directing the level of
expression in the MDCK-iowa cell line. Again, pCFTRiresEGFP-transfected cells
showed a reduced level of expression (%[f| = 2.17, Xf = 68.01).
pacRCI iresEGFP and pAcRC2iresEGFP showed similar expression profiles
following transfection (%[f]=0.21 and 0.3, Xf =50.15 and 42.84, respectively).
Thus, the intron 1 DHS does not seem to boost expression in the MDCK-iowa cell
line. Previous reports suggest that only gut cells upregulate expression in response to
the intron 1 DHS (Smith, AN et al, 1996; Rowntree et al, 2001). This data confirms
that kidney cells do not show a similar upregulation of expression, despite a high
level of endogenous CFTR expression.
5.2.3 Transfection of the T84 cell line
The T84 cell line was derived from the gut, and expresses CFTR at high levels. A
panel of vectors was transfected into the T84 cell line (Fig. 5.3). Once again,
transfection of the pEGFP-N vector produced a high level of expression (%[fj =
I 1.28, Xf = 487.75), while pikbcfproEGFP showed a lower, but still substantial level
of expression (%[f] = 5.33, Xf = 221.58).
Expression from the PAc65kbcfproEGFP vector was greatly reduced (%[f] = 0.1 I, Xf
= 167.78) in comparison to the pi kbcfproEGFP vector. However, these results were
again mirrored when comparing pEGFP-N-transfected cells to pAcRC2cmvEGFP -
transfected cells (%[f| = 0.73, Xf = 444.89). Thus in the T84 cell line, there is no
evidence of control elements in the additional 5' region from -1 kb to -65kb. Again,
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Figure 5.3. Transfection of EGFP reporter constructs into the T84 cell
line. The T84 cell line was transfected with the plasmids (1) pEGFP-N,
(2) pAcRC2cmvEGFP, (3) plkbcfproEGFP, (4) PAc65kbcfproEGFP,
(5) pCFTRiresEGFP, using the LID reagent, or (6) left untransfected. 48
hours after transfection, cells were analysed by FACS (see Methods). This
figure shows: (a) a histogram of the percentage of cells with detectable
EGFP expression and (b) a histogram of the average fluorescence of the
transfected population. The dotplots for these histograms are shown in
Appendix C.11.
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the promoter present in the vector had more of an effect than the vector size upon the
average fluorescence of the transfected population.
No expression was detected in pacRCI iresEGFP or PAcRC2iresEGFP-transfected
cells (data not shown), this was probably due to the poor transfection efficiency in
the T84 line. Thus, it was not possible to analyse the effects of intron 1 upon
expression in this line. Transfection of the pCFTRiresEGFP vector produced few
cells expressing EGFP (%|f] = 0.14) with a low average fluorescence intensity (Xt =
75.63).
5.2.4 Transfection of the Caco-2 cell line
The Caco-2 cell line was derived from a colon carcinoma. This line is frequently
used in studies of CFTR expression (e.g. Smith, AN et al, 1996). The Caco-2 cell
line was transfected with a panel of vectors; the results are shown in Fig. 5.4.
pi kbcfproEGFP-transfected cells produced a low level of expression (%[f| = 1.94, Xf
= 234.45). This cell line is not easily transfected, and even pEGFP-N-transfected cells
produced only a moderate level of expression (%[f] = 6.05, Xf = 944.74).
The differences in expression between pi kbcfproEGFP-transfected cells and
PAc65kbcfproEGFP-transfected cells (%[f] = 0.07, Xf = 69.7) roughly mirrored the
difference between pEGFP-N-transfected cells and pAcRC2cmvEGFP-transfected
cells (%[f] = 0.39, Xf = 479.34). As in the MDCK-iowa and T84 cell lines, the
promoter present in the vector had more of an effect than the vector size upon the
average fluorescence of the transfected population.
No expression was detected in pacRCI iresEGFP-transfected or PAcRC2iresEGFP-
transfected cells in the Caco-2 cell line (results not shown), so it was not possible to
analyse the effects of the intron 1 DHS upon expression.
5.2.5 Transfection of the HBE cell line
A preliminary study was done on the HBE cell line, using the SID transfection
method (see Chapter 4). Fig. 5.5 shows the results of this study.
















































1 2 3 4 5
Figure 5.4. Transfection of EGFP reporter constructs into the Caco-2
cell line. The Caco-2 cell line was transfected with the plasmids (1) pEGFP-
N, (2) pac RC2cmvEGFP, (3) plkbcfproEGFP, (4) PAc65kbcfproEGFP, using
the LID reagent, or (5) left untransfected. 48 hours after transfection, cells
were analysed by FACS (see Methods). This figure shows: (a) a histogram of
the percentage of cells with detectable EGFP expression and (b) a histogram
of the average fluorescence of the transfected population. The dotplots for






































Figure 5.5. Transfection of EGFP reporter constructs into the HBE cell
line. The HBE cell line was transfected with the plasmids (1) pEGFP-N,
(2) plkbcfproEGFP, (3) PAc65kbcfproEGFP, using the SID reagent, or (4) left
untransfected. 48 hours after transfection, cells were analysed by FACS (see
Methods). This figure shows: (a) a histogram of the percentage of cells with
detectable EGFP expression and (b) a histogram of the average
fluorescence of the transfected population. * the average fluorescence
intensity could not be accurately calculated for the PAC65kbcfproEGFP vector.
The dotplots for these histograms are shown in Appendix C.13.
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p] kbcfproEGFP-transfection produced a moderate level of expression in the HBE
cell line (%[f] = 5.53%, 88.56), in contrast to a higher level of expression with
pEGFP-N (%[f] = 11, Xf = 918.94). The PAc65kbcfproEGFP vector showed a very
small number of transfected cells (%[f] = 0.075). The average fluorescence intensity
of this population could not be determined, as the number of transfected cells was too
small to accurately sample the FL1-H intensity distribution of the transfected
population. Unfortunately, time constraints and a reduction in the efficiency of the
SID method prevented further experiments being conducted in this cell line during
this study.
5.2.6 Evaluation of the effects of PAC backbone and vector copy number upon
expression
In every cell line analysed, expression from pacRC2citivEGFP was reduced in
comparison to pEGFP-N, despite the fact that these two vectors contain an identical
expression cassette (EGFP driven by a Pcmv promoter). This seems most likely to be
a direct result of the difference in vector size. However, one should remain aware
that the reduction in expression could be caused by other features of the PAC vector
(for example, components of the PAC backbone); further experiments would be
required to rule this out.
At first, we hypothesised that the reduction might be a simple effect of vector copy
number. Because pEGFP-N is much smaller (with a lower molecular weight) than
PAcRC2cmvEGFP, there will be many more copies of this small plasmid in 1 jig
DNA. Thus, the reduction in expression may be solely due to the delivery of a
smaller number of gene copies in the PAC transfection.
An experiment was devised to test this hypothesis. 42.5 ng pEGFP-N was mixed
with 957.5 ng of an anonymous plasmid - pUCl 8 (which does not contain a
mammalian expression cassette) - to produce an equivalent number of pEGFP-N
vector copies as in I jig pacRC2citivEGFP, while maintaining the correct DNA
weight (1 jig) for optimum LID complex transfection (the vectors were mixed prior
to LID complex formation). This mixture was transfected into the COS-7 cell line
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alongside controls of 1 pg pure pEGFP-N, I pg pAcRC2cmvEGFP, and I pg pUC18.
The FACS results for these transfections are shown in figure 5.6.
When the 42.5 ng pEGFP-N mixed with 957.5 ng pUC18 was transfected, a
substantial level of expression was seen (%[f] = 32.61% and Xf = 4906.71). This
was not reduced to the lower levels seen with PAcRC2cmvEGFP transfection (%[f] =
3.65%, Xf = 441.49); surprisingly, the levels were increased over those seen with 1
pg pure pEGFP-N (%[f] = 22.95, Xf = 4586.43). This suggests that the reduction in
expression levels from PAC vectors is not a result of the lower gene copy number
present in those transfections. The profile of cells transfected with 1 pg pUC18 was
similar to the untransfected control.
One might imagine several ways in which large PAC vectors could affect
transfection. For example, PAC DNA might have a gross affect disturbing the
transfection process (e.g. lipoplex complexes might not form as effectively in the
presence of large molecules). A second experiment was done to test whether PAC
vectors were able to alter transfection efficiency in trans, e.g. of a co-transfected
plasmid molecule. 42.5 ng pEGFP-N was mixed with 957.5 ng PAcRC2b (a PAC
vector identical to pAcRC2cmvEGFP, except that there is a (3galactosidase gene in
place of the EGFP gene - see Appendix D). Hence, this mixture contains
predominantly large PAC DNA, but the EGFP reporter gene itself is contained in a
small plasmid (the vectors were mixed prior to FID complex formation). In addition,
the PAcRC2cmvEGFP PAC was mixed with PACRC2b in the same way, as a control.
These were transfected into the COS-7 cell line alongside controls of 1 pg pure
pEGFP-N, 1 pg pAcRC2cmvEGFP, and 1 pg pAcRC2b. The results are shown in Fig.
5.7.
When the 42.5 ng pEGFP-N mixed with 957.5 ng PACRC2b was transfected into the
COS-7 line, there was a substantial level of expression (%[f] = 39.49, X( = 4540.98).
This was not reduced towards the levels seen with PACRC2cmvEGFP transfection
(%[f] = 4.85, Xf = 752.19); in fact, the levels were at least as high as those in the
pEGFP-N-only transfection (%[f] = 37.43, Xf = 4542.36). Thus, PAC DNA did not
appear to affect the transfection efficiency of a small plasmid vector in
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Figure 5.6.The effects of equalising pEGFP-N and pRC2cmvEGFP
vector copy number. The COS-7 cell line was transfected with (1) 1pg
pEGFP-N, (2) 1 pg PAcRC2cmvEGFP, (3) 42.5 ng pEGFP-N + 957.5 ng
pUC18, (4)1 pg pUC18 using the LID reagent, or (5) left untransfected. 48
hours after transfection, cells were analysed by FACS (see Methods). This
figure shows: (a) a histogram of the percentage of cells with detectable
EGFP expression and (b) a histogram of the average fluorescence of the



































Figure 5.7.The effects of diluting pEGFP-N with PAcRC2b. The COS-7 cell
line was transfected with (1) 1pg pEGFP-N, (2) 1 jig PACRC2cmvEGFP, (3)
42.5 ng pEGFP-N + 957.5 ng PAcRC2b, (4) 42.5 ng PACRC2cmvEGFP +
957.5 ng PAcRC2b (5) 1 pg PACRC2b using the LID reagent, or (6) left
untransfected. 48 hours after transfection, cells were analysed by FACS (see
Methods). This figure shows: (a) a histogram of the percentage of cells with
detectable EGFP expression and (b) a histogram of the average
fluorescence of the transfected population. The dotplots for these histograms
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trans. The reduced expression of cassettes in cis seems to be a direct effect of the
overall size of the DNA molecule. Transfection of the pAcRC2b vector alone
produced a similar profile to the untransfected sample.
The fact that transfection efficiency was not reduced following a 1/24 dilution with
anonymous pUC18 DNA was in itself surprising, and some experiments were done
to investigate this further. pEGFP-N was serially diluted with pUC18 and transfected
into the COS-7 cell line, using the LID reagent (Fig. 5.8). A curve of transfection
efficiency was seen following dilution. Transfection of pure pEGFP-N produced only
a moderate level of expression in this experiment (%[f] = 8.86, Xf= 3774.09) on this
day. Surprisingly, dilution of the plasmid 1/10 or 1/100 with pUC18 seemed to
increase the percent of cells expressing EGFP (%[f] = 15.6 and 10.5 respectively),
without significantly affecting the average fluorescence intensity of the transfected
population (Xf = 3858.18 and 3024.92, respectively). The profile of cells transfected
with 1 pg pUC18 was similar to the untransfected control.
Next, we tested the effects of diluting a PAC reporter construct. pacRC2citivEGFP
was serially diluted with pUC18 and transfected into the COS-7 cell line using the
LID reagent (Fig. 5.9). Again, a curve of transfection efficiency was seen.
Transfection of pEGFP-N produced a substantial level of expression (%[f] = 20.04,
Xf = 4432.6), while pure pacRC2citivEGFP produced a low level of expression (%[f]
= 2.86, Xf = 642.71). The percentage of cells expressing EGFP was increased upon
diluting the pAcRC2cmvEGFP 1/10 or 1/100 with pUC18 (%[f| = 6.25 and 3.84,
respectively). The average fluorescence intensity was not significantly affected in the
1/10 dilution (Xf = 605.26), although there was a slight drop in the average
fluorescence intensity in the 1/100 dilution (Xf = 333.24). Again, transfection of
pUC18 alone produced a similar profile to the untransfected control. Thus, the
mixing effect is not specific to the pEGFP-N vector, and can increase transfection
efficiency for a PAC vector, too. Looking back at Fig. 5.7, we also find evidence that
we may be able to dilute a reporter PAC with a non-coding PAC, without
compromising its transfection efficiency. Mixing 42.5 ng pAcRC2cmvEGFP with
957.5 ng PAcRC2b did not reduce the percentage of cells expressing EGFP (%[f] =
4.91), in comparison with I pg pure PAcRC2cmvEGFP (%[f] =4.85), although the
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Figure 5.8.The effects of serial dilution of pEGFP-N with pUC18. The
COS-7 cell line was transfected with (1) 1(ig pEGFP-N, (2) 100 ng pEGFP-N
+ 900 ng pUC18, (3) 10 ng pEGFP-N + 990 ng pUC18, (4) 1 ng pEGFP-N +
999 ng pUC18 (5) 100 pg pEGFP-N + 999.9 ng pUC18, (6) 1 pig pUC18
using the LID reagent, or (7) left untransfected. 48 hours after transfection,
cells were analysed by FACS (see Methods). This figure shows: (a) a
histogram of the percentage of cells with detectable EGFP expression and
(b) a histogram of the average fluorescence of the transfected population.
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Figure 5.9.The effects of serial dilution of pAcRC2cmvEGFP with pUC18.
The COS-7 cell line was transfected with (1) 1 jixg pEGFP-N, (2) 1 pg
PAcRC2cmvEGFP (3) 100 ng pAcRC2cmvEGFP + 900 ng pUC18, (4) 10 ng
PAcRC2cmvEGFP + 990 ng pUC18, (5) 1 ng PAcRC2cmvEGFP + 999 ng
pUC18 (6) 100 pg pACRC2cmvEGFP + 999.9 ng pUC18, (7) 1 pg pUC18
using the LID reagent, or (8) left untransfected. 48 hours after transfection,
cells were analysed by FACS (see Methods). This figure shows: (a) a
histogram of the percentage of cells with detectable EGFP expression and
(b) a histogram of the average fluorescence of the transfected population.
The dotplots for these histograms are shown in Appendix C.17.
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average fluorescence of the transfected population was slightly reduced (Xt = 302.63
vs. 752.19).
Subsequently, we tested whether it was necessary for the anonymous DNA to be
present in the same complex as the pEGFP-N reporter to produce an increase in
transfection efficiency. 100 ng pEGFP-N was either mixed with 900 ng pUC18 prior
to LID complex formation, or appropriate amounts of lipofectin and P6 were added
to each plasmid to form separate complexes, which were then applied simultaneously
to a sample of COS-7 cells for transfection. In order to rule out the possibility that it
is merely a reduction in the amount of reporter DNA, rather than the inclusion of an
anonymous DNA plasmid, which enhances transfection, two additional controls were
included. In the first control, the amount of DNA within the LID complex was
reduced to 100 ng, while the quantities of the other LID components were kept
constant (0.75 pi lipofectin and 4 pg P6). In the second control, the entire LID
complex was scaled down (thus 100 ng DNA was complexed with 0.075 pi
lipofectin and 0.4 pg P6). These were transfected into the COS-7 cell line, alongside
controls of 1 pg pEGFP-N and 1 pgpUC18 (Fig. 5.10).
Once again, mixing the pEGFP-N plasmid with pUC18 plasmid prior to complexing,
increased expression (%[f] = 32.91, Xf= 4626.76), in comparison to transfection of
pure pEGFP-N plasmid (%(f) = 29.46, Xf 4= 4543.98). When the plasmids were
complexed separately and then applied to the cells simultaneously for transfection,
the expression was reduced (%[f] = 13.85, Xt = 3908.96). This shows that it is
necessary to mix anonymous DNA with the reporter plasmid before complex
formation (so that the two plasmids are present in the same complex) in order to
achieve an increase in transfection efficiency.
In addition, expression was reduced in transfections where the DNA quantity was
reduced within the complex (%[fj = 12.04, X| = 3889.25), or where the entire
complex quantity was reduced (%[f] = 0.33, Xf = 4168.25). This shows that the
increase was not an indiscriminate effect of lowering the transgene copy number.
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Figure 5.9.The effects of serial dilution of PAcRC2cmvEGFP with pUC18.
The COS-7 cell line was transfected with (1)1 jag pEGFP-N, (2) 1 jig
PAcRC2cmvEGFP (3) 100 ng pAcRC2cmvEGFP + 900 ng pUC18, (4) 10 ng
PAcRC2cmvEGFP + 990 ng pUC18, (5) 1 ng PAcRC2cmvEGFP + 999 ng
pUC18 (6) 100 pg PACRC2cmvEGFP + 999.9 ng pUC18, (7) 1 jig pUC18
using the LID reagent, or (8) left untransfected. 48 hours after transfection,
cells were analysed by FACS (see Methods). This figure shows: (a) a
histogram of the percentage of cells with detectable EGFP expression and
(b) a histogram of the average fluorescence of the transfected population.
The dotplots for these histograms are shown in Appendix C.17.
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5.3 Discussion
5.3.1 CFTR regulatory elements
These studies show that the proximal CFTR 5' region is capable of driving EGFP
expression in a range of cell lines. In every cell line tested, pi kbcfproEGFP
transfections produced a lower average fluorescence intensity amongst the
transfected population, in comparison to pEGFP-N transfections. The percentage of
cells expressing EGFP was also lower in every cell line except COS-7 (where they
were approximately equal). Thus, the results of this study are consistent with the
hypothesis that the CFTR proximal 5' region has weak promoter activity, reported by
others (Yoshimura et al, 1991 b), in contrast to the strong Pcmv promoter. The data
presented here are consistent with the proximal promoter region retaining this
characteristic in these transient transfection systems.
The pac65kbcfproEGFP transfections showed a reduction in both the percentage of
cells expressing EGFP and the average fluorescence of the transfected population, in
comparison to pi kbcfproEGFP transfections, in every cell line tested. This result was
mirrored when comparing PAcRC2cmvEGFP (large PAC) and pEGFP-N (small
plasmid) transfections, despite the fact that these vectors contain the same promoter
(Pcmv)- Thus, it seems that a reduction in expression is intrinsic to large PAC
vectors. In light of this effect, any positive or negative modulation of expression per
se by the additional upstream region in the PAC65kbcfproEGFP would be difficult to
discern.
An attempt was made to analyse whether the difference in the average fluorescence
intensity of the pi kbcfproEGFP (pi) and PAC65kbcfproEGFP (p2) vectors was
significantly different to the difference in average fluorescence intensity of the
pEGFP-N (p3) and PACRC2cmvEGFP (p4) vectors, in the cell lines COS-7, MDCK-
iowa, T84 and CaC02. The data for the transfected populations was extracted and
converted from logarithmic to linear format using the Excel software package, for
this purpose. Then, a statistical analysis was performed by Naomi Wray, MMC,
University of Edinburgh.
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A generalised linear model was used (treating the triplicate transfections as a random
effect). We want to test the hypothesis pl/|i2 = Lt3/p4. However, this hypothesis is
non-trivial. The hypothesis |il|l4 = ji2p3 is equivalent, and easier to test. The results
of this analysis are shown in Appendix F2.
In summary, although plp3 and p2p4 were very similar (a difference of 0.1, or less),
this difference was found to be statistically significant in every cell line. The sign of
the test statistic (negative or positive) was not consistent between cell lines (relating
to whether |il|i4 or p2(i3 is greater). The fact that the differences were very slight
and the inconsistency in the statistic sign suggest that the difference was not due to
an enhancer effect of the additional region present in the PAc65kbcfproEGFP vector.
It is difficult to interpret the results of the statistical analysis in terms of the
experiment. Because the sample size is so large (10,000 cells or greater), we can
calculate |il|i4 and |U.2jj.3 very accurately. The significant difference that we see is
likely to be due to experimental artefacts, or small differences in vector structure
(e.g. pi kbcfproEGFP and pEGFP-N are of similar, but not identical size; the same is
true of the pAcRC2cmvEGFP and pAc65kbcfproEGFP vectors), rather than regulatory
elements.
Ann Harris' group has performed some elegant experiments testing the effects of the
-20.9 DHS upon expression. Briefly, two YAC vectors were made containing the
CFTR locus. The first YAC included -50 kb of CFTR 5'region (Vassaux et al,
1997). In the second, truncated YAC the -20.9 DHS and all upstream DNA was
deleted (Nuthall et al, 1999b). Permanent Caco-2 cell lines were made with these two
YACs; expression of YAC-derived CFTR mRNA appeared to be copy-number
dependent, position independent in these lines. In the two permanent lines made from
the intact YAC, the ratio of YAC-derived CFTR mRNA to endogenous CFTR
mRNA was proportional to the ratio of YAC copies to endogenous CFTR copies.
However, in the five permanent lines made from the truncated YAC, less CFTR
mRNA was produced for each YAC copy than for each endogenous CFTR copy.
Semi-quantitative RT-PCR suggested that expression was reduced by -60% in each
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YAC copy, in comparison to each endogenous copy. Thus, there is convincing
evidence that the -20.9 DHS can act as a positive regulatory element.
This experiment has not been repeated in other cell lines, so it is not known whether
this upregulation is specific to the Caco-2 cell line, or a more general phenomenon.
A previous report (Smith et al, 1995) analysed the presence of 5' DHS elements in a
panel of cell lines. The -20.9 DHS was found to be present in every cell line
analysed, including those that did not express CFTR, and the level of DNase
hypersensitivity was not correlated with the level of CFTR expression in these lines.
Hence, the -20.9 DHS appears to be a ubiquitous, rather than tissue-specific,
regulatory element.
Two PMR elements (regions of purine-pyrimidine strand asymmetry) co-localise
with the -20.9 DHS. These elements may play a role in the upregulation of
expression (see Section 1.1.7). While the PMR elements at -20.9 were shown not to
adopt non-B-DNA conformation; it is still possible that they will affect expression by
altering the chromatin structure in this region. There is additional evidence that
chromatin conformation may be involved in transcriptional regulation at the CFTR
locus (Li et al, 1999, Hollingsworth et al, 1994). It is unclear whether histones
become assembled upon transiently transfected DNA. CpG methylation may also be
necessary for proper transcriptional regulation, and this may not be accomplished in
transiently transfected DNA. Hence, genomic integration might be required for some
of the CFTR regulatory elements (for example, the -20.9 DHS) to elicit an effect
upon expression.
One criticism that could be made of the Nuthall et al, 1999 paper is that a semi¬
quantitative technique (phosphoimager detection of 32P signal in an RT-PCR
Southern Blot hybridisation) was used to measure the levels of CFTR expression. As
they have not included quantitative controls, it is difficult to know whether the 60%
reduction in the phosphoimager signal per YAC copy (in relation to each endogenous
CFTR copy) is truly representative of a 60% reduction in mRNA levels; in reality,
the effect may be smaller or greater. While there is likely to be a relationship
between the phosphoimager signal and the cDNA copy number, the ratio is unlikely
to be 1:1. A quantitative technique, such as the TaqMan RT-PCR assay (Heid et al,
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1996), or primer extension analysis of mRNA (Walmsley et al, 1998) would provide
a more accurate measure of the mRNA levels (Carey and Smale, Transcriptional
Regulation in Eukaryotes, Chapter 5).
Certainly, modulation of expression by the -20.9 DHS appears to be subtle (for
example, in relationship to the large differences seen between the strong Pcmv
promoter and weak CFTR promoter). Because the effect of vector size upon
expression has proved to be so extreme, it would be difficult to analyse whether the
PAc65kbcfproEGFP exhibits this subtle upregulation of expression. The data
presented here cannot distinguish between the hypothesis that the additional region
has no effect, or a small positive effect, upon expression of the EGFP transgene.
When the pacRC1 iresEGFP and PACRC2iresEGFP vectors were transfected into the
COS-7 and MDCK-iowa cell lines, they produced similar levels of expression. Thus,
it appears that the intron 1 element does not modulate expression in either of these
lines. It is unfortunate that poor transfection efficiency in the T84 and Caco-2 cell
lines prevented an analysis of the gut-cell specific enhancement of expression by the
intron 1 element. These cell lines were generally difficult to transfect; when coupled
with the effects of a weak CFTR promoter, large PAC context, and inefficient
translation from an IRES, it is perhaps not surprising that no expression was detected
from the PAcRC1 iresEGFP and PAcRC2iresEGFP constructs.
The efficiency of transient transfection in the T84 and Caco-2 cell lines could
probably be further improved by novel transfection methods. Alternatively, it might
be possible to generate stably transfected cell lines, or even transgenic mice, to
address this question (although this would no longer be an accurate model for the
effects of these vectors in a transient transfection/gene therapy context).
Previous reports (Smith, AN et al, 1996; Mogayzel and Ashlock, 2000, Rowntree et
al, 2001) have shown that the intron 1 DHS element upregulates expression in a
tissue specific fashion, in gut epithelial cells that express CFTR. This element can
successfully increase expression from the CFTR proximal promoter in reporter
constructs, even in a transient transfection assay. In other words, while the -20.9
DHS may require genomic integration to elicit an effect upon expression, it seems
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unlikely that this will be required for the intron 1 DHS to affect expression. Hence,
the intron 1 element might be capable of modulating expression in gene therapy
vectors.
The results presented here confirm that the intron 1 element does not upregulate
expression in a cell line that does not express CFTR (COS-7) or in a cell line that
expresses CFTR at high levels, but does not derive from the gut (MDCK-iowa).
These results are consistent with the hypothesis that this element is specific to gut-
type cells expressing CFTR. If this proves to be true, the intron I DHS may
ultimately be irrelevant to CF gene therapy vectors, as this therapy is likely to focus
on the respiratory tissues. The high levels of CFTR expression in some tissues
outside the gut (e.g. the kidney tubules, pancreatic ducts and tracheal submucosal
glands), suggests that there must be other tissue-specific regulatory elements at the
CFTR locus, in addition to the intron 1 DHS.
CFTR is expressed at high levels in only a small number of cells in both the
respiratory tract - a subpopulation of cells in the submucosal gland (Engelhardt et al,
1992), and the gut - ductal cells of the intestinal crypts (Trezise and Buchwald,
1991; Crawford et al, 1991). It may be necessary to produce cell lines that
approximate these cell types, to see tissue-specific upregulation of expression. It is
also possible that in vivo organ structures are required to stimulate CFTR expression
in these populations of cells. Despite a multitude of studies investigating the
endogenous CFTR location, the identity of CFTR-expressing cells has not been
precisely elucidated. Other groups have encountered similar difficulties in dissecting
CFTR regulatory elements, according to their effect on a LacZ transgene (Imler et al,
1996; Chou et al, 1991).
5.3.2 The effects of vector size and plasmid mixing upon expression
In every cell line analysed, the vector size (e.g. plasmid or PAC), had a large effect
on the percentage of cells expressing EGFP, while the promoter species (e.g. Pcmv or
CFTR 5' region) had a smaller effect. However, in three out of four cell lines
analysed, the promoter had the major effect upon the average fluorescence of the
transfected population, while the vector type had a lesser effect. The exception to this
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rule was COS-7, where the vector type had a larger effect upon the average
fluorescence of the transfected population. This suggests that the COS-7 cell line is
atypical, and may have been artificially selected to promote transfection of small
plasmids (but does not accomplish this with large plasmids). Although experiments
in the COS-7 line paint a bleak picture of PAC construct transfection, this does not
seem to be a typical result, and may not be reflected in vivo.
Although transfection is used in a wide range of biological applications, many facets
of this process are poorly understood. This would certainly not be the first time that
PAC vectors had been observed to exhibit reduced expression levels in comparison
to small plasmids, but little has been done to investigate the specifics, or origins, of
this effect.
Preliminary experiments comparing the PAcRC2b and pCMV[3 (3galactosidase-
expressing vectors confirmed that transfection efficiency was reduced for large PAC
vectors, in comparison to small plasmid vectors (results not shown). One might
expect that this be solely due to a reduction in the numbers of cells transfected with
the large PAC vector. FACS analysis of EGFP expression has allowed us to dissect
the components of transfection. This report showed that the reduction in PAC
expression is a combination of a reduction in both the numbers of cells expressing
the transgene and the level of expression per cell. This study showed that vector copy
number is not responsible for this effect, and that the effect cannot act in trans (e.g.
upon a co-transfected small plasmid).
It would be interesting to test whether this effect is a feature of large vector size per
se or if specific sequences within the PAC reduce expression. Studies on other large
vectors, such as BACs, and small plasmids incorporating PAC backbone elements
could address this issue.
One hypothesis is that the larger PAC vectors are less efficiently transferred to the
nucleus after cell entry. We would expect this to produce a large reduction in the
average fluorescence of the transfected population (as less copies of the gene would
get into the nucleus in every cell that has taken up DNA). However, we would expect
this to have only a smaller, secondary effect in reducing the percentage of cells
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transfected (in cases where the number of copies within the nucleus is lowered to
such extent that the amount of EGFP produced is reduced below the threshold of
detectability). In fact, %[f] and Xf are reduced by the same magnitude. Thus, while
differential nuclear translocation is an attractive hypothesis and may be a
compounding factor, it is not sufficient to explain these results alone.
It was very surprising to discover that dilution of plasmid DNA does not compromise
transfection efficiency: in fact, a dilution of up to 1/100 enhanced transfection.
Although we cannot explain this effect, there are a number of potential applications.
In applications where expensive, high quality (e.g. endotoxin-free) DNA must be
used, it might be cost-effective to generate a large bulk of a generic plasmid, which
can then be mixed with smaller amounts of a custom-made plasmid. Many studies
(especially in vivo studies) are limited by sample number; it may be possible to mix
multiple reporter constructs without compromising the efficiency of transfection,
allowing multiple readings to be done on a single sample. It would be interesting to
test whether mixing the reporter construct with other types of DNA, for example
genomic or CpG methylated DNA, could increase the transfection efficiency even
further. It will be necessary to test whether these effects of plasmid mixing extend to
in vivo applications.
These plasmid-mixing experiments would certainly provide a convenient explanation
for one report. Braun and colleagues (Braun et al, 1998) performed a trial
investigating the possibilities of mixing up to four plasmids encoding different viral
membrane bound glycoproteins for DNA immunization: they found that that mixing
the plasmids had very little effect upon the magnitude or bias of the immune
response to the individual components.
In summary, these studies investigated the mechanics of CFTR transcriptional
regulation and the possibility of recapitulating such regulation in gene therapy
vectors. The proximal 5' region was capable of recapitulating the activity of the
CFTR basal promoter in these transfection studies and may be suitable for use in
gene therapy vectors. Further studies will be needed to fully assess the influence of
the -20.9 and intron 1 DHS elements upon expression in a gene therapy context.
Chapter 5: Transfection of immortalised cell lines 194
Chapter 6: Primary tracheal air-interface cultures
195
6.1 Introduction
Although permanent cell lines form a good starting point for the analysis of gene
therapy vectors, these have proved not to be very good models of gene transfer in
vivo. One avenue for testing genomic context vectors would be animal experiments.
However, the cost and time scale of such an approach is restrictive. An ex vivo model
for analysing genomic context vectors should provide an alternative, but more
realistic model for gene therapy.
Several ex vivo culture systems have been developed to model the respiratory system.
For example, slices of whole lung tissue from mouse and humans have been
successfully cultured on a membrane at air interface (McBride et al, 2000), and intact
tracheae have been cultured ex vivo (Scott et al, 2000). In a bronchial xenograft
model (Zhang et al, 1998b> human bronchial cells are seeded into denuded rat
tracheae, which are then implanted into the flanks of mice; this model recapitulates
many features of the native tissue, such as the cylindrical airway shape. In a simpler
model, several groups have dissociated cells from the bronchus or trachea of mice
(Davidson et al, 2000) humans (Gruenert et al, 1995; Zhang et al, 2001), or other
species (Kondo et al, 1997), and cultured these cells on a membrane at air-interface.
Although these cultures do not maintain the original tissue architecture, the cells
appear to differentiate to form a polarised, pseudostratified culture, with many
features of the native epithleium.
For this study, the primary culture of tracheal cells at air-interface was selected. In
this method, the trachea is dissected and cells are dissociated. Fibroblast and red
blood cells are selectively removed, leaving a suspension of predominantly epithelial
cells. The cells are then seeded on a semi-permeable membrane and cultured at air-
interface.
Initially, both sheep and mouse tracheal cultures were attempted, but the sheep was
eventually chosen for this ex vivo study, because the human respiratory system is
more similar to that of the sheep than to that of the mouse (see section 1. 1. 12 for a
comparison of the mouse and sheep as model organisms for CF gene therapy).
Another advantage of using the sheep over the mouse for these primary cultures is
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their greater tissue volume. Thus, while the cells from two mouse tracheae must be
combined to generate a single air-interface culture well, the cells from a single sheep
trachea can generate up to 48 culture wells. This serves to reduce the number of
animals required for experiments and increases sample homogeneity.
This culture method has been developed in concert with A. Doherty, working on a
separate project. Results were combined and crosschecked in order to decide upon
the best methods and protocols, and several aspects (such as electron microscopy)
were performed in tandem for the two projects. However, the data presented here is
specifically from this PhD project.
The culture architecture was characterised by scanning and transmission electron
microscopy. This was done over a four-week time course, at one-week intervals, to
record the development of the cultures and select the time-point that most closely
mimics the in vivo structure. The electrical resistance across the culture was recorded
to monitor the formation of tight junctions. Visual examination under the light
microscope was performed routinely.
Transfection was optimised at a number of time points. Finally, some of the EGFP
reporter constructs (see Chapter 3, and fold-out Appendix E) were introduced into
these cultures. The FACS dotplots from which these calculations are derived are
shown in Appendix C.
6.2 Results
6.2.1 Establishing Primary Cultures
Tracheae were obtained from the Moredun Research Institute: primary cultures were
established as descried in the Materials and Methods Section. Briefly, tracheae were
dissected and the cells were dissociated overnight. Red blood cells were removed
from the suspension by preferential lysis (see Methods). This step was added to the
established protocol because these were found to be a major contaminating cell type.
Fibroblasts were then removed by selective adherence, leaving a suspension
containing predominantly epithelial cells. Cells were seeded on the semi-permeable
membrane of a Costar Transwell insert that had been pre-coated with collagen. 24
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hours after seeding, the media above the insert was removed, leaving only the media
below the membrane to feed the cells: this creates an air-interface, mimicking that of
the airway surface. Cells were cultured for up to five weeks. This method was
adapted from the protocol by L. Hyndman and H. Davidson-Smith; 'Batch 0' was set
up with the kind help of L. Hyndman.
The number of cells obtained from a single trachea varied between experiments,
sufficing to produce between eighteen and forty-eight cultures. The quantity of cells
obtained was a function of trachea size and other factors. For example, the centrifuge
used for spinning down the cells from suspension, and the length of time allowed for
fibroblast adhesion affected the harvesting efficiency.
6.2.2 Electrical Resistance
The electrical resistance across the culture was measured with a voltohmeter, in order
to monitor the formation of tight junctions (see Methods). Tight junctions,
connecting adjacent cells, prevent an electrical current from flowing through gaps
between the cells. Thus in the presence of tight junctions, the electrical current must
travel transepithelially, resulting in a high resistance. As the insert has an area of 0.3
2 ^
cm , the original readings were multiplied by 0.3 to calculate the resistance in Q.cirf.
Fig. 6.1 shows the series of resistance readings for each batch of primary cultures
(batches are numbered 0- 13).
Resistance readings varied greatly, both between and within batches of cultures (see
Fig. 6.1). A reading of >300 £2.cm2 was considered indicative of tight junctions
(personal communications from Donald Davidson and Hazel Davidson-Smith), and
where possible, experiments were only performed on cultures that exhibited
resistances of >300 £2.cm2.
Before transfection, cultures were treated for 20 minutes with 6 mM EGTA, to
disrupt tight junctions (this is required for successful transfection of these cultures -
Coyne et al, 2000; Cohen et al, 2001). Transepithelial resistance was used to monitor
the disruption of tight junctions; EGTA treatment resulted in a drop in resistance to
below 166 £2.cm2 (often as low as 30-60 £2.cm2).
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Figure 6.1. Primary tracheal culture resistance readings. This figure shows
the resistance readings for primary tracheal cultures batches 0-13 (as labelled).
Each series shows the resistance of the culture of corresponding number at
different time points, and with EGTA treatment (as labelled)
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Figure 6.1 (continued)
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One might expect EGTA to have a long-term effect reducing the efficiency of tight
junction formation and hence resistance. Surprisingly, the opposite was seen. By two
days after EGTA treatment, the cells had re-formed tight junctions, and the
resistances were often higher than before EGTA disruption. Batch 5 shows a striking
example of this; before EGTA treatment, the resistances were between 439 and 526
Q.cm", whereas after recovery from EGTA treatment, the resistances were between
780 and 1566. Cultures from the same batch that were not treated with EGTA did not
show a similar rise in resistance at this time point (resistances among these cultures
were between 318 and 645 Q.cm2). This phenomenon was also observed in batches 2
and 3, and to a lesser degree in batches 6, 7, 9 and 12.
6.2.3 Visual Observations
A number of observations were made when routinely measuring the electrical
resistance of the cultures, and changing the growth media, or during routine
examinations under the microscope. Most notably, the presence of beating cilia was
observed on some cells in almost every culture. Ciliary action was indicated by a
shimmering effect over individual cells, or patches of cells, when focusing just above
the plane of the epithelial cell sheet under the light microscope.
Detached cells were often seen at the edge of a culture, under the light microscope.
These cells were motile, describing regular circular patterns, or exhibiting a jiggling
movement. At first, this caused concern over the possibility of contamination with a
motile microorganism. However, the moving cells seemed to be of epithelial, rather
than microbial, morphology and no other evidence of microbial contamination was
present. It seems likely that these were dead epithelial cells that had migrated to the
edge of the culture, and were being shunted about by ciliated cells in that region.
Several cultures were ruined when the sheet of cells pulled away from the edge of the
culture insert (specifically, from batches 4, 5 and 10). This made it impossible to get
an accurate reading of the electrical resistance (these gaps result in a low resistance
reading because the electrical current can travel through the gaps at the edge of the
culture, rather than transepithelially).
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There is some evidence that this was due to insufficient collagen coating of the
Costar inserts. In batch 10, almost all of the cultures showed sheets of cells pulling
away from the edge of the insert. Cultures # 25 - 28, however, did not show this
behavior, and exhibited unusually high resistances. These four cultures had been
seeded on inserts that had been collagen-coated at 4°C for several days (as they were
left over from a previous batch), while the other cultures were seeded on inserts that
had been freshly coated with collagen for only five hours. Thus, it seems likely that
insufficient collagen coating resulted in poor cell adhesion to the insert in batch 10.
After this observation, the protocol was changed, so that inserts were always
collagen-coated at for at least 24-hours before seeding; this seemed to reduce the
instances where cultures became detached from the edges.
Fungal contamination was seen in two culture wells (#1 1 from batch 2 and #19 from
batch 12): this appeared a few days after seeding the cultures. The appropriate wells
were disposed, and surrounding wells did not become infected. The source of this
fungus is unknown, but it is tempting to speculate that it was derived from the sheep
animals, as they are not kept in sterile living conditions. The entire batch 8 was
discarded as it was found to be contaminated the day after seeding, probably with
bacteria (the media had turned yellow).
6.2.4 Electron microscopy
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM)
were performed on the cultures for further characterisation. Duplicate samples were
selected for both SEM and TEM. Samples were taken at time points of
approximately 1, 2, 3, and 4 weeks (the exact dates were dictated in part by the
availability of tracheas for seeding and the opportunity for sample submission for
electron microscopy processing, thus the time points are not exactly seven days
apart). Specifically, 'week 1' is batch 9 cultures #15 + 26 (SEM) and #14 + 23
(TEM) at 6 days post-seeding, 'week T is batch 9 cultures #19 + 25 (SEM) and #23
+ 27 (TEM) at 13 days post-seeding, 'week 3' is batch 7 cultures #2+13 (SEM) and
#1+8 (TEM) at 21 days post-seeding, and 'week 4' is batch 6 cultures #1+5 (SEM)
and #2 + 6 (TEM) at 25 days post-seeding.
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All samples used for electron microscopy had high resistances (Fig. 6.1), and
microscopic examination showed that the morphology was typical for that batch. The
initial fix was performed as described in the Methods section. Samples were
processed for electron microscopy as a service by Steve Mitchell at the Department
of Veterinary Medicine, University of Edinburgh. A parallel analysis of other
primary air-interface cultures was done by A. Doherty, and this provided additional
confirmation of the findings presented here.
6.2.4.1 Scanning electron microscopy
The apical surface of the cultures was characterised by SEM. Figures 6.2 and 6.3
show scanning electron microscopy images of cultures from weeks 1 through 4.
The cultures predominantly resembled a 'moonscape' of non-ciliated cells at every
time point. Very short, fingerlike structures, or bumps, were seen on many cells;
these appeared to be microvilli. A few cells exhibited longer hair-like structures,
which appeared to be cilia (Fig. 6.2). These ciliated cells were infrequent in the
culture, but were present at every time point.
Ciliated cells appeared to be organized into clusters within the 'moonscape'. The
number of ciliated cells within each cluster increased as the culture period progressed
(Fig. 6.3). At week 1, one to two ciliated cells were seen in close proximity
(amounting to approximately 1 % of cells in the total culture). At week 2, clusters of
three to four cells were seen (approximately 2% of cells in the total culture). At week
3, clusters of six to eight cells were seen (approximately 5 % of cells in the total
culture), and by week 4, clusters of eight to twenty-five cells, in nearly confluent
patches were observed (amounting to approximately 15% of cells in the total
culture).
Duplicate samples were processed, and the abundance of ciliated cells became more
variable as the cultures progressed. Thus while the duplicates of week one and two
cultures contained almost identical numbers of ciliated cells, there was greater
heterogeneity in the number of ciliated cells between duplicates at weeks three and
four.
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Hence, these primary tracheal cultures showed features of the endogenous tracheal
epithelium on their apical surface, most notably, cilia. Cilia were less abundant than
in the native trachea. The week four cultures showed the greatest frequency of
ciliated cells, therefore these approximated the best model of the endogenous trachea.
6.2.4.2 Transmission electron microscopy
Figures 6.4 and 6.5 show the transmission electron microscopy images of cultures
from weeks 1 through 4.
At every time point, the samples were predominantly composed of a pseudostratified
epithelial bilayer (Fig. 6.4). This mimics the structure of the endogenous trachea,
where the flatter basal cells lie partially below the columnar cells (see Fig. 1.4).
Microvilli could be seen on many cells at the apical surface. These short, finger-like
structures appeared to be protrusions of the cell membrane.
Cilia were seen on cells in the week 3 and week 4 samples (Fig. 6.4 and 6.5). These
appeared as long, dark structures, embedded in the membrane. These were
morphologically distinct from the microvilli; they are darker, wider, and longer, and
appear as distinct structures. While the microvilli sometimes appear to branch, the
cilia never do. Most convincingly, the 9 + 2 structure of microtubules could be
visualised where the sectioning plane cut across the cilia (Fig. 6.4). Cilia were only
seen upon a few cells in the specimens examined, although in the week 4 sample,
two adjacent cells with cilia were seen.
The appearance of the specimens remained relatively consistent throughout the
culture period from one to four weeks. Some patches within the cultures
demonstrated additional layers of cells (e.g. in the week 2 culture, Fig. 6.5), or
thinner layers with a flatter cells in the lower layer (e.g. in the week 4 culture, Fig.
6.5). However, the majority of the culture was composed of a pseudostratified bilayer
at every time point, and no trend was seen as the cultures progressed, relating to a
change in cell morphology or arrangement. Although there was some evidence of an
increase in the number of ciliated cells from weeks one to week four, it would not be
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appropriate to use this method for a quantitative measure of ciliated cells, as only a
narrow cross-section of the culture was examined for each specimen.
6.2.5 Optimising transfection
Before transfection, the cultures were treated with 6 mM EGTA for twenty minutes
to disrupt the tight junctions, as previously described. Two transfection methods,
LID and SID, were compared for efficiency in transfecting the air-interface primary
cultures. These reagents were compared to roughly optimise transfection efficiency
in the primary cultures at time point of week 1, week 2, and week 4:
'Week 1': Nine of the batch 6 cultures displaying high resistances (Fig. 6.1) were
treated with EGTA, then transfected with the pEGFP-N plasmid using either the SID
or the LID method, at day 5 post-seeding. At day seven post-seeding, FACS was
performed.
'Week 2': Another nine of the batch 6 cultures displaying high resistances (Fig. 6.1)
were treated with EGTA at day 12 post-seeding, then transfected with the pEGFP-N
plasmid using either SID or LID At 14 days, FACS analysis was performed.
'Week 4': Nine of the batch 12 cultures displaying high resistance (Fig. 6.1) were
treated with EGTA at 25 days post-seeding, then transfected with the pEGFP-N
plasmid using either the SID or the LID method. At 27 days post-seeding, FACS was
performed.
The result of the FACS analysis for these samples is shown in Figure 6.6. EGFP-
expressing cells were detected following both SID and LID transfection of the
pEGFP-N plasmid at all three time-points. This project did not allow the extensive
period of study required to fully optimise transfection.
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Figure 6.6. SID and LID transfection of air-interface primary cultures. Air
interface cultures at 1-week, 2-weeks and 4-weeks post-seeding were transfected
with the pEGFP-N plasmid using the SID or LID reagent, or left untransfected, as
labelled. At 48-hours post-transfection, cells were analysed by FACS (see
Methods). This figure shows the dotplots for these transfections.
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Figure 6.6. (continued)
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6.2.6 Transfection of primary cultures with a panel of vectors
Electron microscopy studies revealed that week 4 was the time point that most
closely resembled the native tracheal epithelium. Thus, this time point was selected
for transfection with a panel of genomic context vectors. The LID method was
selected for transfection.
Fifteen of the batch 13 cultures showing a high resistance (Fig. 6.1) were treated with
EGTA at 28 days post-seeding and transfected with the vectors pEGFP-N,
PAcRC2cmvEGFP, pi kbcfproEGFP, PAc65kbcpfroEGFP, or left untransfected, in
triplicate. Cultures with slightly higher or lower resistance were distributed evenly
amongst the treatments, to prevent a bias. At day 30, EGFP expression was analysed
by FACS (Fig. 6.7). Fluorescent cells were detected following transfection with all
four vectors. This experiment was repeated on batch 11 cultures in duplicate at 25
days post-seeding, and a similar result was obtained.
6.3 Discussion
No ex vivo model will fully recapitulate the complex interactions of the in vivo multi-
organ system. Such models must be extensively characterised, to define which
features of the native tissue have been retained. However if ex vivo cultures are used
prudently, bearing in mind their strengths and weaknesses, they can serve a useful
function, acting as a bridge between in vitro studies on permanent cell lines, which
are fairly artificial, and in vivo studies, which can be costly and time-intensive. One
could take the view that ex vivo experiments are superfluous in developing
therapeutic treatments, as it will always be necessary to test the efficacy and safety of
these treatments in animals before using them in humans. However, from an ethical
standpoint it is surely essential to use both in vitro and ex vivo experiments to reduce,
refine and replace the experiments done of animals.
The primary tracheal cultures discussed in this chapter have been characterised to a
high degree, as part of this study and other projects. The morphology seen in these
cultures is similar to the native tissue; the cells form a pseudostratified bilayer, with
evidence of basal and columnar cells. Cilia are present in the culture and become
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Figure 6.7. Transfection of EGFP reporter constructs into air-interface
primary cultures. Air interface cultures 4-weeks post-seeding were transfected
with pEGFP-N, pAcRC2cmvEGFP, p1 kbcfproEGFP, PAC65kbcfproEGFP,
complexed with LID, or left untransfected, as labelled. At 48-hours post-
transfection, cells were analysed by FACS (see Methods). This figure shows the
dotplots for these transfections.
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Figure 6.7. (continued)
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Statistics for: 1KB3 , FL2-H v FL1-H , Ungated Statistics for: 65KB1 , FL2-H v FL1-H , Ungated
Region I Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y1 10000 100.00 100.00 12.28 Total (Y) 20000 100.00 100.0O 11.86
(xi 11.55 (X) 10.21
R1 (Y)| 7 0.07 0.07 27.75 R1 (Y) 2 0.01 0.01 33.22
(xj 136.31 (X) 119.93
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Figure 6.7. (continued)
(m) PAC65kbcfproEGFP transfected -2
10* 10' 10' 10' io4
FL1-H
Statistics for: 65KB2 FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 20000 100.00 100.00 9.9C
(X) 9.1S
HI (Y) 6 0.03 0.03 19.61
m 79.46
(n) PAC65kbcfproEGFP transfected -3
10* 10' 10' 10' io4
FL1-H
Statistics for; 65KB3 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 20000 100.00 100.00 11.64
(X) 10.81
R1 (Y) 3 0.01 0.01 99.55
(X) 402.42
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more numerous with time (although at no time point in this study did they become as
numerous as in the native tissue). It was interesting that ciliated cells seemed to
develop in clusters: in other words, ciliated cells were usually observed in close
proximity to one another (although not necessarily in adjacent cells of direct contact),
rather than in a more random scattered arrangement. One might be tempted to
speculate that some form of cell to cell signalling is occurring to stimulate the
development of these cilia. It would be fascinating to see what the cultures would do
given a longer period to develop, or upon the inclusion of secreted cell-signalling
factors in the growth media.
A high transepithelial resistance indicated the presence of tight junctions in most of
the cultures. A confluent, adherent layer of cells was required to accurately measure
the resistance, and a sufficient collagen base was required for this layer to continue to
adhere to the insert support. Treatment with 6mM EGTA for 20 minutes was
sufficient to temporarily disrupt these tight junctions, although they generally
recovered within the following 48-hours.
Successful transfection of the pEGFP-N vector into week 1, 2 and 4 primary cultures
was demonstrated, using both the LID and SID reagents.
It would be very interesting to determine the identity of the transfected cells, one
preliminary attempt was made to do this (by separating the transfected population
according to FL1-H: FL2-H ratio, with a FACSCalibur machine, then adhering the
cells to a slide, and staining with Hematoxylin/Eosin to visualise cell structures such
as cilia), sadly this was unsuccessful.
Week four cultures were successfully transfected with a panel of EGFP-expressing
vectors. There was evidence of EGFP expression with the pEGFP-N,
PAcRC2cmvEGFP, p 1 kbcfproEGFP and PAc65kbcfproEGFP vectors.
It was unfortunate that these studies were completed during the 2001 period when the
foot and mouth epidemic was limiting animal movement and availability in Britain.
Indeed, this halted the ex vivo phase of the project for a couple of months, and
limited the number of sheep tracheae available for use in this study.
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7.1 Conclusion
7.1.1 Vector construction (Chapter 3)
Two small plasmids (plkbcfproEGFP and pCFTRiresEGFP) and four large PAC
vectors (pAc65kbcfpro, pAcRC2cmvEGFP, pAcRCliresEGFP, and pAcRC2iresEGFP)
were created, coupling CFTR sequences to the EGFP reporter gene. These vectors
were used in transfection studies, to evaluate the effects of CFTR regulatory
elements upon transcription, and to analyse the suitability of EGFP as a reporter gene
for CFTR promoter activity.
The small plasmids were made by conventional cloning procedures, while the large
PAC vectors were made by a double-recombination method incorporating both
homologous recombination and Cre/loxP recombination, as previously described
(Boyd et al, 1999b). The greatest number of recombinant clones was derived by
using a high insert: vector ratio in this double-recombination method.
Two aspects of vector construction have been validated by this project: (l) the
successful creation of pAc65kbcfproEGFP, PAcRC2cmvEGFP, PAcRCl iresEGFP, and
pAcRC2iresEGFP showed that it is possible to use a PCR product as an insert in the
double recombination method; (2) there was originally doubt as to whether the loxP
sequence could be successfully introduced onto the end of a PCR product by its
inclusion in the a primer: one might predict that the palindromic loxP site would
anneal to itself to form a loop during the PCR process and would thus be deleted
from the product in subsequent cycles (see Section 3.2). The successful generation of
these PAC vectors shows that it is possible to introduce this sequence by its inclusion
in a primer, despite the palindromic nature of the loxP sequence. These innovations
in vector construction should prove useful in the creation of further vectors.
Further to this, colony PCR was shown to be a suitable method for detecting
recombinant clones generated by the double recombination method. It proved
possible to perform PCR-sequencing directly from the product of a colony PCR.
These methods will allow rapid and efficient detection and analysis of recombinant
clones in the future.
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Where a PCR-step was included in the construction process, the corresponding
region was sequenced to check for mutations. Despite the use of Expand™ high
fidelity Taq polymerase and HPLC-purified primers, many mutations were detected.
The vectors reported here were found to he mutation-free with the following
exceptions: (1) every pAcRCliresEGFP and PAcRC2iresEGFP clone that was
sequenced contained the mutation G A in the IRES portion of the vector. ApaLl
restriction has demonstrated that this mutation appears to derive from the parent
vector. Thus, the published sequence for the p.IRES2EGFP vector is probably
incorrect at this basepair; (2) the pacRCI iresEGFP and pAcRC2iresEGFP vectors
both contain the mutation AT (at positions 72127 and 96232, respectively), between
the polyadenylation site of EGFP and the loxP site. This region is derived from the
loxP primer; hence, his mutation may reflect aberrant synthesis of the loxP primer,
such that a proportion of the primers contain the divergent sequence. This mutation
does not affect transcription, and is therefore inconsequential.
7.1.2 Optimisation of transfection efficiency (Chapter 4)
Several reagents were compared to optimise transfection efficiency in the COS-7,
MDCK-iowa, T84, Caco-2, and HBE cell lines. Initial experiments used a
(3galactosida.se plasmid, with an ELISA or luminometer assay to detect expression. In
subsequent experiments, cells were transfected with FGFP-expressing plasmids and
expression was measured by FAGS. FAGS has proved to be a superior method for
analysing expression as this method allows the dissection of the number of cells
expressing versus the level of expression per cell.
This report demonstrated that EGFP expression could be measured by a celi's FLl-
H: FL2-H ratio. In cells that do not express EGFP, the fluorescence ratio is
approximately 1:1. However, following transfection with an EGFP-expressing
plasmid, an additional population of cells appears where FLH-l>FLH-2. RT-PCR
showed that this population represents cells expressing EGFP.
The I: I ratio of FL1-H: FL2-H in untransfected cells suggests that where cellular
components produce background fluorescence, they do so evenly across the
spectrum. Thus, a cell with low background fluorescence has both low FL1-H and
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FL2-H while a cell with high background fluorescence has both high FL1-H and high
FL2-FI. In contrast, the Green Fluorescent Protein does not emit light evenly across
the spectrum, but rather has a peak of emission at ~488nm, in the green region of the
spectrum, hence making a greater contribution to a cell's FL1-H fluorescence than
FL2-H fluorescence. Thus in cells expressing EGFP, FL1-H>FL2-H.
Based on this relationship, a dual-dotplot method of analysis was developed to
analyse the FACS data. This method proved to be superior to the traditional
histogram analysis, as it allowed a more robust distinction of EGFP-expressing cells
(including those expressing low levels of EGFP). With this dotplot method, the
difference between the transfected and untransfected populations is qualitative, rather
than quantitative. Thus, a single transfected cell can be robustly detected in a sample
of 10,000 cells or greater. Semi-quantitative RT-PCR showed that the FL1-H
intensity of the cells is probably a direct measure of the level of EGFP expression in
these cells, in keeping with the report by Subramanian and Srienc, 1996.
The Saint-Mix™ transfection reagent showed superior transfection efficiency, in
comparison to the DOTAP liposome. A ratio of 20 |ll Saint-Mix™: 1 pig DNA was
found to produce the best results. Although the Saint-Mix™ reagent showed promise
at the start of the study, this reagent produced inconsistent results, and the
transfection efficiency generally declined throughout the course of the study; the
reasons for this were unknown.
In initial experiments utilising the pCMVp plasmid, the PEI reagent appeared to be
superior to the Saint-Mix™ reagent, producing more (3galactosidase in the lysate of
transfected cells. However, contradictory results were found when EGFP-expressing
plasmids were transfected, and expression was analysed by FACS. In this case,
Saint-Mix™ transfected a larger proportion of cells than PEI did. It appears that in
the presence of a strong Pcmv promoter, PEI might artificially boost expression, as
the average fluorescence intensity of the transfected population was high higher with
PEI than with Saint-Mix™, in pEGFP-N transfections. The same did not apply to
plkbcfproEGFP transfections.
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A new transfection method, the SID method, was developed for this work. SID
combines the Saint-Mix™ reagent with the integrin-targeting peptide P6. The
inclusion of the P6 peptide increased the efficiency of transfection above that
observed with Saint-Mix™ alone, the optimum ratio for transfection was found to be
20 |il Saint-Mix™: 1 |ig P6: 1 |ig DNA, for most cell lines. This method produced
efficient transfection in many cell lines, but sadly showed the same inconsistencies
reported for the Saint-Mix™ method. Thus while SID shows great potential, the
causes of this inconsistency would have to be pinpointed and eliminated before this
method would be suitable for routine transfection studies.
The LID method (combining 0.75 p.1 of the liposome Lipofectin with 4 jug of the
integrin targeting peptide P6, and 1 jig of DNA) was found transfect the greatest
percentage of cells in every cell line except HBE, and produced consistent results.
This method was selected for further transfection studies.
7.1.3 In vitro transfection (Chapter 5)
The reporter constructs described in Chapter 3 were transfected into cell lines to
analyse the effects of CFTR regulatory elements upon EGFP expression.
The 797 bp region 5' of the CFTR gene in the pi kbcfproEGFP vector drove a low
level of EGFP expression in every cell line tested. This is consistent with reports in
the literature, demonstrating that this region encompasses the proximal CFTR
promoter (Yoshimura et al 1991b). This study shows that the proximal CFTR 5'
region maintains its function in a transient transfection system, and could be used as
a promoter in gene therapy vectors.
There was no evidence for modulation of expression by the additional upstream
region in the pAc65kbcfproEGFP vector. However, it is not possible to rule out a
subtle modulation of expression (such as that reported by Nuthall et al, 1999b), due
to the complications of vector size effects in this study.
The intron 1 DHS did not appear to affect expression in the COS-7 or MDCK-iowa
cell lines. An analysis of the effects of this element in gut cell lines was frustrated by
poor transfection efficiency of those lines, coupled with reduced expression from
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large PAC vectors, a weak CFTR promoter, and inefficient translation from an IRES.
In previous reports, this element has been shown to increase expression in a transient
transfection system, in the Caco-2 and CHO-K1 gut cell lines, but not in a bronchial
cell line that expressed CFTR at high levels (Smith, AN et al, 1996; Mogayzel and
Ashlock, 2000). In addition, analysis of DNase 1 hypersensitivity shows this element
to be specific to cells of the gut, in contrast to the lung (Smith, A et al, 1996). It is
particularly interesting that the intron 1 element did not upregulate expression in the
MDCK-iowa kidney cell line. This provides further evidence that the intron 1 is not
ubiquitous, and does not upregulate expression in the kidney, despite the fact that this
tissue expresses high levels of CFTR.
Large PAC vectors exhibited reduced expression in comparison to small plasmid
vectors in permanent cell lines, as shown by a comparison of the vectors
PAcRC2cmvEGFP and pEGFP-N. Both the number of cells expressing EGFP and the
average fluorescence intensity of this population were reduced with the PAC vector,
in comparison to the small plasmid vector. This is not an effect of the reduced gene
copy number in PAC transfections, and does not affect co-transfected plasmids, as
demonstrated by mixing experiments.
Mixing experiments revealed an interesting phenomenon: diluting a reporter plasmid
with an anonymous DNA molecule actually increased expression levels. This was
true for both PAC and plasmid reporter constructs. The anonymous DNA molecule
was essential, and had to be mixed with the reporter construct before complex
formation for this increase in tranfection efficiency. While we cannot yet explain the
mechanism of this effect, there are many potential applications.
7.1.4 Characterisation and transfection of primary cultures
This report showed that that the sheep primary tracheal air-interface culture system
demonstrates features of the native tracheal epithelium and is a reasonable model
system for gene therapy studies. Electron microscopy demonstrated a
pseudostratified epithelial-cell arrangement, similar to the native airway surface
epithelium. Some cells in the culture exhibited cilia; these became more numerous as
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the culture progressed. Tight junctions were demonstrated in the cultures, by virtue
of high transepithelial resistance.
Both SID and LID transfection methods were successful in transfecting the primary
cultures. The LID method produced a greater level of expression than the SID
method in these experiments, hence this method was selected to transfect a panel of
vectors into then primary cultures. The pEGFP-N, p 1 kbcfproEGFP,
PAcRC2cmvEGFP and PAc65kbcfproEGFP vectors all demonstrated expression when
transfected into week 4 primary cultures, using the LID method. A comparison of
transfection efficiencies demonstrated that while PAC vectors show greatly reduced
expression in comparison to their small piasmid counterparts in permanent cell lines;
the difference is not as severe in ex vivo cultures. Thus, PAC GCVs may be suitable
candidates for in vivo trials.
EGFP has proved to be a valuable reporter gene in the analysis of CFTR promoter
elements. The ability to distinguish between the percentage of cells expressing EGFP
and the level of expression per cell, and the greater sensitivity of detection afforded
by FACS analysis were crucial to these studies.
7.2 Future work
7.2.1 EGFP detection
The FACS dual-dotplot analysis method proved to be a superior detection method.
Further refinements to the method may increase the sensitivity of detection even
further. For example, it could be possible to create a 3-dimensional plot of all three
fluorescence readings taken by the FACS machine (FL1-H, FL2-FI and FL3-H), this
may allow an even more specific dissection of the transfected population. Here, the
fluorescence settings on the FACS machine were at 438 for all fluorescent channels
(see Methods for machine settings). It appeared to be necessary to keep the FLl -H
and FL2-H settings equal, and set the machine to 0% compensation (corrects for
fluorescence from alternate channels) to maintain a I: I ratio of these fluorescence
readings (this is not surprising). However, it may be possible to get a better
dissection of the transfected population by altering these settings.
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Fluorescence microscopy was attempted early in the project. Transfection of reporter
constructs such as pEGFP-N (where a large number of cells expressed high levels of
EGFP) produced fluorescent cells that could be visualised under the microscope.
However, it was difficult to distinguish fluorescent cells when the PAC constructs
were transfected, due to the small numbers of cells expressing EGFP and the low
fluorescence intensity in these cells. In addition, fluorescence microscopy is
primarily qualitative, rather than quantitative. Hence, this method proved unsuitable
for this work. However, it may be possible to develop software for the digital
fluorescence microscope to improve this method for our purposes. For example, it
may be possible to compare the ratio of fluorescence from different channels, as was
done in the FACS dotplot, and perform subtraction analysis based on this ratio to
correct for background fluorescence. Applying such software to the digital image
might create a visual picture of green fluorescence that is more representative of
EGFP expression.
7.2.2 Vector construction
The pacRC 1 iresEGFP and PAcRC2iresEGFP vectors were created to test Ihe effects
of the intron 1 DHS upon expression. This approach was selected for a number of
reasons. We hypothesized that CFTR may require its endogenous location, or may
require the presence of other genomic elements, to accomplish regulation of
expression. Hence, it seemed most appropriate at the start of the project to preserve
this intron in its natural context, by maintaining as much of the intact CFTR locus as
possible. It proved to be easy to create such constructs by altering the PACRClb and
PAcRC2b vectors with the double recombination method.
Before the construction of these vectors, Heather Davidson (a member of the
Edinburgh MMC group) created the vector pACRC2EGFP. This vector was
engineered to encode a fusion protein, containing CETR exon 1, intron I and a
portion of exon 2, fused at the N-terminus to the EGFP gene; with 65 kb of CFTR 5'
region driving expression (this vector was created using the double-recombination
method). This vector was transfected into the COS-7 and MDCK-iowa cell lines as
part of this project, to test the effects of the intron 1 elements: however, no
fluorescent cells were detected (data not shown). Barbara Stevenson (another
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member of the Edinburgh MMC group) created the vector pS 1G for a different
project. This vector fuses GFP to the C-terminus of CFTR: expression is driven by a
Pcmv promoter. When this vector was transfected into the COS-7 cell line,
fluorescent cells were detected, however the average fluorescence intensity of the
transfected population was very weak (see Fig. 4.2).
Although GFP fluorescence is a property of the chromophore region of the protein,
there is evidence that changes to other regions of the protein may affect the intensity
and spectral profile of fluorescence. Specifically, there are reports that protein
fusions may affect EGFP fluorescence (Cha et al, 2000). We believe this is what is
happening with the pSIG and pAcRC2EGFP vectors. When the pCFTRiresEGFP
vector was transfected into the COS-7 cell line (Fig. 5.1), cells appeared to express
EGFP. Although the average fluorescence intensity of the transfected population (Xf
= 131.75) was reduced in respect to pEGFP-N (Xf = 4247.85), it was significantly
above background levels (Xf = 4.01). Although it is not strictly appropriate to
compare values between experiments, this value exceeded the fluorescence intensity
of the pSIG vector (Xf -97.14, as measured by the histogram method, Fig. 4.2). In
light of this comparison, and the failure to detect EGFP expression from the
pacRC2EGFP vector, the IRES approach was selected for the creation of additional
vectors pacRCI iresEGFP and pAcRC2iresEGFP.
These studies were unable to resolve the effects of the CFTR intron 1 DBS upon
EGFP expression in gut cell lines. The transfection of control constructs pEGFP-N,
pacRC2citivEGFP, and pCFTRiresEGFP showed that these lines have a generally
low transfection efficiency, that expression is reduced with large PAC vectors, and
that translation from an internal ribosome entry site is inefficient in these cell lines.
In creating additional reporter constructs, it will probably be necessary to use small
plasmid vectors and/or find an alternative to the IRES system to create vectors with
detectable levels of expression.
One potential way to overcome the low transfection efficiency with PAC vectors
would be the production of immortalised cell lines. In fact, several stable cell lines
were made by integrating the pi kbcfproEGFP construct into the COS-7 cell line, as
part of this project. However, EGFP expression in these lines did not appear to be
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copy-number dependent, and appeared to suffer from position effects (results not
shown). YAC vectors containing more distal CFTR 5' regions, and 3' regions appear
to exhibit copy-number dependent, position independent expression (Vassaux and
Huxley, 1997); this may be a result of insulator/boundary elements surrounding the
CFTR locus, or may be an intrinsic effect of large YAC sequences. Thus, it may be
possible to analyse the effects of CFTR regulatory elements by creating permanent
cell lines with the larger PAC vectors. Even if copy-number dependent, position
independent expression were not achieved, these permanent cell lines could be useful
in analysing the effects of pharmacological elements (such as forskolin and PMA)
upon expression.
A fusion where GFP is linked to the N-terminus of CFTR has been created (Moyer et
al, 1998): this fusion protein expresses strong fluorescence, and maintains CFTR
channel activity. It would seem logical to duplicate this fusion in GCVs. This method
is being pursued by other members of the Edinburgh MMC; however, it will be
difficult to engineer vectors containing fusions to the CFTR N-terminus, using our
current methods.
One paper by Ann Harris' group (Smith, AN et al, 1996) suggests that CFTR intron 1
does not require its endogenous location to affect expression, and that it is capable of
upregulating expression from proximal 5' region of CFTR, where other CFTR
genomic context elements are absent. In light of this information, a reasonable
approach to assess the effects of CFTR intron 1 upon EGFP expression would be to
insert this element into the p 1 kbcfproEGFP vector. This vector could be created by
conventional cloning, by amplifying the intron 1 DHS region with the polymerase
chain reaction, and then inserting this product into the remaining portion of the
multiple cloning site (upstream of the proximal promoter), or into a restriction site
downstream of the EGFP gene, in the p 1 kbcfproEGFP vector.
Two reports have shown that the intron 1 element can upregulate expression of the
Luciferase reporter gene (Smith, AN et al, 1996; Mogayzel and Ashlock, 2000).
EGFP reporter plasmids would give a more detailed picture of the dynamics of this
upregulation, for the reasons described in Chapter 4.
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It would be interesting to create EGFP constructs including other CFTR introns or 3'
region, to test the effects of the various CFTR DHS elements upon expression.
Finally, it would be useful to create additional constructs, with a cut-down version of
the CFTR promoter. Other reports suggest that the DHS at -20.9 may upregulate
CFTR expression by 60% in the Caco-2 cell line (Nuthall et al, 1999b). The methods
used here were not sensitive enough to distinguish this relatively subtle increase in
expression. It would be useful to create a cut-down vector, containing a small region
encompassing the -20.9 DHS, linked to the proximal promoter in a small construct,
to further evaluate the effects of this DHS upon expression.
EGFP has many other applications in the study of CFTR function, which are more
divorced from this project. One example relates to the question of whether the CFTR
functional channel is a dimer. Fluorescence resonance energy transfer (FRET) is a
powerful technique to study protein interactions (Pollock and Heim, 1999). In this
method, fusion proteins are made between the proteins in question and differently
coloured GFP variants (with different excitation and emissions spectra -see Section
1.3.1). The proteins are then co-transfected into cell lines. If the proteins in question
are not interacting, than each fluorescent protein will only glow when excited with
light in the appropriate region of the spectrum corresponding to its own excitation
spectra. However, if the proteins in question are interacting, then the close proximity
will result in "cross-talk" between the fused GFPs, and both GFP variants will
fluoresce when only one is excited. Thus, CFTR could be fused with differently
coloured GFP molecules, and this FRET technique could be used to determine
whether they are interacting, e.g. forming dimers.
GFP-CFTR fusions will also be valuable in studying CFTR trafficking within the
cell: this approach is being pursued by other groups (Moyer et al, 1998; Moyer et al,
1999; Foffing-Cueni et al, 2001).
7.2.3 Size effects/Plasmid mixing effects
Additional transfection studies could be used to investigate the vector size effect (e.g.
differential expression in PACs and plasmids), and the effects of plasmid mixing. It
would be useful to test a large BAG vector containing the EGFP reporter gene under
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the control of a Pcmv promoter, to see if it is large vector size per se which reduces
expression. Conversely, small plasmid vectors could be created containing PAC
backbone elements to rule out the possibility that it is these which are reducing
expression.
The plasmid mixing experiments unveiled an unexpected interaction: that diluting a
reporter plasmid with an anonymous plasmid appears to increase its transfection
efficiency. This effect cannot yet be explained, and it would be useful to perform
further experiments to investigate the mechanics of this process. Firstly, it will be
necessary to repeat this experiment with different reporter genes, and different
transfection regents (so far only LID and SID have been tried), to determine whether
this phenomenon is universal. It would also be interesting to perform plasmid mixing
with fluorescently labelled DNA vector (such as pGeneGrip) to determine the fate of
the DNA after it has entered the cell (by microscopy). It would be interesting to
investigate the effects of mixing the reporter plasmid with different forms of DNA,
such as mammalian chromosomal DNA (this might mask the presence of the
bacterial plasmid and thereby increase transfection efficiency). This effect certainly
appears promising, and warrants further investigation.
7.2.4 Primary Cultures
The sheep primary tracheal air-interface cultures (described in Chapter 6)
demonstrate features of the endogenous trachea and are a useful ex vivo model.
However, further experiments are required to characterise these cultures. For
example, antibody-staining experiments should be performed to fully characterise the
cell types present in these cultures.
One attempt was made to identify the cell types which are being transfected by
mechanical FACS sorting (e.g. separating the population of cells which are
expressing EGFP). The cells were subsequently applied to a poly-L-lysine coated
slide, fixed, and stained with hemotoxylin/eosin to visualise cell structures. This
attempt failed, as the cells were lysed at some point during the process (only cell
debris remained). It is likely that this was a result of using a FACSCalibur to sort the
cells: this cytometer sorts cells mechanically and does not preserve cell viability. The
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more sophisticated FACSVantage cytometer, which sorts the cells magnetically and
maintains their viability, might produce better results.
In retrospect, it might have been possible to determine the identity of the expressing
cells more simply with fluorescence microscopy. The pEGFP-N plasmid produced
reasonable transfection efficiency, and the average fluorescence intensity of the
transfected population was significantly above background, such that these cells
could probably be distinguished by microscopy. However, it might be difficult to
determine whether it is the underlying, or top layer of cells (in the pseudostratified
bilayer) expressing EGFP with this method. It would probably be necessary to
combine this with cell staining, or irnmunohistochemistry (e.g. for markers of cell
identity, or antibodies that recognise structures such as cilia), to determine the
identity of the transfected cells.
In the lung, CFTR expression is not uniform amongst epithelial cells, but appears to
be higher in certain subpopulations of cells, in both the submucosal glands and the
airways (Engelhardt, 1992 and 1994). Some of these cell types may be represented in
the primary air-interface cultures. Reporter constructs containing the EGFP gene
would be ideally suited to test whether CFTR promoter elements can restrict
expression to specific cell types.
Ann Doherty and Peter Thorpe, members of the Edinburgh fvIMC group, are
pursuing some of these experiments relating to primary cultures. In addition, Ann
Doherty is attempting to establish similar cultures from lower portions of the airway,
such as the bronchus, which may prove to be the target for gene therapy. Ultimately,
other ex vivo primary culture methods and in vivo animal experiments will be
required to refine gene therapy vectors prior to commencing a clinical trial.
7.3 Closing remarks
This project investigated the use of EGFP as a reporter to evaluate CFTR regulatory
elements, in gene therapy vectors. We can make some general conclusions about the
strengths and weaknesses of the methods used in this study.
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Vector size dramatically affected transfection efficiency in cell lines: this made it
difficult to assess the effects of regulatory elements upon expression by comparing
expression from small plasmid and large PAC vectors. This study highlighted the
limitations of working with transformed cell lines, such as COS-7, when the end
purpose is to evaluate vectors designed for use in vivo. The air-interface ex vivo
system described here is a more accurate approximation of the native epithelium.
Studies in air-interface cultures revealed the unexpected observation that the effect of
vector size was less pronounced than in e.g. COS-7 cells. There is however a clear
and substantial effect of the promoter (heterologous vs. autologous). An inherent
problem with all such comparative studies is the day-to-day variation in transfection
efficiency. Consequently, it was necessary to transfect vectors simultaneously to
allow a comparison of their effects. This obligation restricted the size and scale of
experiments.
Nevertheless, this report has shown that EGFP can be used as a reporter of weak
promoters, such as the CFTR proximal 5' region. The dual dotpiot method has
proved to be a superior method of analysing FACS data, creating a very sensitive and
quantitative assay for EGFP expression. Finally, an interesting interaction was
uncovered: that dilution of a reporter gene does not necessarily reduce its
transfection efficiency.
EGFP has proved to be an excellent reporter of CFTR promoter activity in gene
therapy vectors. Further studies utilising this reporter gene are warranted.
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Appendix A — Primers (oligonucleotide sequences). The primers 5'cfpro, 3'cfpro, loxP, cf5491
and cmvl, which were used in vector construction, were HPLC-purified to decrease the possibility of
aberrant sequences within these primers. All other primers were made by 3 OD select, desalted
purification.






69 -> 136 (f)










1865 -> 1800 (r)
(3 gal 1 GAATTATTTTTGATGGCG pcmvp: 1363-> 1380 (f)
Pgal2 CGCTGATTTGTGTAGTCGGTT pcmvP: 1614-> 1594 (r)
pgalint TGATGGTGCTGCGTTGGAG pcmvp: 1501 -> 1529 (f)
EGFPs GCTGTTCACCGGGGTGGTGC pEGFP-N 699 ->718 (f)











66414 -> 66439 (f)
Ex9R CCTGCTCCAGTGGATCCAGCAAC PAcRClb:
67469 -> 67447 (r)
Ex 19F GCGATCTGTGAGCCGAGTC PAcRClb:
69552 -> 69570 (f)
Ex24R CCGCACTTTGTTCTCTTCTATG PAcRClb:
70347 -> 70326 (r)
seqF GGACTCAGATCTCGAGCTCAAG p 1 kbcfproEGFP 21-> 42
(f)
seqR CCAGCTCGACCAGGATGGGCACC plkbcfproEGFP 935 ->
913 (r)
seqF2 GGAAACGCCTGGTATCTTTATAGTCC plkbcfproEGFP 4720 -»
4745 (f)
seqR2 GAAGAAGATGGTGCGCTCCTGGAC plkbcfproEGFP 1180 ->
1157 (r)
prlF CCACCCTTGGAGTTCACTCACC PAc65kbcfproEGFP:
65253 -> 65274 (f)
prlR TCCTTCCTCCTCTCCTCCTTCG PAc65kbcfproEGFP:
65791 -> 65770 (r)
254
pr2F AGGGAGGCTGGGAGTCAGAATC PAc65kbcfproEGFP:
65718 -» 65739 (f)
pr2R CTTCAGGGTCAGCTTGCCGTAG pac65kbcfproEGFP:




-> 9541 1 (r)
pr3F ATCCTGGTCGAGCTGGACGGC PAc65kbcfproEGFP:
























70370 •> 70389 (f)
PAcRC2i resEGFP:
94475 ->
cf5491 AACTCAAGCAAGTGCAAGTCTAAG pacRCI iresEGFP:






cmvl GTAACAACTCCGCCCCATTGACGC pEGFP-N 498 -> 521
PAC
RC2b
*for orientation, (f) = forward (r)=reverse
255




= match = deletion = mismatch
C . G
Top row = Contig, bottom row = Predicted sequence






II I I I I I I II II II I I I I II I I I II I I I I I I II I I I I I I II I I II II I II
117 TTTCGGCTCTCTAAGGCTGTATTTTGATATACGAAAGGCACATTTTCCTT 166
CCCTTTTCAAAATGCACCTTGCAAACGTAACAGGAACCCGACTAGGATCA
i M i II11 M M I I 11 M I M M M i I i M I i I I M M I II M I I M M i
167 CCCTTTTCAAAATGCACCTTGCAAACGTAACAGGAACCCGACTAGGATCA 216
TCGGGAAAAGGAGGAGGAGGAGGAAGGCAGGCTCCGGGGAAGCTGGTGGC
I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I ! I I I I I I I I I I I I I
217 TCGGGAAAAGGAGGAGGAGGAGGAAGGCAGGCTCCGGGGAAGCTGGTGGC 266
AGCGGGTCCTGGGTCTGGCGGACCCTGACGCGAAGGAGGGTCTAGGAAGC
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
267 AGCGGGTCCTGGGTCTGGCGGACCCTGACGCGAAGGAGGGTCTAGGAAGC 316
TCTCCGGGGAGCCGGTTCTCCCGCCGGTGGCTTCTTCTGTCCTCCAGCGT
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I
317 TCTCCGGGGAGCCGGTTCTCCCGCCGGTGGCTTCTTCTGTCCTCCAGCGT 366
TGCCAACTGGACCTAAAGAGAGGCCGCGACTGTCGCCCACCTGCGGGATG
I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I
367 TGCCAACTGGACCTAAAGAGAGGCCGCGACTGTCGCCCACCTGCGGGATG 416
GGCCTGGTGCTGGGCGGTAAGGACACGGACCTGGAAGGAGCGCGCGCGAG
II 11 III11 I M 11 II11 I 11 1111 I 11 M 11 I 11 11! III 111II M I
417 GGCCTGGTGCTGGGCGGTAAGGACACGGACCTGGAAGGAGCGCGCGCGAG 466
GGAGGGAGGCTGGGAGTCAGAATCGGGAAAGGGAGGTGCGGGGCGGCGAG


















I I I I I I I I I I I I I I I I I II I I I I I I I I I I I II I I I I I I I II I I I I I I I I I
767 TAGGTCTTTGGCATTAGGAGCTTGAGCCCAGACGGCCCTAGCAGGGACCC 816
CAGCGCCCGAGAGACCTAACTATAACGGTCCTAAGGTAGCGA
I li II M II!! M 1111:11! M ! 1111111II!! 11II111
817 CAGCGCCCGAGAGACCTAACTATAACGGTCCTAAGGTAGCGA 858
257
B2 : Sequence of PAC65kbcfproEGFP:
Percent Similarity: 100.000
AACTTTTCGGCTCTCTAAGGCTGTATTTTGATATACGAAAGGCACATTTT
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
65362 AACTTTTCGGCTCTCTAAGGCTGTATTTTGATATACGAAAGGCACATTTT 65411
CCTTCCCTTTTCAAAATGCACCTTGCAAACGTAACAGGAACCCGACTAGG
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I
65412 CCTTCCCTTTTCAAAATGCACCTTGCAAACGTAACAGGAACCCGACTAGG 65461
ATCATCGGGAAAAGGAGGAGGAGGAGGAAGGCAGGCTCCGGGGAAGCTGG
I I I I I II I I I ! I it'll I I II I I I I I I I I I I I I I I I II I I I I ! I I I I I I I I
65462 ATCATCGGGAAAAGGAGGAGGAGGAGGAAGGCAGGCTCCGGGGAAGCTGG 65511
TGGCAGCGGGTCCTGGGTCTGGCGGACCCTGACGCGAAGGAGGGTCTAGG






I I I I I I I I I I I III I I I I I I I I I I I I I I I I I i I I I I I I il I I I I I I I I I I I
65612 GCGTTGCCAACTGGACCTAAAGAGAGGCCGCGACTGTCGCCCACCTGCGG 65661
GATGGGCCTGGTGCTGGGCGGTAAGGACACGGACCTGGAAGGAGCGCGCG
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
65662 GATGGGCCTGGTGCTGGGCGGTAAGGACACGGACCTGGAAGGAGCGCGCG 65711
CGAGGGAGGGAGGCTGGGAGTCAGAATCGGGAAAGGGAGGTGCGGGGCGG
I I I I I I I II I I I I I i I I M I I I I I
65712 CGAGGGAGGGAGGCTGGGAGTCAGAATCGGGAAAGGGAGGTGCGGGGCGG 65761
CGAGGGAGCGAAGGAGGAGAGGAGGAAGGAGCGGGAGGGGTGCTGGCGGG
I M 111 M 111 M 111 11 11 II111! I i I I M III 11 I I M 11 I i 11
65762 CGAGGGAGCGAAGGAGGAGAGGAGGAAGGAGCGGGAGGGGTGCTGGCGGG 65811
GGTGCGTAGTGGGTGGAGAAAGCCGCTAGAGCAAATTTGGGGCCGGACCA
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I III I I I II I I I I I I I II I I I
65812 GGTGCGTAGTGGGTGGAGAAAGCCGCTAGAGCAAATTTGGGGCCGGACCA 65861
GGCAGCACTCGGCTTTTAACCTGGGCAGTGAAGGCGGGGGAAAGAGCAAA
III IIIII III II11 III I III Mil III Mil I Mill III III 11 III
65862 GGCAGCACTCGGCTTTTAACCTGGGCAGTGAAGGCGGGGGAAAGAGCAAA 65911
AGGAAGGGGTGGTGTGCGGAGTAGGGGTGGGTGGGGGGAATTGGAAGCAA
11 I I I II I I I I I ! M I I ] I 11 M I M M 11 M M I 11 I I I M I ! M M I
65912 AGGAAGGGGTGGTGTGCGGAGTAGGGGTGGGTGGGGGGAATTGGAAGCAA 65961
ATGACATCACAGCAGGTCAGAGAAAAAGGGTTGAGCGGCAGGCACCCAGA


















II111111 Mil 111III Ml 11 III 11 III 11 Mil III II III III!
GTAGTAGGTCTTTGGCATTAGGAGCTTGAGCCCAGACGGCCCTAGCAGGG 66061
ACCCCAGCGCCCGAGAGACCTAACTATAACGGTCCTAAGGTAGCGAGGAT
IMIIIII111II11 III I III 1111III Mil 11II III 11 III 111II
ACCCCAGCGCCCGAGAGACCTAACTATAACGGTCCTAAGGTAGCGAGGAT 66111
CCACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGT
11II111 Mill 11 III II11 Mil 11 III I III M II III IIIIIII
CCACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGT 66161
GGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCA
I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
GGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCA 66211
GCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTG
I I I I I I I I I I I I I I I I I I II I I I I I I II I I I I I I I I I I I I I I I I I I I I I I
GCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTG 66261
AAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGT
I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I
AAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGT 66311
GACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
I I II I II II I I I II I II I I I II I I I I II I I I I II I II I II I I II I I I I I I
GACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA 66361
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAG
I I I I I I I I I I I I. I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAG 66411
GAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGA
I I I II I I I I I I I I I II I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I II
GAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGA 66461
GGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCA






I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
TACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCAT 66611
CAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGC
I M M II I I I I M II I II I I I I I II ; I II I I I I I I II I II I I I M I I I M
CAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGC 66661
TCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTG
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I
TCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTG 66711
CTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCC
11111111111111111111111111; 1111111! 111111111111 ((i
66712 CTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCC 66761
CAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCG
1111111111111111111! 111IIIII! 1111! I! 1111111! III11!
66762 CAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCG 66811
GGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGCGACTCT
I I I I II I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
66812 GGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGCGACTCT 66861
AGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAA
I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I II I I I I I I I I I I I I I I
66862 AGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAA 66911
AACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGT
I I I I I I I II I I II II I I II I I II I II I I I I I I II I II II I I I I I I II I II
66912 AACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGT 66961
TGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATA
I II I II I I I I I I I I I I I II I II I I I I II II I II I I I I I I II I I I I II I I I
66962 TGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATA 67011
GCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGT
I I I ! I I I I I I I I I I I I I I I I I I I I I I II I I i I I I I I II I I I I I I I I I I I I
67012 GCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGT 67061
GGTTTGTCATATGATAACTTCGTATAATGTATGCTATACGAAGTTAT
I I I II I I I II I I I II I I I II I I II i II I I I II II I I II I I I I I I I I I
67062 GGTTTGTCATATGATAACTTCGTATAATGTATGCTATACGAAGTTAT 67108
260









I I I II I I I I I I I I I I I I I I I I I I II I I I I I I I I II I II I I I I I I II I I I I
962 8 7 TGGGAGGTCTATATAAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTA 9633 6
GCGCTACCGGACTCAGATCTCGAGCTCAAGCTTCGAATTCTGCAGTCGAC
I II I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I
96337 GCGCTACCGGACTCAGATCTCGAGCTCAAGCTTCGAATTCTGCAGTCGAC 96386
GGTACCGCGGGCCCGGGATCCACCGGTCGCCACCATGGTGAGCAAGGGCG
I I II I I I II I I I I I I I I II I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I
96387 GGTACCGCGGGCCCGGGATCCACCGGTCGCCACCATGGTGAGCAAGGGCG 96436
AGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGAC
I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I II I I I I I I I I I I I I
96437 AGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGAC 96486
GTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCAC
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I
96487 GTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCAC 96536
919 CTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCG
I I I I I I I I I I I I I I I I I I I II I I I I I I I II I II I II I I I I I I I I I I I I I I
96537 CTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCG 96586
TGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTC
I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
96587 TGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTC 96636
AGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCAT
I I I I I I I II I I I I I I I I I II I I I I I I I I I I II I I I I I I I I II I I I I II I I
96637 AGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCAT 96686
GCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCA
I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I
96687 GCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCA 96736
ACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAAC
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
96737 ACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAAC 96786
CGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGG




I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
96837 GCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCG 96886
ACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATC
I I I I I I I I I I I II I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I II I I II
96887 ACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATC 96936
GAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCAT
II11II III I III ! I II11 I I I 1111 III 11II IIII 111 11 11 III11 I
96937 GAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCAT 96986
CGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGT
I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
96987 CGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGT 97036
CCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTG
I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
97037 CCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTG 97086
GAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAA
I I I II I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I
97087 GAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAA 97136
GTAAAGCGGCCGCGACTCTAGATCATAATCAGCCATACCACATTTGTAGA
I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I
97137 GTAAAGCGGCCGCGACTCTAGATCATAATCAGCCATACCACATTTGTAGA 97186
GGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAAC
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
97187 GGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAAC 97236
ATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAAT
I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I
97237 ATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAAT 97286
GGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTT
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
97287 GGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTT 97336
TTCACTGCATTCTAGTTGTGGTTTGTCATATGATAACTTCGTATAATGTA 7 0
I I I I I I I I I I I I I I I I I I I I I II I I I I I I II I I I I I I I I I I I I I I II I I I
97337 TTCACTGCATTCTAGTTGTGGTTTGTCATATGATAACTTCGTATAATGTA 97386
6 9 TGCTATACGAAGTTATTAGGTCCCTCGACTACGTCGTTAAGGCCGTTTCT
I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
97387 TGCTATACGAAGTTATTAGGTCCCTCGACTACGTCGTTAAGGCCGTTTCT 97436
GACAGAGTAAAATTCTT
I I I I I I I I I I I I I I II I
97437 GACAGAGTAAAATTCTT 97453
B4: Sequencing results for PACRCliresEGFP:
Percent Similarity: 99.942
Mismatch at 71081, Deletion at 72127
AACTCAAGCAAGTGCAAGTCTAAGCCCCAGATTGCTGCTCTGAAAGAGGA
I II I I I I I I I I I I II I I I I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I II I
70441 AACTCAAGCAAGTGCAAGTCTAAGCCCCAGATTGCTGCTCTGAAAGAGGA 70490
GACAGAAGAAGAGGTGCAAGATACAAGGCTTTAGAGAGCAGCATAAATGT
I I I I I I I I I II I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I
70491 GACAGAAGAAGAGGTGCAAGATACAAGGCTTTAGAGAGCAGCATAAATGT 70540
TGACATGGGACATTTGCTCATGGAATTGGAGCTCGTCGACGGTACCGCGG
I I I I I IIII I! II I I I I I II I I I I I II I I I I II II I II II I I I I I I I II I
70541 TGACATGGGACATTTGCTCATGGAATTGGAGCTCGTCGACGGTACCGCGG 70590
GCCCGGGATCCGCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAA






I !11II I I I I I II I I 1111111 I II 111 I III 11 I I 1111 11 11 ! I I III
70691 ATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTT 70740
CTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAG
II I I I I I I I I I I I I I II I II II I I I II II I I I II I I I I I I I I I I I I II II
70741 CTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAG 70790
GTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGA
I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
70791 GTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGA 70840
CAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCCACCTGG
II I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
70841 CAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCCACCTGG 70890
CGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAA
I I I I I II I I I I I I I I J I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
70891 CGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAA 70940
AGGCGGCACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGA
I I I I II I II I I I I I II I I I I I I I I I I I I I I I II I I I II I I I I I I I I I I I I
70941 AGGCGGCACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGA 70990
779 GTCAAATGGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCA 828







I I I I I I I I II I I I I II I I I I I I I I I I II I I I I I I I II I I I I I I I I I I I I I
71091 TTACATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCCCCCCGAACCAC 71140
GGGGACGTGGTTTTCCTTTGAAAAACACGATGATAATATGGCCACAACCA
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
71141 GGGGACGTGGTTTTCCTTTGAAAAACACGATGATAATATGGCCACAACCA 71190
TGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTC
I I I ! I I I I I I I I I I I I I I I I I I ! I I I I I I I I I I I I I I I I I I I I I I I I I I I
71191 TGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTC 71240
GAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGG
111II1111111 111 1111111111 III 11!111111II1111111II11
71241 GAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGG 71290
CGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCA
I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I II I I I I I I I I I I I I I I I I !
71291 CGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCA 71340
CCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTAC
I I I II I I I I I I I I I I I I 1 I I I I I I: I I I I I I I I I I I I II I I I ! I I I I I I I I
71341 CCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTAC 71390
GGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTT
I I I I I I II I II I II I I I I I I II I I I ! I I I I I I II I I I I II I I I I I I II II
71391 GGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTT 71440
CTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCT
I I I I I I I I I I I I II I I I I I I I I I II I I I I I I I I I I I I I I II I I I I I I I I I
71441 CTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCT 71490
TCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGC
I I I I I I I II I I I I II I I I I I I I I i I I II I I I I I I II I II I II I I I I I I I I
71491 TCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGC 71540
GACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGA






MIMMMIMMI III lllllll MINIM Mill NMMIMM
71641 TCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAG 71690
ATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCA







I I I I I: I I I I I I I I I I I ! I I I I I I I I I I II I I I II I I I I i I I I I I M I I I I
71791 ACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGAT 71840
CACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCAT






I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
71941 TACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCC 71990
CCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTT
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
71991 CCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTT 72040
ATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCAC
II I I I I I I I I I III I II II I I I I I II I I II II II ! I ! I I II I I II II I II
72041 ATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCAC 72090
AAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGG.TTGTCATATGATA






B5: Sequencing results for PftCRC2iresEGFP:
Percent Similarity: 99.942
Mismatch at 95186, deletion at 96232
AACTCAAGCAAGTGCAAGTCTAAGCCCCAGATTGCTGCTCTGAAAGAGGA
1111i111II11111 j 11111!1111111 ill 111111111111111111
94546 AACTCAAGCAAGTGCAAGTCTAAGCCCCAGATTGCTGCTCTGAAAGAGGA 94595
GACAGAAGAAGAGGTGCAAGATACAAGGCTTTAGAGAGCAGCATAAATGT
11 11111 I I 11 11 11 11111 111 111 I II11111 i 11 111 ! I 11 11 1111
94596 GACAGAAGAAGAGGTGCAAGATACAAGGCTTTAGAGAGCAGCATAAATGT 94645
TGACATGGGACATTTGCTCATGGAATTGGAGCTCGTCGACGGTACCGCGG
I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I
94646 TGACATGGGACATTTGCTCATGGAATTGGAGCTCGTCGACGGTACCGCGG 94695
GCCCGGGATCCGCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAA
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
94696 GCCCGGGATCCGCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAA 94745
GCCGCTTGGAATAAGGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACC
I I I I I I I I I II I I I I II ! I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
94746 GCCGCTTGGAATAAGGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACC 94795
ATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTT
I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I
94796 ATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTT 94845
CTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAG
II11 ii 111 11111111III I 111 M 11 11 M 111111 11II11 1111 I
94846 CTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAG 94895
GTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGA
I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I II I I I
94896 GTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGA 94945
CAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCCACCTGG
I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
94946 CAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCCACCTGG 94995
CGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAA
II I I II I I I I I I ! I I I I I I II I I I I I I I I I I I II I I II II I I I I I I I I I I
94996 CGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAA 95045
AGGCGGCACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGA













I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I l il I I I I I I I I
95246 GGGGACGTGGTTTTCCTTTGAAAAACACGATGATAATATGGCCACAACCA 95295
TGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTC






IMMMMiMlUMMI! i MMIU Mi IIMhIM i:
95396 CGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCA 95445
CCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTAC
I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
95446 CCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTAC 95495
GGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTT
I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I II I I I
95496 GGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTT 95545
CTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCT






I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
95646 GACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGA 95695
CGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACG
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
95696 CGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACG 95745
TCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAG
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I
95746 TCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAG 95795
ATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCA
Ill I I I I I I § I I I I I I
95796 ATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCA 95845
GCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACT
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
95846 GCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACT 95895
ACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGAT
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
95896 ACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGAT 95945
CACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCAT
I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
95946 CACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCAT 95995
GGACGAGCTGTACAAGTAAAGCGGCCGCGACTCTAGATCATAATCAGCCA
III I !! 11 M 111 III i! ! I I I! i M M I M I I I ! I M I ! I II !
95996 GGACGAGCTGTACAAGTAAAGCGGCCGCGACTCTAGATCATAATCAGCCA 96045
TACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCC






I I II I I I I I I II I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I
96146 ATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCAC 96195
AAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGG.TTGTCATATGATA
I I I I I I I I I I I II I I I I I I I I I I I I I II I I I i I I I I I I I I I I I I I I I I I
96196 AAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCATATGATA 96245
ACTTCGTATAATGTATGCTATACGAAGTTAT
I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I
96246 ACTTCGTATAATGTATGCTATACGAAGTTAT 96276
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Appendix C. Dotplot Data. This appendix shows the original FACS
dotplots used to make the histogram figures.
CI Figure 4.6 dotplots
(a) pure pEGFP-N transfected (b) pure untransfected
Region 1 Count % Gated % Total Mean ]
Total m 10000 100.00 100.00 613 32
(X 1829 39
R1 (Y)j 3284 32.84 32.84 1715 44
(x3 5416 2^
(c) 3:1 mix (lransfected:untransfected)
10' 10' 10'
FL1-H
Region | Count % Gated % Total Mean
Total (Yi 10000 100.00 100 00 3.59I
(X 3 8d
R1 (Y)l 0 0.00 0 00
(xil
(d) 1:1 mix (transfected:untransfected)
Region Count % Gated % Total Mean
Total (y! 10000 100.00 100.0c 403.83
(x) 1242 98
ri (y; 2217 22.17 22.17 1686 69
ix: 5471.78
(e) 1:3 mix (transfected: untransfected)
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 242 0^
(X) 729.52
R1 (Y) 1264 12.64 12 64 1720 43
(X) 5577.83
(f) 1:9 mix (transfected: untransfected)
Region Count % Gated % Total Mean
Total (Y 1000( 100.00 100 oc 94 54
ix: 275 27
R1 (Yt 464 4.64 4.64 1761 22j(x) 5667.42
Region I Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.00 35 54
(X 100.6C
R1 (Y)| 190 1.90 1.90 1403.48!
(Xj 4857.0C
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C2 Figure 4.10 dotplots
Statistics for: COSND1 , FL2-H v FL1-H , Ungated Statistics tor: COSND2 , FL2-H v FL1-H , Ungated
Region I Count % Gated % Total Mean Region ! Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.00 3.20 Total (Y)1 10000 100.00 100.00 3. ie
(X 2.80 (X 2.8C
R1 (Y)l 0 0.00 0.00 R1 (Y)| 0 0.00 0.00
(Xl (X)
(c) PEI-plkbcfproEGFP iransfected -1
FL1-H
Statistics for: COSPEil , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 16.46]
(X) 78.60
R1 (Y) 1215 12 15 12.15 107.32
(X) 622.69
Statistics for: COSPEI2 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 18.4S
(X) 89.6C
R1 (Y) 1301 13.01 13.01 113.3C
(X) 663.45
(e) Saint-Mix-plkbcfproEGFP transfected -1 (f) Saint-Mix-plkbcfproEGFP transfected -2
Statistics for: C0SSNT1 , FL2-H v FL1-H , Ungated Statistics for: C0SSNT2 , FL2-H v FL1-H , Ungated
Region 1 Count % Gated % Total Mean Region Count % Gated % Total Mean 1
Total (Y1 10000 100.00 100.00 53.31 Total (Y) 10000 100.0C 100.00 53.71
(XI 277.49 (X) 278.49
R1 (Y)| 2941 29.41 29.41 163.40 R1 (Y) 2894 28.94 28 94 167.83
(x] 929.16 (X 947.96!
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C2 Figure 4.!odotplots (continued)
(g) DOTAP-plkncfproEGFP -1
FL1-H
Statistics for: COSOTPt, FL2-H v FL1-H , Unoaled
Region Count % Gated % Total Mean
Total (Y]( ioood 100.00 100.0C 25.3c
(X 106.9€
HI ir 921 9.21 9.21 195.47
(X 1100.96
(h) DOTAP-pl kbcfproEGFP -2
FL1-H
Statistics for: CQSDTP2 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean I
Total (Y! 10000 100.00 100 00 28.88
(x: 122.90
ri (y: 971 9.71 9.71 217.44
(x; 1205.20
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C3 Figure 4.11 dotplots
(a) untransfected -1 (b) untransfected -2
"i i
10' 10' 10' 10' 10'
FL1-H
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.06 2.26
(X) 2.35
R1 (Y) 0 0.00 o.oc
(X)
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 2.01
(X) 2.04
R1 (Y) 0 0.00 0.00
(X)
(c) PEI-pEGFP-N transfected -1 (d) PEI-pEGFP-N transfected -2
Statistics for: MDCKPEI1 , FL2-H v FL1-H , Ungated
Region I Count % Gated % Total Mean
Total m 10000 100.00 100.00 45.58
(X 122.24
R1 (Y)| 431 4.31 4.31 839.98
(xj 2615.34
Region T Count % Gated I % Total Mean
Total (Y)J 10000 100.001 100.00 31.96
(X 89.56
R1 (Y)l 337* 3.37 3.37 822.12
(xil 2525.83!





Statistics for: MDCKSNT1 , FL2-H v FL1-H , Ungated Statistics for: MDCKSNT2 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y) 10000 100.0C 100.00 6.87 Total (Y) 1000C ioo.oq 100.00 7.76j
(X) 30.38 (X) 32.49j
R1 (Y) 825! 8.25 8.25 61.58 R1 (Y) 704 7.04 7.04 84.48
(X) 346.97 (X) 436.67
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C3 Figure 4.11 dotplots (continued)
(g) DOTAP-pEGFP-N transfected -1
FL1-H
Statistics for: MDCKDTP1 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (y) 1000c 100.00 100.00 2.77
(x) 3.04
R1 (y> 2e 0.26 0.26 47.26
(x: 262.74
(h) DOTAP-pEGFP-N transfected -2
10* 10' 10' 10* 10'
FL1-H
Statistics for: MDCKDTP2 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (y! 10000 100.00 100.0c 2.58
(x: 2.89
ri (y: 25 0.2j 0.25 49.58
(x 276.77
273







Region 1 Count % Gated % Total Mean
Total (Y| 10000 100.0C 100.0d 2.7S
(XI 3.06
R1 (Y)| 0 0.00 0.00
(x3
(c) SID-pEGFP-N transfected -1
Region 1 Count % Gated % Total Mean
Total (Y)| 10000 100.0C 100.06 2.72
(X 2.56
R1 (Y)| 0 o.oc 0.06
(x3
(d) SED-pEGFP-N transfected -2
Statistics for: C0S1A FL2-H v FL1-H , Ungated
(e) Saint-Mix-pEGFP-N transfected -1
Statistics for: C0S1B , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y 10000 100.00 100.00 189.63j Total (Y) 10000 100.00 100.00 212.12(xi 684.24 (X) 758.91
R1 (Y 2005 20.05 20.05 914.40 R1 (Y) 2008 20.08 20.08 994.96
,x: 3381.49 (X 3718.83
(f) Saint-Mix-pEGFP-N transfected -2
Statistics for: C0S3A FL2-H v FL1-H , Ungated Statistics for; COS3B FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean 1 Region Count % Gated % Total Mean
Total (Y) 10006 100.00 100.00 279.10 Total (Y! 10006 100.06 100.00 273.46
(X) 941.19 (X] 931.77
R1 m 2262 22.62 22.62 1200.13 ri (y; 2214 22.14 22.14 1177.86
(X) 4127.411 (x: 4151.5S
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C4 Figure 4.14 dotplots (continued)
(g) LID-pEGFP-N transfected -1 (h) LID-pEGFP-N transfected -2
X
E
Statistics for: C0S4A FL2-H v FL1-H , Ungated Statistics for: C0S4B FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y) 10000 100 00 loo.oq 356.81 Total (Y) 10000 100.00 100.00 306.29
(X) 1302.67 (xj 1070.09
R1 (Y) 3104 31 04 31 04 1126.2c R1 (Y! 2671 26.71 26.71 1123.15
m 4172.72 (x: 3982.07








Statistics for: COS5A FL2-H v FL1-H , Ungated Statistics for: COS5B FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean 1 Region Count % Gated % Total Mean
Total (Y) 1000C 100 OC 100.00 34.60 Total (Y) 1000C ioo.od 100.00 30.92
(X) 106.61 (X) 104.05
R1 (Y) 282 2.82 2.82 1117.0a R1 (Y) 285 2.85 2.85 985.50
(X) 3674.55| (X) 3557.37
275





10* 10' 10' 10' 10'
FL1-H
(b) untransfected -2
Statistics for: MDCKNDA , FL2-H v FL1-H , Ungated
(c) SID-pEGFP-N transfected -1
Statistics tor: ND2 , FL2-H v FL1-H Ungated
Region Count % Gated % Total Mean Region j Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 1.37 Total (Y| 1000C 100.00 100.00 1.34
(X) 1.32 (X 1.38
R1 (Y) 0 0.00 0.00 R1 (Y)| 0 0.00 0.00
(X) (X
(d) SID-pEGFP-N transfected -2
Region Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.00 31.86
(X) 103.27]
R1 m 597 5.97 5.97 491.48
(X) 1688.67
(e) Saint-Mix-pEGFP-N transfected -1
Region j Count % Gated % Total Mean
Total m 1000C 100.00 100.00 17 6S
(Xl 58 77
R1 (Y^ 384 3.84 3 84 421.57
ixi 1492.83
(0 Saint-Mix-pEGFP-N transfected -2
Statistics for: MDCK3A , FL2-H v FL1-H , Ungated Statistics for: MDCK3B , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean Region Count % Gated % Total Mean 1
Total (Y) 10000 100.00 100.00 3.37 Total (Y> 1000C 100.0C 1OO.O0 4.7q
(X 11.44 (X) 17.59
R1 (Y) 504 5.04 5.04 36.33 R1 (Y) 687 6.87^ 6.87 44.58
(X) 197.42 (X) 233.09
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C5 Figure 4.16 dotplots (continued)
(g) LID-pEGFP-N transfected -1 (h) LID-pEGFP-N transfected -2
10* 10' 10' 10' 10' 10' 10' 10' 10' 10'
FL1-H FL1-H
Statistics for: MDCK4A , FL2-H v FL1-H , Ungated Statistics lor: MDCK4B , PL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean Region 1 Count % Gated % Total Mean
Total (Y 1000C 100.00 100.0C 40.87 Total (Yl 1000C 100.00 100.0C 41.47
(X 134.77 (X 133.42
R1 (Y 697 6.97 6.97 536.95 R1 (Y]| 677 6.77 6.77 534.3C
(x: 1884.21 (x! 1892.27









1V i— I 1—
10* 10' 10' 10' 1
FL1-H
Statistics for: MDCK5A , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y 10000 100.00 100.0C 1.60
(X! 2.40
R1 (Y: 137 1.37 1.37 13.58
(*; 70.23
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C6 Figure 4.17 dotplots







Region Count % Gated % Total Mean 1
Total (Y) I000C 100.0Q 100.00 3.29
(X 3.33
R1 (Y 0 0.0( 0.00
(X • - 1
Statistics for: CAC02NDB , FL2-H v FL1-H , Ungated






Region Count % Gated % Total Mean
Total (Y) 1000C 100 OC 100.0C 3.1C
(X) 3.12
R1 (Y) 0 ooq o.oc
(X)
(d) SID-pEGFP-N transfected -2
10' 10* 10'
FL1-H
Statistics for: CAC022A , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y 10000 100.00 100.00 25.21
(X 84.87
R1 (Y 601 6.01 6 01 364 95
(X 1359 98
(e) Saint-Mix-pEGFP-N transfected -1
10" 10' 10'
FL1-H
Region Count % Gated 1 % Total Mean
Total (Y 10000 1 oo oq 100.00 27.92
(X) 93.45)
R1 (Y) 620 62q 6.20 393 60
(X I 1452.39
(0 Saint-Mix-pEGFP-N transfected -2
Statistics for: CAC023A , FL2-H v FL1-H , Ungated Statistics for: CAC023B , FL2-H v FL1-H , Ungated
Region Count I % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y) ioooq loo.oo 100.00 12.33 Total (Y 10000 100.00 100.00 14.87
(X) 35.97 (X) 48.7S
R1 (Y) 443 4.43 4 43 181 69 R1 (Y) 491 4.91 4.91 242.76
(X) 720.20 (X) 935.47
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C6 Figure 4.17 dotplots (continued)
(g) LID-pEGFP-N transfected -1 (h) LID-pEGFP-N transfected -2
10' 10' 10
FL1-H
Region Count % Gated % Total Mean
Total {Y 1000c 100.00 100.06 20.571
<x: 78.22
ri (y: 80s 8.09 8.os 224.85
(x: 937.41
Region Count % Gated % Total Mean 1
Total (y) 10000 100.00 100.00 22.24
(x) 77.391
R1 (y) 797 7.97 7.97 246.53
(x 938.311
(i) Lipofectin-pEGFP-N transfected -1 (j) Lipofectin-pEGFP-N transfected -2
Region 1 Count % Gated % Total Mean
Total (y)| 10000 100.00 100.0c 3.24
(x 5.00
R1 (yll 56 0.56 0 5c 78.82
(x] 396.071
Region Count % Gated % Total Mean
Total (y: 10000 100.0C 100.0C 2.96
(x: 3.9C
ri (y; 53 0.5c 0.5c 47.02
(x: 215.14
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C7 Figure 4.18 dotplots
(a) untransfected -1 (b) untransfected -2
10' 10' 10'
FL1-H
Statistics for: T84ND1 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 2.06
(X) 2.36
R1 (Y) 0 0.00 0.00
(X)
(c) untransfected -3
Region 1 Count % Gated % Total Mean
Total (Y)i 10000 100.00 100.00 2.05
(X 2.26
R1 (Y>; 0 0.00 0.00<x]
(d) SID-pEGFP-N transfected -1
Region I Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.0C 2.05
(x5 2.32
R1 (Y)l 0 0.00 o.oc
(x
Region 1 Count ]% Gated % Total Mean
Total (Y)| 100001 100.00 100.00 14.68
(X 61.83
R1 m 1423 14.23 14.23 84.43
(xil 411.181
(e) SID-pEGFP-N transfected -2 (f) SID-pEGFP-N transfected -3
10' 10' 10'
FL1-H
Region 1 Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.00 14.02
(X 57.11
R1 (Y)| 1623 16.23 16.23 71.55(xil 332.92
Region Count I % Gated % Total 1 Mean
Total (Y) ioooq 100.00 100.oq 14.63
(X 64.75
R1 (Y 164q 16.40 16.40 73.64
(X) 375.37
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C7 Figure 4.18 dotplots (continued)
Statistics for: T84SNT 2 , FL2-H v FL1-H , Unqated
Region Count % Gated % Total Mean
Total (Y I000C 100.00 100.00 17 36
(X) 80.24
R1 (Y) 1562 15.62 15.62 91.62
(X 490.01
Statistics for: T84SNT3 , FL2-H v FL1-H , Ungated
Region I Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 12.35
(xj 52.1C
R1 (Y)i 1247 12.47 12.47 77.32
(X 391.29
(i) LID-pEGFP-N transfected -1
FL1-H
Statistics for: T84LID1 , PL2-H v FL1-H , Ungated
Region ] Count % Gated % Total Mean
Total (Y)l 1000d 100.00 100.0C 19.71
(* 92.59
R1 (V)| 2245 22.49 22.49 78.12
IX* 399.27
(j) LID-pEGFP-N transfected -2
FL1-H
Statistics for: T84LID2 , FL2-H v FL -H . Ungated
Region Count I % Gated % Total Mean I
Total (Y) 1 oooq ioo.oc 100 OC 13 50
(X) 61.67
R1 (Y 2053 20.53 20.5: 56.34
(X 287.55!
(k) LID-pEGFP-N transfected -3 (1) DOTAP-pEGFP-N transfected -1
Region 1 Count % Gated % Total Mean
Total (Y)| 10000 100 OC 100.00 19.29
(X 91.32
R1 (Yi 2165 21.65! 21.65 78 91
(xl 408 48
Statistics for: T84DTP1 , FL2-H v FL1-H , Ungated
Region 1 Count % Gated % Total j Mean
Total (Y)| 1000C 100.00 100.00 7 95
(Xl 29.69!
R1 (Y)| 932 9 33 9.33 54 22
(X 282.25
281
C7 Figure 4.18 dotplots (continued)
(m) DOTAP-pEGFP-N transfected -2 (n) DOTAP-pEGFP-N transfcted -3
10' 10' 10'
FL1-H
Region 1 Count % Gated % Total Mean
Total (Y| 10000 100.00 100.00 8.15
(x3 29.92
R1 (Y)| 811 8.11 8.11 66.55
(x] 330.72
Region Count % Gated % Total Mean I
Total (Y 10000 100.00 100.00 9.17
(XI 34.44
Rt (Y 815 8.13 8.13 76.47
(X 381.93
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C8 Figure 4.19 dotplots
(a) untransfected -1 (b) untransfected -2
Statistics f or: HBENDA . FL2-H v FL1-H . Ungated
Region Count % Gated I % Total Mean
Total (Y) 10000 ioo.oq 100.00 2.4C
(X 2.42
R1 (Y) 0 o.oq o.oo
(X)
Region Count % Gated % Total Mean
Total (Y) 1000C 100 oq 100.0C 2.55
(X 2 55
R1 (Y 0 0.00 O.OC
(X)
(c) SID-pEGFP-N transfection -1 (d) Saint-Mix-pEGFP-N transfection -2
Region I Count % Gated % Total Mean
Total (Yj 10000 100.00 ioo.oq 17.6C
(X 76.62
R1 (Y)| 1114 11.14 11 14 130.38
(X)| I 661.02
Region | Count % Gated % Total Mean
Total (Yj 10000 100 00 100.00 24.29
(X 109.41
R1 (Y)| 1186 11.86 11.80 173.89
(XI 893 74





Statistics tor: HBESNT01 , FL2-H v FL1-H , Ungated Statistics tor: HBESNT02 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 31.71 Total (Y) 10000 100.00 100.00 24.44
(X) 140.41 (X) 105.74
R1 (Y) 1431 14.31 14.31 189.43 R1 (Y) 1215 12.15 12.15 164.64
(X) 954.66 (X 839.12
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C8 Figure 4.19 dotplots (continued)
FLl-H
Statistics for: HBEL4A FL2-H v FLl-H , Ungated
Region | Count % Gated % Total Mean 1
Total (Yi 10000 100.00 100.00 17.30
(xj 75.30
R1 (Y)l 722 7.22 7.22 190.48
(* 999.20
Statistics for: HBEL4B , FL2-H v FL1-H , Ungated
Region 1 Count % Gated % Total Mean
Total (Y* 10000 100.00 100.00 19.50
(xi 88.92
R1 (Yj 824 8.24 8.24 196.91<x3 1043.90
(i) DOTAP-pEGFP-N transfected -1
FLl-H
Statistics for: HBEDTPA , PL2-H v FLl-H , Ungated
Region Count % Gated % Total Mean
Total (YJ 10000 100.00 100.0C 13.51
(X 37 8^
ri <Y 338 3.3£ 3.3? 214.27
(x: 972.40
(j) DOTAP-pEGFP-N transfected -2
FLl-H
Statistics tor: HBEDTPB , FL2-H v FLl-H , Ungated
Region Count % Gated % Total Mean I
Total (Y) ioood 100.00 100 oc 7.03
fX) 16.70
R1 (Y 20C 2.0C 2 0C 151.07
(X 675.711
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C9 Figure 5.1 dotplots
(a) untransfected -1 (b) untransfected -2
Region Count | % Gated % Total Mean
Total (Y 10000 100.00 100.00 3.71
(X) 3.96!







10* 10' 10' 10' 10'
FL1-H
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 3.76
(X) 4.05
R1 (Y) 0 0.00 0.00
(X)
(d) pEGFP-N transfected -1
Statistics for: ND3 , FL2-H v FL1-H ,
(e) pEGFP-N transfected -2
Statistics for: EGFPN1 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean Region I Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 3.73 Total (Y)| 10000 100.00 100.00 313.24
(X) 4.01 (X 1144.1C
R1 (Y) 0 0.00 0.00 R1 (Y)j 2792 27.92 27.92 1079.85
(X) (X 4055.75
(f) pEGFP-N transfected -3
10' 10' 10'
FL1-H
Statistics for: EGFPN2 FL2-H v FL1-H , Ungated Statistics for: EGFPN3 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 451.99 Total (Y) 10000 100.00 100.00 443.72
(X) 1605.92 (X 1608.91
R1 (Y) 3684 36.84 36.84 1172.11 R1 (Y 3633 36.33 36.33 1175.92
(X 4304.11 (X 4383.7C
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C9 Figure 5.1 dotplots (continued)
(g) PACRC2cmvEGFP Iransfected -1 (h) PACRC2cmvEGFP transfected -2
Statistics for: RC2CG1 , FL2-H v PL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100. OC 8.07
(X) 16.83
R1 (Y) 289 2.89 2.8S 106.42
(X) 432.07
(i) PACRC2cmvEGFP transfected -3
Region 1 Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.0C 9.6^
(X 24.99j
R1 (Y)| 390 3.9C 3.9C 128.87](xl 533.89




Statistics tor: RC2CG3 , FL2-H v FL1-H , Ungated
(k) plkbcfproEGFP transfected -2
Statistics tor: 1 KB 1 , FL2-H v FL1-H Ungated
Region I Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.00 10.14 Total (Y 10000 100.00 100.00 69.35
(X 26.21 (X) 367 9d
R1 (Yjl 365 3.65 3.65 150.71 R1 (Y) 3441 34.41 34.41 191 78](xj 601.91 (X 1060.89
(1) plkbcfproEGFP transfected -3
Region Count % Gated 1 % Total Mean
Total (Y) 10000 loo.oq loo.oo 81.74
(XI 443.851
R1 (Y) 3979 39.79 39.79 197.37
(X) 1108.68
Region Count % Gated % Total Mean
Total (Y) 1000C 100.0C 100 OC 78.53
(X) 421.34
R1 m 3798 37.98 37.98 198.13
(X) 1102 0C
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C9 Figure 5.1 dotplots (continued)
(m) PAC65kbcfproEGFP transfected -1 (n) PAC65kbcfproEGFP transfected -2
'"i— "i— i— -I




Statistics for: 65KB1 . FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y 10000 100.00 100.00 5.68
(X 6.52
R1 (Y 228 2.28 2.28 23.43
<x 92.56
(o) PAC65kbcfproEGFP transfected -3
Region Count % Gated % Total Mean
Total (Yj 10000 100.00 100.00 5.74
(X 6.7€
R1 (Y)| 186 1.86 1.86 30.22
(Xj 125.02
(p) pCFTRiresEGFP transfected -1
Statistics for: 65KB3 FL2-H v FL1-H , Ungated
(q) pCFTRiresEGFP transfected -2
Statistics for: I2ES11 FL2-H v FL1-H , Ungated
Region ! Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y]| 10000 100.00 100.00 5.38 Total (Y) 10000 100.00 100.00 8.05
(xj 5.7£ (X) 18.21
R1 (Y)| 145 1.45 1.45 26.29 R1 (Y) 1151 11.51 11.51 26.04
(XI 112.66 (X) 121.30




Region Count % Gated % Total Mean ^
Total (Y 10000 100.0C 100.00 8.03
(X) 17.51
R1 (Y\ 99d 9.90 9.90 28.18
m 134.03
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 8.45
(X) 16.46
R1 (Y) 857 8.57 8.57 30.65
(X) 139.93
287
C9 Figure 5.1 dotplots (continued)
Statistics for: RC1IG1 . FL2-H v FL1-H , Ungated
Region 1 Count % Gated % Total Mean 1
Total (YJ 10000 100.00 100 00 5.41
(xi 4 40
R1 (Y)| 2 0.02 0 02 6 2d
(xj 17 09
(t) PACRCliresEGFP transfected -2
FL1-H
Statistics for: RC1IG2 FL2-H v FL1-H , Ungated
Region 1 Count % Gated % Total Mean 1
Total (Y)| 50000 100.00 100.00 5.09
(X 4.1 S|
R1 (Y)| 9 0.02 0.02 11.09
(x5 39 46j
Statistics for: RC1IG3 FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean 1
Total (Y) 5000C 100 00 100 00 5.59
(X 4.70
R1 (V 1 ■ 0.03 0.03 15.91
(X 44.24]
(v) PACRC2iresEGFP transfected -1
FL1-H
Statistics tor: RC2IG2 FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y] 5000C 100 00 100.00 4.5C
ix: 4.1C
ri IY: 21 0 04 0.04 7.61
(x; 20.61
(w) PACRC2iresEGFP transfected -2
FL1-H
Statistics tor: RC21G3 . FL2-H v FL1-H , Ungated
Region Count % Gated | % Total Mean
Total (Y) 5000C too.od too.oo 4.44
(X) 1 4.09
R1 (Y) 0 031 0 03 8.41
(X) 1 23.55
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i ■ ■ """i——-"■"-I
10' 10' 10' 10J 10'
FL1-H
(b) untransfected -2
Region | Count % Gated % Total Mean
Total (Y) 10000 100.0C 100.00 1.4C
(X) 1.4C
R1 (Y) 0 o.oc 0.00
(X)
(c) untransfected -3
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.oc 1.38
(X) 1.3S
R1 (Y) 0 0.00 o.oc
(X)






Statistics tor: MND3 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 10000 100.0( 100.00 1.47
(X) 1.51
R1 (Y) 0 o.oc 0.00
(X)
(e) pEGFP-N transfected -2
Region I Count % Gated % Total Mean
Total (Y* 10000 100.00 100.00 83.3S
(X 251.44,
R1 (Yll 120! 12.05 12.05 638.46
(xj 2028.80
(f) pEGFP-N transfected -3
Region Count % Gated % Total Mean
Total (Y 10000 100.00 100.00 92.87
(X 258.0^
R1 (Y 1202 12.02 12.02 695.03
(X 2065.17
Region Count % Gated % Total Mean
Total (Y) 1 oooq 100.00 100.00 75.59
(X) 221.16]
R1 (Y) 1101 11.01 11.01 655.58
(X) 1974.18
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CIO Figure 5.2 dotplots (continued)







(h) PACRC2cmvEGFP transfected -2
Region Count I % Gated [ % Total Mean
Total (Y ioooq 100.0a 100.00 28.27
(X 58.94
R1 (Y 293 2.93 2.93 744.28
(X I 1 1777 86(
(i) PACRC2cmvEGFP transfected -3
10' 10' 10'
FL1-H
Region Count % Gated % Total Mean j
Total (Y) 1000C 100.00 100.00 25.06
(X) 52.55
R1 (Y) 32C 3 20 3.20 581 82j
(X) 1428.831
(j) plkbcfproEGFP transfected -1
Region 1 Count % Gated % Total Mean
Total (Y)| 1000C 100.00 100.00 25.26
(X 55.55
R1 (Y)j 31C 3.13 3.13 602.44
tx! 1556.64
(k) plkbcfproEGFP transfected -2
Region I Count % Gated % Total Mean
Total (Y)| 1000C 100.0C 100.00 5.65
(X 25.12
R1 (Y)| 593l 5.93 5.93 72.9C
(X 400.67
(1) plkbcfproEGFP transfected -3
Statistics for: M1KB2 FL2-H v FL1-H , Ungated Statistics lor: M1KB3 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y) 1000C 100.00 ioo.oo 6.35 Total (Y) 10000 100.00 100.00 6.72
(X) 29.23 (X) 30. U
R1 (Y) 737 7.37 7.37 67.42 R1 (Y) 746 7.46 7.46 72.5C
(X 377.82 (X) 386 9C
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CIO Figure 5.2 dotplots (continued)
(m) PAC65kbcfproEGFP transfected -1 (n) PAC65kbcfproEGFP transfected -2
,tti— i '"i— i
10* 10' 10' 10' 10'
FL1-H
Statistics for: M65KB1 , FL2-H v FL1-H , Ungated
(o) PAC65kbcfproEGFP transfected -3
"H— i
10' 10' 10* 10' 10'
FL1-H
Statistics for: M65KB2 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean I Region Count % Gated % Total Mean I
Total (Y) 10000 100.00 100.00 1.60 Total (Y) 10000 100.0C 100.00 1.50
(X) 2.52 (X) 2.4 Ti
R1 (Y) 48 0 48 0.48 39.oq R1 (Y) 42 0.42 0.42 44 99
(XI 216.251 (X) 257.04)
(p) pCFTRiresEGFP transfected -1
Region 1 Count % Gated I % Total Mean
Total (Y* 10000 100.00 100.00 1.58
(X ) 2.3C
R1 (Y)| 60 0.60 0.60 27.48
<xi 150.9C










Region 1 Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.00 1.98
(X 3.5S
R1 (Y)| 244j 2.44 2.44 15.43(xj 81.IS
(r) pCh'l RiresEGFP transfefcted -3
Region Count % Gated 1 % Total 1 Mean
Total (Y> 10000 loo.oq loo.oq 1.75
(X) 2.66
R1 (Y) 179 1.79 1.79 12.44
(X) 1 62.98
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 1.72
(X) 2.83
R1 (Y) 229 2.29 2.29 11.56
(X) 59.86
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CIO Figure 5.2 dotplots (continued)
(s) PACRCliresEGFP transfected -1 (t) PACRCliresEGFP transfected -2






/rr, ""I 1 """"1
10* 10" 10' 10' 10'
FL1-H
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 1.48
(X) 1.49
R1 (Y) 1S 0.15 0.15 13.14
(X) 50.78
Region Count I % Gated % Total Mean
Total (YJ 1 oooq loo.oo 100.00 1.48
(X) 1.50
R1 (Y) 2a 0.20 0.20 12.71
(X) 46 69
(v) PACRC2iresEGFP transfected -1
Region I Count % Gated % Total 1 Mean
Total (Yl 10000 100.00 loo.oq i.5i
(X 1.6C
R1 (Y)| 29 0.29 0.29 13.66
(x5 52.9S
(w) PACRC2iresEGFP transfected -2
Statistics for: MRC2IG1 , FL2-H v FL1-H , Ungated
Region Count I % Gated I % Total Mean
Total (Y) ioooq ioo.oq 100.00 1.68
(X) 1.69
R1 (Y) 29 0.29 0.26 11.37
(X) 42.82
(x) PACRC2iresEGFP transfected -3
Statistics for: MRC2IG2 , FL2-H v PL1-H , Ungated Statistics for: MRC2IG3 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean ' Region 1 Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 1.62 Total (Y1 10000 100.00 100.00 1.61
(X) 1.71 (xi 1.6S
ri m 32 0.32 0.32 12.91 R1 (Y)| 33 0.33 0.33 10.18
(X) 48.66 (x5 37.02
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CI 1 Figure 5.3 dotplots
(a) untransfected -1
FL1-H
Statistics for: ND1 , FL2-H v FL1-H Ungated
Region Count % Gated % Total Mean
Total (Y) toooo 100.00 100.0C 2.73
(X) 3.09
R1 (Y) 0 0.00 0.00
(X) --
FL1-H
Statistics for: ND2 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean I
Total (Y) 10000 100.00 100.0C 2.32
(X) 2.59
R1 (Y) 0 0.00 0.00
(X -•
Statistics for: ND3 . FL2-H v FL1-H Ungated
Region I Count % Gated % Total Mean
Total (Y)| 1000d 100.0C ioo.oq 2.25
(X 2.51
R1 (Y)| 0 o.oc 0.00
<x]
(d) pEGFP-N transfected -1
FL1-H
Statistics tor: EGFPN1 FL2-H v FLt-H , Ungated
Region I Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.00 17.01
(X 76.64
R1 (Y)| 1263 12.68 12.68 116.7C(xil 582.3S
(e) pEGFP-N transfected -2
FL1-H
Statistics for: EGFPN2 FL2-H v PLt-H , Ungated
Region Count % Gated % Total Mean I
Total (Y) 10000 100.00 100.0C 13.67
(X) 59.05
R1 (Y) 1131 11.31 11.31 102.84
(X) 499.29
(f) pEGFP-N transfected -3
FL1-H
Statistics for: EGFPN3 FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 1000C ioo.oq 100.00 9.55
(X) 39.75
R1 (Y) 984 9.84 9.84 78.7C
(X 381.58
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CI 1 Figure 5.3 dotplots (continued)
(g) PACRC2cmvEGFP transfected -1
FL1-H
Statistics for: RC2CG1 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean I
Total (Y 10000 100.00 100.00 3.23
(X 6.13
ri (y: 112 1.12 1.12 51.31
(x: 259.6Q
(i) PACRC2cmvEGFP transfected -3
FL1-H
Statistics for: RC2CG3 , fL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean |
Total (Y) 10000 100.0C 100.0C 2.82
(X) 4.19
R1 (Y) 20 0.2C 0.2C 165.09
(X) 552.83
(N
(h) PACRC2cmvEGFP transfected -2
FL1-H
Statistics for: RC2CG2 , FL2-H v FL1-H , Ungated
Region I Count % Gated % Total Mean I
Total m 1000Q 100.0C 100.00 6.21
M 8.79
R1 (Yi 88 0.88 0.88 294,29
(X)| I I I 522.23
(j) plkbcfproEGFP transfected -1
FL1-H
Statistics for: 1KB1 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 1000C 100.00 100.0C 4.85
(XI 14.49
R1 (Y) 465 4.65 4.65 49.50
(X) 243.59
(1) plkbcfproEGFP transfected -3
1 1 —-i
10* 10' 10' 10' 10'
FL1-H
(k) plkbcfproEGFP transfected -2
10' 10' 10' 10' 10'
FL1-H
Statistics tor: 1KB2 , FL2-H v FL1-H , Ungated Statistics lor: 1KB3 , FL2-H v FL1-HUngated
Region Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y) 1000C 100.00 100.0C 4.43 Total (Y) 10000 100.00 100.00 4.98
(X) 13.65 (X) 15.94
R1 (Y) 533 5.31 5.3c 40. IS R1 (Y) 601 6.01 6.01 43.85
(X) 203.42! (XI 217.72
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CI I Figure 5.3 dotplots (continued)






Statistics for: 65KB4 FL2-H v FL1-H , Ungated
(o) PAC65kbcfpro transfected -3
10* 10' 10* 10'
FL1-H
Statistics for; 65KB2 , FL2-H v FL1-H , Ungated
Region Count 1 % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y) 2000a loo.oo 100.00 2.69 Total (Y 20000 100.00 100.0C 2.0C
(X) 3.34 (X) 2.37
R1 (Y) 39 0.17 0.17 29.50 R1 (Y) 14 0.07 0.0^ 77.68
(X | 131.04 (X) 184.71
(p) pCFTRiresEGFP transfected -1
Region Count % Gated % Total Mean
Total (Y; 20000 100.00 100.00 2.38
(X: 2.85
R1 (Y1 21 0.10 0.10 45.8C
(x: 187.6C
(q) pCFTRiresEGFP transfected -2
Statistics for: I2ES14 FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 2000C 100.00 100.0C 2.14
(X) 2.57
R1 (Y) 25 0.12 0.12 56.97
(X) 132.00
(r) pCFTRiresEGFP transfected -3
Region Count % Gated % Total Mean
Total (Yl 20000 100.0c 100.00 2.37
(X 2.78
R1 (Y 3d 0.17 0.17 16.91
(X 57.24
Region Count % Gated I % Total Mean
Total (Y) 20000 loo.oq ioo oc 2.87
(X) 3.4s
R1 (Y) 29 0.14 0.14 11.95
(XI 1 37.57
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CI2 Figure 5.4 dotplots
(a) untransfected -1 (b) untransfected -2
Statistics for: CND1 , FL2-H v FL1-H , Ungated Statistics for: CND2 , FL2-H v FL1-H , Ungated
Region I Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Yj 10000 100.00 100.00 2.72 Total (Y) 10000 100.00 100.00 2.66
(X 3.21 (X) 2.96
R1 (Y)| 0 0.0C 0.00 R1 (Y) 0 0.00 0.00
«] (X)
(c) untransfected -3 (d) pEGFP-N transfected -1
Statistics for: CND3 , FL2-H v FL1-H , Ungated Statistics tor: CEC^PNI , FL2-H v FL1-H , Ungated
Region 1 Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Yt 10000 100.00 100.00 2.70 Total (Y) 10000 100.00 100.00 14.66
(X 3.01 (X) 57.50
R1 (Y)| 0 0.00 0.00 R1 (Y) 577 5.77 5.77 203.04
(xj (X) 937.70
(e) pEGFP-N transfected -2 (f) pEGFP-N transfected -3
Statistics lor: CEGFPN2 , FL2-H v FL1-H , Ungated Statistics lor: CEGFPN3 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean Region Count % Gated % TotalJ Mean
Total (Y) 10000 100.00 100.00 14.58 Total (Y) 1000C 100.0C 100.0C 16.5C
(X) 59.40 (X) 64.51
R1 (Y 657 6.57 6.57' 181.77 ri m 582 5.82 5.82 222.30
(X) 858.26 (X) 1038.2d
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C12 Figure 5.4 dotplots (continued)
(g) PACRC2cmvEGFP transfected -1 (h) PACRC2cmvEGFP-transfected -2
10' 10' 10' 10'
FL1-H
Statistics for: CRC2CG1 , FL2-H v FL1-H , Ungated Statistics for: CRC2CG2 , FL2-H v FL1-H , Ungated
Region 1 Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y| 10000 100.00 100.00 3.25 Total (Y) 10000 100.00 100.00 3.8C
(X 4.82 (X) 6.52
R1 (Y)| 48 0.48 0.48 63.99 R1 (Y) 45 0.45 0.45 172.15
(XI 343.08 (X) 726.65
(i) PACRC2cmvEGFP transfected -3 (j) plkbcfproEGFP transfected -1
Statistics for: CRC2CG3 , FL2-H v FL1-H , Ungated Statistics tor: C1KB1 FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean Region 1 Count % Gated % Total Mean
Total (Y 10000 100.00 100.00 2.87 Total (Y)| 10000 100.00 100.00 4.26
(X) 3.81 (X 9.84
R1 (Y 24 0.24 0.24 67.33 R1 (Y)| 205 2.05 2.05 59.86
(X 368.29 (*1 312.36
(k) plkbcfproEGFP transfected -2 (1) plkbcfproEGFP transfected -3
Region I Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.00 3.7^
(X 7.56
R1 (Y)| 198 1 98 1.98 40.68
(xj 217.34
Region I Count % Gated I % Total Mean
Total (Yl 1000C ioo.oq loo.oo 3.17<xj 5.92
R1 (Yl 180 1.8q 1.80 32.34<xj 173.62
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CI 2 Figure 5.4 dotplots (continued)








10* 10' 10' 10' 10'
FL1-H
Statistics for: C65KB1 , FL2-H v FL1-H , Ungated
Region Count I % Gated I % Total Mean 1
Total (Y1 50000I 100.00 100.00 2.74
(X 1 1 2.90
R1 (Y) 43i 0.091 0.09 9.21
ixj 1 1 36.10
(n) PAC65kbcfproEGFP transfected -2
FL1-H
Statistics for: C65KB3 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y]| 50000 100.00 100.0C 2.84
IX) 3.11
R1 (Y) 25 0.05 O.Of 21.33
m 103.3C
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CI3 Figure 5.5 dotplots
(a) untransfected -1 (b) untransfected -2
Region Count % Gated % Total Mean
Total (Y 10000 100.00 100.oc 2.84,
(X 3.02
R1 (Y 0 0.00 o.oc
(X
Region Count % Gated % Total Mean
Total (Y) 10000 100.0C 100.00 3.21
(X) 3.4c
ri m 0 0.00 0.00
m
(c) pEGFP-N transfected -1 (d) pEGFP-N transfected -2
to* 10' 10' 10'
FL1-H
Region [ Count % Gated % Total I Mean
Total (Y¥ 10000 100.00 100.0q 24.01
(X 102.74f
R1 (Y)| 1160 11.60 11.6(3 174.3£
<x] 854.76
Region Count % Gated % Total 1 Mean
Total (Y) 1000C 100.00 100.00 25.22
(XI 105.73
R1 (Y 104C 10.40 10.40 207.30
(X 983.11
(e) plkbcfproEGFP transfected -1 (f) plkbcpfroEGFP transfected -2
Statistics tor: H1KBA FL2-H v FL1-H , Ungated Statistics tor: H1KBB FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean Region 1 Count % Gated % Total Mean
Total (Y 10000 100.00 100.00 6.56 Total m 10000 100.0C 100.OC 5.6c
(X) 14.52 (xi 11.7S
R1 (Y 604 6.04 6.04 34.21 R1 (Y)| 501 5.01 5.01 31.4C
(X 172.11 (xil 161 84
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CI3 Figure 5.5 dotplots (continued)
(g) PAC65kbcfpro transfected -1
10* 10' 10' 10' 10'
FL1-H
Statistics for: H65KBA . FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 1000C 100.0C 100.00 3.9C
(XI 3.92
R1 (Y) 11 0.11 0.11 62 4-
(X) 328.9C
(h) PAC65kbcfpro transfected -2
10' 10' 10' 10' 10'
FL1-H
Statistics lor: H65KBB . FL2-H v FL1-H . Ungated
Region Count % Gated % Total Mean
Total (YJ 10000 100.00 100.00 3.91
(X) 3.68
R1 (Y) 4 0.04 0.04 26.2C
(X) 117.97
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CI4 Figure 5.6 dotplots
(a) untransfected -1 (b) untransfected -2
Statistics for: ND1 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 5.75
(X) 6 08





Region I Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.00 5.75
(X 6.12
R1 (Y)| 0 0.00 0.00
m









Region Count % Gated % Total Mean
Total (YJ 10000 100 OC 100.00 5.6q
(X) 5.9q
R1 M 0 o.oq 0.00
(X
(e) pEGFP-N transfected -2
10' 10' 10'
FL1-H
Region Count % Gated % Total Mean
Total (Y 1000C 100.00 100.00 297.45
(X 1155.22
R1 (Y 2478 24.78 24.78 1160.94
(X 4621.31
(f) pEGFP-N transfected -3
10' 10' 10'
FL1-H
Region 1 Count % Gated % Total Mean
Total (Yl 10000 100.00 100.OC 252.56
(X 983.71
R1 (Y)| 2218 22.18 22 18 1083.01
(Xl 4377 82
Region 1 Count 1 % Gated % Total Mean
Total (Y]| 100001 100.00 100.0C 273.55
(X 1053.28
R1 (Y)| 2189| 21 89l 21.86 1198.77
(x5 1 4760.16
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CI4 Figure 5.6 dotplots (continued)
FLl-H
Statistics for: RC2CGFP1 , FL2-H v FL1-H , Ungated
Region I Count % Gated % Total Mean I
Total (Y)| 1000C too.oc 100.00 11.78
(xl 24.29
R1 (Y)| 393 3.93 3.93 121.62
(X 454.09
Statistics for: RC2CGFP2 , FL2-H v FL1-H , Ungated
Region I Count % Gated % Total Mean
Total (YJ 10000 100. oc 100.0C 12.04
(X 26.4S
R1 (Y)| 385 3.85 3.85 136.67(X)| 526.76
(j) pEGFP-N/PUC18 transfected -1
10'-,
rLl-H
(i) PACRC2cmvEGFP transfected -3





(k) pEGFP-N/PUC18 tranfected -2
FLl-H
Statistics for: -NPUC182 , FL2-H v FLl-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 379.32
(X) 1513.84
R1 (Y 3137 31.37 31.37 1179 07
(X 4795.25
(1) pEGFP-N/PUC18 transfected -3
FLl-H
Statistics for: -NPUC183 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 1000C 100 OC 100.0C 385.06
(X) 1520.86
R1 (Y) 3151 31.51 31.51 1 178 54
(X) 4782.86
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C14 Figure 5.6dotplots (continued)
Statistics tor: 1UGPUC181 , FL2-H v FL1-H , Ungated
Region 1 Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.00 4.87
(X 3.91
R1 (Y)| 0 0.00 0.00
(x3
(n) PUC18 transfected -2
FL1-H
Statistics for: 1UGPUC182 , FL2-H v FL1-H , Ungated
Region I Count % Gated % Total Mean
Total (Yj 1000C 100.0C 100.00 4 97
(X 3.9S
R1 (Y)| 0 o.oc 0.00
txj
(o) PUC18 transfected -3
FL1-H
Statistics for: 1UGPUC183 . FL2-H v FL1-H , Ungated
Region I Count % Gated % Total Mean
Total (Y)| 10000 100 OC 100.00 4.9C
(x3 3.9S
R1 (Y)| 0 O.OC 0.00
(*]
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CI5 Figure 5.7 dotplots
(a) untransfected -1 (b) untransfected -2
' r ,,Tml 'I 1 I
10* 10' 10' 10' 10'
FL1-H
Region 1 Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.00 3.15
(X 3.34
R1 (Y)l 0 0.00 0.00
(xj
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 3.07
(X) 3 22
R1 (Y) 0 0.00 0.00
(X)
(c) untransfected -3 (d) pEGFP-N transfected -1
Region I Count % Gated % Total Mean
Total m 10000 100.00 100.0C 3.21
(XI 3.35
R1 (Y)| 0 0.00 o.oc
(XI
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 433.42
(X) 1541.441
R1 (Y) 3209 32.09 32.09 1282.03
(X) 4736.46
(e) pEGFP-N transfected -2 (0 pEGFP-N transfected -3
Region Count % Gated % Total Mean 1
Total (Y) 1000C 100.00 100.00 445.23
(X) 1600.53
R1 (Y) 3635 36 35 36.35 1169.49
(X) 4348.29
Region Count % Gated % Total Mean
Total (Y) 10000 100.0C 100.0C 536 02
(X 1889 66
m (Y 4384 43 84 43.84 1144.62
(X 4232.38
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CI5 Figure 5.1 dotplots (continued)





Region I Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.00 15.88
(X 29.37
R1 (Y)| 357 3.57 3.57 165.9C
(x! 570.62
(i) PACRC2cmvEGFP transfected -3
10' 10' 10'
FL1-H
Region Count % Gated I % Total Mean
Total (Y 10000 loo.oq 100.00 24 17
(X 56.45




(j) pEGFP-N/RC2b transfected -1
Region Count % Gated % Total Mean
Total (Y 1000C 100.0C 100.00 24 15
(X 54 06
R1 (Y 511 5.11 5.11 257.07
IX 860.97
(k) pEGFP-N/RC2 transfected -2
10' 10' 10'
FL1-H
Region Count % Gated % Total Mean
Total (Y) 1000C 100.00 100.00 483 14
(X) 1684.85
R1 (Y 3684 36 84 36.84 1257.28
(X 4518 52
(1) pEGFP-N/RC2b transfected -3
10' 10' 10'
FL1-H
Region 1 Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.00 500.96
(X 1794.98
R1 (Yll 4100 41.00 41.00 1171.68
(xil 4327.34
Region Count % Gated % Total Mean
Total (Y) 10000 loo.oq 100.00 562 9£
(X) 1966.15
R1 (Y) 4063 40.6- 40.63 1323.81
(X) 4777.08
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CI5 Figure 5.1 dotplots (continued)
Statistics for: CG+RC2B1 , FL2-H v FL1-H , Ungated Statistics for: CG+RC2B2 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean 1 Region Count % Gated % Total Mean
Total (Y 10000 100.00 100.00 8.89 Total (Y 10000 100.00 100.00 8.52
(X 22.31 (X) 21.07
R1 (Y) 551 5.51 5.51 63.23 R1 (Y) 534 5.34 5.34 61.02
(X) 321.42 (X 310.71






10' 10' 10' 10' 10'
FL1-H
Region Count I % Gated % Total Mean
Total (Y) 1000q 100.00 100.00 7.0C
(X) 14.97
R1 (Y) 389 3.89 3.89 53.96
(X) 275.75
Region 1 Count % Gated % Total Mean
Total (Y1 10000 100.00 100.00 5.23
(xil 4.47
ri m o 0.00 0.00
(xil
(q) PACRC2b transfected -2
FL1-H
Statistics for: RC2B2 FL2-H v FL1-H , Ungated
Region I Count % Gated I % Total Mean
Total (Y) 10000 ioo.oq 100.0C 5.38
(X) 4.55
R1 (Y) 0 o.oq o.oc
(X)
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CI6 Figure 5.8 dotplots








Region Count % Gated % Total Mean
Total (Y; 10000 100.00 100.0C 3.40
(x: 3.51





Region Count % Gated % Total Mean
Total W 1000C 100.00 100.00 3.38
(X) 3.44
R1 (Y 0 o.od o.od
(X
(d) 1 microg pEGFP-N transfected -1
Statistics for: ND3 , FL2-H v FL1-H Ungated
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 3.42
(X) 3.50
R1 (Y) 0 0.00 o.oc
(X)
(e) 1 microg pEGFP-N transfected -2
10' 10' 10'
FL1-H
Statistics tor: 1UG-N1 FL2-H v FL1-H , Ungated
Region I Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.00 101.41
(X 342.3C
R1 (Y)| 881 8.81 8.81 1034.97
(X* 3780.4C
(f) 1 microg pEGFP-N transfected -3
10' 10' 10'
FL1-H
Statistics tor: 1UG-N2 FL2-H v FL1-H , Ungated Statistics for: 1UG-N3 FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 108 44 Total (Y) 10000 100.00 100 00 102 31
(X 360.70 (X) 329.88|
R1 (V 906 9.06 9.06 1084.06 R1 (Y) 871 8.71 8.71 1042.78]
(X) 3878.80 (X) 3663.08
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C16 Figure 5.8 dotolots (continued)
(g) lOOng pEGFP-N + 900 ng pUC18 transfected -1 (h) lOOng pEGFP-N + 900 ng pUC18 transfected -2
10* 10' 10' 10'
FL1-H
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 197.26
(X) 703.80
R1 (Y) 1702 17.02 17.02 1115.35
(X) 4094.96
(i) lOOng pEGFP-N + 900 ng pUC18 transfected -3
10' 10' 10'
FL1-H
Region Count % Gated % Total Mean
Total (Y) 10000 100.06 100.00 185.66j
(X) 632.55)
R1 (Y) 1575 15.75 15.75 1091.50
(X) 3933.10






Region Count I % Gated % Total Mean
Total (Y) loooq 100.06 100.00 139.3c
(X) 505.98
R1 (Y) 1402 14.02 14.02 925.36
(X) 3546 41
(k) lOng pEGFP-N + 990 ng pUC18 transfected -2
10' 10' 10'
FL1-H
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 72.47
(X) 279.27
R1 (Y) 1117 11.17 11.17 591.14
(X 2447.67
(1) lOng pEGFP-N + 990 ng pUC18 transfected -3
10' 10' 10'
FL1-H
Region 1 Count % Gated % Total Mean
Total (Y)| 10000 100 00 100.00 117.62
(X 416.12
R1 (Yll 110! 11.05 11.05 974.91
ixj 3684.45
Region Count % Gated 1 % Total 1 Mean
Total (Y) 10006 ioo.oq loo.oq 78.7C
(X) 281.6£
R1 (Y 928 928 9.28) 743.06
(X 2942 64
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C16 Figure 5.8 dotplots (continued)
(m) lng pEGFP-N + 999 ng pUC18 transfected -1 (n) Ing pEGFP-N + 999 ng pUC18 transfected -2
Region Count % Gated % Total Mean 1
Total (Y) 10000 100.00 100.00 53.34
(X) 198.29
R1 (Y) 665 6.65 6.65 710.23
(X) 2901.21
(o) lng pEGFP-N + 999 ng pUC18 transfected -3
Region I Count % Gated I % Total Mean
Total (Y)| 10000 ioo.oq loo.oo 75.34
(X 254.85
R1 (Y i 736 7.30 7 36 908.95
(X 3358.67]
(p) lOOpg pEGFP-N + 999.9 ng pUC18 transfected -1
Region 1 Count % Gated % Total Mean
Total (Y)| 1000C 100.0C 100.00 73.6C
(X 230.98
R1 (Y)| 6271 6.27 6.27 1006.95
«xl 3537.26
(q) lOOpg pEGFP-N + 999.9 ng pUC18 transfected -2
Region I Count % Gated % Total Mean I
Total (Y| 10000 100.00 100.00 16.95
(X 34.90
R1 (Y)| 111 1.11 1.11 693.02
(x3 2490.421




10* 10' 10' 10'
FL1-H
Region Count % Gated 1 % Total Mean
Total (Y) 1000C lOO.Oq 100.00 19.07
(X) 40.86
R1 (Y)| 104 1.04 1.04 938.62
(X) 3192.61
Statistics tor: PUC181 , FL2-H v FL1-H , Ungated
Region I Count % Gated % Total Mean
Total (Y)| 1000C 100.0C 100.00 8.91
(X 6.87
R1 (Y]| 0 o.oc 0.00
«xi
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CI6 Figure 5.8 dotplots (continued)
(s) 1 microg pUC18 transfected -2
FL1-H
Statistics loi: PUC182, FL2-H > FL1-H, Unaaled
Region Count % Gated % Total Mean
Total (Y 10000 100.0C 100.00 8.88
(X! 6.87
R1 (Y 0 o.oc o.oq
ix:
(t) 1 microg pUC18 transfected -3
FL1-H
Statistics lor: PUC183 , FL2-H v FL1-H , Undated
Region Count % Gated % Total Mean
Total (Y 10000 100.00 100 OC 9.07
(X 7.04
R1 (Y 0 0.00 O.OC
(X
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CI7 Figure 5.9 dotplots
(a) untransfected -1
FL1-H
Statistics for: ND1 , FL2-H v FL1-H Ungated
Region Count % Gated % Total Mean
Total (Y 10000 100.0C 100.0C 2.72
(xj 2.8C




Statistics for: ND2 , FL2-H v FL1-H Ungated
Region Count % Gated % Total Mean
Total (Y 10000 100.oc 100.00 2.56
(X 2.60




Statistics for: ND3 , FL2-H v FL1-H Ungated
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 loo.ob 2.68
(X) 2.6S
R1 m 0 0.00 o.ob
(X)
Statistics for: EGFPN1 FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (YJ 1000C 100 OC 100.00 228.68]
(X 812.96
R1 (Y 180C 18.0G 18.03 1201.52
(x; 4442.69
(e) pEGFP-N transfected -2
FL1-H
Statistics for: EGFPN2 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y 10000 100.00 100.00 277.06|
(X 1002.38]
R1 (Y) 2184 21 84 21 84 1213.53
(XI 4535.17
(f) pEGFP-N transfected -3
FL1-H
Statistics tor: EGFPN3 FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y 10000 100.00 100 OC 244.61
(X 881.68
R1 (Y 2025 20 25 20 25 1173.71
(X 4319.94
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C17 Figure 5.9 dotplots (continued)
(g) PACRC2cmvEGFP transfected -1 (h) PACRC2cmvEGFP transfected -2
Region 1 Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.00 9.5d
(X 20.92
R1 (Y)| 244 2.44 2.44 229.70
(xJ 727.64
Region 1 Count 1 % Gated % Total Mean
Total (yJ 1000o| 100.00 100.00 10.53
(x ] 26.20
R1 (Y)| 346| 3.46 3.46 191.93
ixi 1 668.od
(i) PACRC2cmvEGFP transfected -3 (j) lOOng PACRC2cmvEGFP + 900 ng pUC18 transfected -1
Statistics for: RC2CG3 , FL2-H v FL1-H . Ungated Statistics tor: 100NG1 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y 10000 100.00 100.00 8.46 Total (Y) 10000 100.00 100.00 10.91
(X 18.45 (X) 32.34
R1 (Y 268 2.68 2.68 134. R1 (Y) 567 5.67 5.67 126.74
(*; 532.38 (X) 516.12
(k) lOOng PACRC2cmvEGFP + 900 ng pUC18 transfected -2 (1) lOOng PACRC2cmvEGFP + 900 ng pUC18 transfected -3
10'-, 7 lO'-j
Statistics for: 100NG2 , FL2-H v FL1-H , Ungated Statistics for: 100NG3 . FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 15.93 Total M 10000 100.0C 100.00 12 64
(X) 46.89 (X 43.17
R1 (Y 750 7.50 7.50 159.37 RI (Y: 558 5.58 5.58 160.32
(X) 581.18 (X 718.48
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C17 Figure 5.9 dotplots (continued)
(m) 10ng PACRC2cmvEGFP + 990 ng pUC18 -1
FL1-H
Statistics lor: 10NG1 . FL2-H v FL1-H . Ungated
Region 1 Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.0C 5.62
(X 13.28
R1 (Y)( 285 2.85 2.85! 71.62
(X)| 360.61
(n) 10 ng PACRC2cmvEGFP + 990ng pUC18 -2
FL1-H
Statistics lor: 10NG2 . FL2-H v Fli-H . Ungated
Region [ Count % Gated % Total Mean
Total (Y)| 10000 100.00 100.00 7.2S
(xl 20 31
R1 (Y)| 477 4.77 4 77 68 2S
<xl 356 5C
(o) 10ng PACRC2cmvEGFP + 990 ng pUC18 -3 (p) lng PACRC2cmvEGFP + 999 ng pUC18 -1
Statistics for: 10NG3 , FL2-H v FL1- H , Ungated
Region 1 Count % Gated % Total Mean
Total (Y)| 1000C 100.0C 100.00 6.14
(X 14.12
R1 (Y)| 39d 3.90 3.90 61.08
(x3 282.61
Region 1 Count % Gated % Total Mean
Total (Y) 10000 100.00 100.0C 4.73
(X 6.41
R1 (Y)| 98 0.9^ 0.98 57.61
(X 301.20
(q) lng PACRC2cmvEGFP + 999 ng pUC18 -2
FL1-H
Statistics lor: 1NG2 . FL2-H v FL1-H . Ungated
Region Count % Gated % Total Mean
Total (Y) 1000C 100.00 100 od 5 34
(X) 7.24
R1 m 144 1.44 1.44 49.02
(X) 252.4S
(r) 1 ng PACRC2cmvEGFP + 999 ng pUC18 -3
FL1-H
Statistics for: 1NG3 . FL2-H v Fll-H , Ungated
Region Count % Gated % Total Mean
Total (Y 1000C 100 00 100.0C 4.88
(x: 6.60
R1 (Y 12C 1.26 1.2C 49.35
(X 251 70
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CI7 Figure 5.9 dotplots (continued)
(s) lOOpg PACRC2cmvEGFP + 999.9 ng pUC18 -1
FL1-H
Statistics for: 100PG1 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.0C 4.24
(X) 4.68
R1 (Y) 32 0.32 0.32 80.9S
(X) 427.08
FL1-H
Statistics for: 100PG3 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 4.10
(X) 4.73
R1 (Y) 23 0.23 0.23 118.30
(X) 647.57
Statistics for: PUC181 , FL2-H v FL1-H , Ungated Statistics lor: PUC182 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y) 10000 100.0C 100.0C 2.57 Total (Y: 10000 100.00 100.00 2.5S
(X) 2.56 (x: 2.72
RI (Y) 0 o.oc 0.00 RI (Y: 0 0.00 0.00
(X) (X
(w) 1 microg pUC18 transfected -3
FL1-H
Statistics for: PUC183 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y 1000C 100.0C 100.00 2.64
(X 2.7C
RI m 0 0.00 0.00
(X)
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Region Count % Gated % Total Mean
Total (Y) 10000 100.0C 100.00 2.79
(X) 3.06j
R1 (Y) 0 O.OC 0.00
(X)
(c) untransfected -3
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 2.78
(X) 2 9E
R1 (Y) 0 0.00 o.oc
(X)
(d) 1 microg pEGFP-N transfected -1
10* 10' 10' 10'
FL1-H
Statistics for: ND3 , FL2-H v FL1-H Ungated
(e) 1 microg pEGFP-N transfected -2
10' 10' 10'
FL1-H
Statistics for: EGFPN1 FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Y) 1000C 100.0C 100.00 2.85 Total (Y) 10000 100.00 100.00 416.58
(X) 3.10 (X) 1505.50
R1 (Y) 0 O.OC 0.00 R1 (Y) 3257 32.57 32.57 1238.88
(X) (X) 4581 4?
(f) 1 microg pEGFP-N transfected -3
10" 10' 10'
FL1-H
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.0C 359.79
(X) 1276.30
ri m 2703 27.03 27.0- 1264.35
(X) 4654.45
Region Count % Gated % Total Mean
Total (Y 10000 100.00 100.0C 352.31
(X 1278.23
R1 {Y 2879 28.79 28.79 1181.42|
(X 4396 00
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CI 8 Figure 5.10 dotplots (continued)
(g) 100 ng pEGFP-N + 900ng pUC18, mixed -1
FL1-H
Statistics for: MIX 1 , FL2-H v FL1-H Ungated
Reqion Count % Gated % Total Mean
Total (Y) 10000 100.00 100.0C 402.8C
(X) 1481.41
R1 (Y) 3420 34.20 34.2C 1140.05
(X) 4292.76
(h) 100 ng pEGFP-N + 900 ng pUC18, mixed -2
FL1-H
Statistics for: MIX2 , FL2-H v FL1-H Ungated
Region Count % Gated % Total Mean
Total (Y 1000C 100.00 100.00 459 8^
(X 1674.60
m m 3484 34.84 34.84 1248.08
(X 4734.39
Statistics for: MIX3 , FL2-H v FL1-H Ungated
Region Count % Gated % Total Mean
Total (Y) 10000 100.0C 100 00 399.00
(X) 1459.2d
R1 m 2969 29.65 29 69 1282.66
(X 4853.13
(j) 100 ng pEGFP-N + 900 ng pUC18, separate -1
FL1-H
Statistics for: SEP1 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 10000 100.00 100.00 161.6c
(X 551.3c
R1 (Yi 1415 14.15 14.15 1071 4c
(x: 3826 01
Statistics for: SEP2 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 1000C 100.00 100.00 148.8C
(X) 558.57
R1 (Y 1434 14.34 14.34 996.391
(X 3854.94
(1) 100 ng pEGFP-N + 900 ng pUC18, separate -3
FL1-H
Statistics for: SEP3 , FL2-H v FL1-H Ungated
Region Count % Gated % Total Mean
Total (Y 1000C 100.0C 100.00 146.28
(X 537.5c
R1 (Y 1307 13.07] 13.07 1052.27
(X 4045.92
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C18 Figure 5.10 dotplots (continued)
(m) 100 ng pEGFP-N + 0.75 Lipofectin -1 (n) 199 ng pEGFP-N + 0.75 Lipofectin -2
Region Count % Gated % Total Mean
Total (Yy 10000 100.00 100.0C 167.15
(X) 577.34
R1 (Y) 1242 12.42 12.42 1307.18
(X 4607.84
(o) 100 ng pEGFP-N + 0.75 Lipofectin -3
Region 1 Count 1 % Gated % Total Mean
Total (Y)| 10OOOl 100.00 100.0C 99.41
(X 1 371.6S
R1 (Y)| 1136| 11.36 11.36 835.75
(x3 1 3227.35
(p) 100 ng pEGFP-N + 0.075 Lipofectin -1
Region Count % Gated % Total 1 Mean
Total (Y) 10000 100.00 100.0q 134.48
(X) 478.10
R1 (Y) 1234 12.34 12.34 1051.82
(X) 3832.60
(q) 100 ng pEGFP-N + 0.075 Lipofectin -2
Region Count % Gated % Total Mean
Total (Y1 10000 100.0C 100.00 6.00
(X) 13.98j
R1 (Y 28 0.28 0.28 1203.2l]
(x; 3958.6S
(r) 100 ng pEGFP-N + 0.075 Lipofectin -3
X
El
Statistics for: 100.0752 , FL2-H v FL1-H , Ungated Statistics for: 100.0753 , FL2-H v FL1-H , Ungated
Region 1 Count % Gated % Total Mean Region Count % Gated % Total Mean
Total (Yl 10000 100.00 1OO.O0 8.41 Total (T 10000 100.00 100.0C 5.07
(xl 24.54 (X 12.77
R1 (Y)| 38 0.38 0.38 1482.52 R1 (Y 34 0.34 0.34 694.57
(xj 5656.24 (X 2889.86J
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CI8 Figure 5.10 dotplots (continued)
FL1-H
Statistics for: PUC181 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y 10000 100.00 100.0C 4.53
(x) 3.90
R1 (Yt 0 0.00 0 oc
(*; ••
(t) 1 microg pUC18 transfected -2
FL1-H
Statistics for: PUC182 , FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y) 1000C 100.0C 100.00 5.3a
(X) 4.47
R1 (Y) 0 o.oc 0.00
(X)
(u) 1 microg pUC18 transfected -3
FL1-H
Statistics for: PUC183 . FL2-H v FL1-H , Ungated
Region Count % Gated % Total Mean
Total (Y 10000 100.00 100.0C 4.94
(X 4.17
R1 (V 0 o.ofl o.oc
or
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Appendix D: Vector Structure. This appendix shows diagrams of the
parent/control vectors pEGFP-1. pEGFP-N, pIRES2EGFP, pCMV(3
(figures adapted from the Clontech website) PACRClb and PACRC2b,




pEGFP-1 encodes a red-shifted variant of wild-type green fluorescent protein GFP which has been
optimized for brighter fluorescence and higher expression in mammalian cells. (Excitation maximum =
488 nm; emission maximum = 507 nm.) pEGFP-1 encodes the GFPmutl variant which contains the
double-amino-acid substitution of Phe-64 to Leu and Ser-65 to Thr. The coding sequence of the EGFP
gene contains more than 190 silent base changes which correspond to human codon-usage preferences.
Sequences flanking EGFP have been converted to a Kozak consensus translation initiation site to
further increase the translation efficiency in eukaryotic cells. pEGFP-1 is a promoterless EGFP vector
which can be used to monitor transcription from different promoters and promoter/enhancer
combinations inserted into the MCS located upstream of the EGFP coding sequence. SV40
polyadenylation signals downstream of the EGFP gene direct proper processing of the 3' end of the
EGFP mRNA. The vector backbone also contains an SV40 origin for replication in mammalian cells
expressing the SV40 T antigen. A neomycin-resistance cassette (Neor) allows stably transfected
eukaryotic cells to be selected using G418. The Neor cassette consists of the SV40 early promoter, the
ncomycin/kanamycin resistance gene of Tn5, and polyadenylation signals from the Herpes simplex
virus thymidine kinase (HSV TK.) gene. A bacterial promoter upstream of this cassette confers
kanamycin resistance in E. coli. The pEGFP-1 backbone also provides a pUC origin of replication for




pEGFP-N 1 encodes a the EGFP reporter gene. The MCS in pEGFP-N 1 is between the immediate
early promoter of CMV (PtMV IE) and the EGFP coding sequences. Genes cloned into the MCS will be
expressed as fusions to the N-terminus of EGFP if they are in the same reading frame as EGFP and
there are no intervening stop codons. SV40 polyadenylation signals downstream of the EGFP gene
direct proper processing of the 3' end of the EGFP mRNA. The vector backbone also contains an
SV40 origin for replication in mammalian cells expressing the SV40 T-antigen. A neomycin-
resistance cassette (neor), consisting of the SV40 early promoter, the neomycin/kanamycin resistance
gene of Tn5, and polyadenylation signals from the Herpes simplex thymidine kinase gene, allows
stably transfected eukaryotic cells to be selected using G418. A bacterial promoter upstream of this
cassette (Pamp) expresses kanamycin resistance in E. coli. The pEGFP-Nl backbone also provides a




pIRES2-EGFP contains the internal ribosome entry site (IRES) of the encephalomyocarditis virus (ECMV)
between the MCS and the enhanced green fluorescent protein (EGFP) coding region. This permits both the
gene of interest (cloned into the MCS) and the EGFP gene to be translated from a single bicistronic mRNA.
plRES2-EGFP is designed for the efficient selection (by flow cytometry or other methods) of transiently
transfected mammalian cells expressing EGFP and the protein of interest. This vector can also be used to
express EGFP alone or to obtain stably transfected cell lines without time-consuming drug and clonal
selection.
The MCS in plRES2-EGFP is between the immediate early promoter of cytomegalovirus (F^mvie) an(l the
IRES sequence. SV40 polyadenylation signals downstream of the EGFP gene direct proper processing of
the 3' end of the bicistronic mRNA. The vector backbone also contains an SV40 origin for replication in
mammalian cells expressing the SV40 T antigen. A neomycin-resistance cassette (Neor), consisting of the
SV40 early promoter, the neomycin/kanamycin resistance gene of Tn5, and polyadenylation signals from
the herpes simplex virus thymidine kinase (FISV TK) gene, allows stably transfected eukaryotic cells to be
selected using G418. A bacterial promoter upstream of this cassette expresses kanamycin resistance in E.
coli. The pIRES2-EGFP backbone also provides a pUC origin of replication for propagation in E. coli and




pCM Vbeta is a mammalian reporter vector designed to expression beta-galactosidase in mammalian cells
from the human cytomegalovirus immediate early gene promoter. pCMVbeta contains an intron (splice
donor/splice acceptor) and polyadenylation signal from SV40, and the full-length E. coli beta-
galactosidase gene with eukaryotic translation initiation signals. pCMVbeta expresses high levels of beta-
galactosidase and can be used as a reference (control) plasmid when transfecting other reporter gene
constructs and can be used to optimize transfection protocols by employing standard assays or stains to
assay beta-galactosidase activity. Alternatively, the beta-galactosidase gene can be excised using the Not I
sites at each end to allow other genes to be inserted into the pCMVbeta vector backbone for expression in
mammalian cells or to insert the beta-galactosidase fragment into another expression vector.
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PAt RC l b encodes CFTR, including the genomic sequence of CFTR from 65 kb 5' to the ATG start site, then the cDNA
sequence from exon l through exon 24. Downstream of this, a PC MV promoter drives expression of the pgalactosidase
gene. A loxP site allows the vector to be manipulated by a double recombination method (Boyd et al, 1999b). A
Kanamycin resistance cassette (Km) allows selection for cells bearing the plasmid in E. coli. The vector contains a
PAC backbone.
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PACRC2b encodes CFTR, including the genomic sequence of CFTR from 65 kb 5' to the ATG start site through intron
l, and then the cDNA sequence from exon 2 through exon 24. Downstream of this, a Pcmv promoter drives expression
of the Pgalactosidase gene. A loxP site allows the vector to be manipulated by a double recombination method (Boyd et
al, 1999b). A Kanamycin resistance cassette (Km) allows selection for cells bearing the plasmid in E. coli. The vector
contains a PAC backbone.
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Appendix E: Fold-out diagram of EGFP reporter vectors.
CMV mum pEGFP-N (4.7 kb)
-■..^.CMVjp^lPACRC2cmvEGFP (111 kb)
1 kb CFTR 5' plkbcfproEGFP (4.9 kb)
65kb CFTR 5'
- |pAc65kbcfproEGFP (81 kb)






■ IREsJifiFPj PAcRC2iresEGFP (110 kb)
CFTR-
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Appendix F: Statistical Analysis.
Fl: T-Test
Figure 4.4 (RT-PCR)

















































































































































































F2. Test statistic p 1 u4 = u2u3
EGFPN RC2cmvEGFP 1 kbcfproEGFP 65kbcfproEGFP F 1F2 p.7p4
R Vcr F
, 1
vG" F Vcr F Vcr
1.6 1.7COS-7
Re pi 1 785 (257) 481 (197) 714 (135) 423 (127)
Repl 2 800 (253) 506 (262) 704 (166) 413 (137)
Repl 3 806 (251) 508 (206) 413 (126)
OVER 797 600 499 267 704 421 416 80
MDCK-
iowa
Repl 1 615 (280) 525 (290) 494 (193) 466 (181)
1 2 1.1Repl 2 595 (291) 472 (275) 499 (190) 5! 1 (173)
Repl 3 595 (284) 491 (290) 497 (188) 421 (173)
OVER 601 388 496 469 496 62 466 316
T84
Repl 1 517 (223) 432 (182) 474 (177) 442 (159)
I.I 1.1Repl 2 487 (220) 441 (207) 452 (178) 415 (214)
Repl 3 455 (220) 409 (197) 466 (175) 442 (188)
OVER 486 1032 427 94 464 247 432 64
Caco-2
Repl 1 558 (229) 444 (213) 461 0 94) 346 (105)
1.2 1.2Repl 2 534 (231) 521 (216) 455 (166) 376 (158)
Repl 3 564 (239) 418 (21 1) 429 0 74) |
OVER 552 394 461 326 408 233 361 1 11
Where p = the mean of the average fluorescence intensity
Vg" = the square root of the mean square
For COS-7:
T = 6.03
Significant difference
For MDCK-iowa:
T = -0.62
Significant difference
For T84:
T = -1.08
Significant difference
For Caco-2:
T = 0.79
Significant difference
 
